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Incidence rates of whooping cough were dramatically decreased by immunization 
with whole cell pertussis (wP) vaccines in the 1940s. However, concerns about the safety 
of the wP vaccine resulted in development of new pertussis vaccines using acellular 
components of B. pertussis. However, B. pertussis continues to circulate and cause 
whooping cough disease, even with the safer acellular pertussis (aP) vaccines. Over the 
last decade, in spite of the high vaccination coverage in many countries, there has been a 
significant rise in whooping cough infection in industrialized countries. The filamentous 
hemagglutinin (FHA) and pertussis toxin (PTx) are two antigens included in all currently 
licensed aP vaccines. Both FHA and PTx induce an immune response sufficient for 
protection, although anti-PTx antibodies correlate more with protection. 
Most studies assessing the efficacy of aP vaccines have used serum titers as the 
primary means to measure an antibody response to a given antigen. Single cell techniques 
however offer an opportunity to better understand the biochemical attributes of individual 
 vii 
antibodies induced upon aP vaccination. In this study, we characterized the antibody 
responses to FHA and PTx after adult aP booster vaccination. Monoclonal antibodies 
derived from single B cells which responded to FHA and PTx were purified, the binding 
affinities to the antigens evaluated, mechanisms of neutralization of FHA and PTx 
toxicity evaluated, and the binding epitopes of the antibodies analyzed. This study is the 
first to provide insight into the anti-FHA and PTx antibody repertoire after pertussis 
vaccination, and also identifies useful antibodies for further elucidation of the structure 
and function of these antigens.  In addition, the mechanisms of neutralization of two 
potently neutralizing anti-PTx monoclonal antibodies, 1B7 and 11E6 are presented. 
Antibody binding to live B. pertussis, inhibition of PTx binding to a model receptor 
fetuin and effects on PTx trafficking in CHO-K1 cells were evaluated. Further 
understanding of the molecular mechanisms of 1B7 and 11E6 neutralization provides a 
platform for engineering or isolating such unique anti-PTx antibodies for passive 
immunization therapies. 
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Chapter 1: Background and significance 
 
1.1 WHOOPING COUGH INFECTION 
Whooping cough is a contagious upper respiratory infection caused by the Gram-
negative, aerobic coccobaccillus, Bordetella pertussis (Mattoo and Cherry 2005). Other 
members of the Bordetella genus include B. parapertussis which also infects humans, 
and B. bronchiseptica, which has a broad mammalian host range including humans. B. 
pertussis infection typically results in a prolonged cough lasting over two weeks 
(Trollfors and Rabo 1981, Postels-Multani, Schmitt et al. 1995, Birkebaek, Kristiansen et 
al. 1999, Senzilet, Halperin et al. 2001, Strebel, Nordin et al. 2001, Gilberg, Njamkepo et 
al. 2002). The coughing is paroxysmal and can severely disturb sleep. Choking and 
vomiting may also occur (von Konig, Halperin et al. 2002). Other complications, 
although infrequent have also been recorded, such as syncope (Jenkins and Clarke 1981) 
and encephalopathy (Halperin and Marrie 1991). People are susceptible to whooping 
cough infection throughout their lifetime. Severe infection is however more often 
observed in infants and young children, and the infection may be fatal in infants less than 
6 months. Antibiotics such as erythromycin may be used to treat infection early in disease 
development (Bass 1986). Antibiotics are however usually ineffective past the catarrhal 
stage of infection when the symptoms are mediated by toxins expressed by the bacteria 
(Pittman 1984). 
Incidence rates of whooping cough were dramatically decreased by immunization 
with whole cell pertussis (wP) vaccines in the 1940s (Cherry 2012). However, concerns 
about the safety of the wP vaccine resulted in development of new pertussis vaccines 
using acellular components of B. pertussis (Sato and Sato 1999). Even with the safer 
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acellular pertussis (aP) vaccines, B. pertussis continues to circulate and cause whooping 
cough disease, in spite of the high vaccination coverage in many countries,  (Celentano, 
Massari et al. 2005, Quinn and McIntyre 2007, Hozbor, Mooi et al. 2009, (CDC) 2012), 
and over the last decade, there has been a significant rise in whooping cough infection in 
industrialized countries (Figure 1.1).  
 
 
Figure 1.1: Reported incidence of pertussis cases in the US from 1922-2014.       
*2014 numbers are provisional (CDC.gov). 
 
More troubling, disease rates have been rising steadily over the past few decades, 
to a 50-year high of approximately 42,000 cases in 2012 (Tanaka, Vitek et al. 2003, 
Lavine, King et al. 2013). aP vaccination prevents the severe manifestations of disease, 
but has been unable to eliminate subclinical infection (Lavine, King et al. 2011).  In fact, 
the temporal decline in post-vaccination immunity has altered disease demographics such 
0
50000
100000
150000
200000
250000
300000
1922 1932 1942 1952 1962 1972 1982 1992 2002 2012
US reported pertussis cases: 1922-2014 
 3 
that adults and adolescents now constitute the dominant reservoir (Senzilet, Halperin et 
al. 2001).  
Various reasons have been attributed to the current rise in observed clinical 
pertussis cases, including increased awareness (Jackson and Rohani 2014), and antigenic 
divergence between vaccine and circulating clinical strains (Octavia, Sintchenko et al. 
2012, Lam, Octavia et al. 2014). However, the pertussis resurgence, closely beginning 
around the introduction of acellular pertussis (aP) vaccines, raised concerns that the 
immunity from aP vaccines may be incomplete or wanes more quickly than protection 
after natural infection (Cherry 2010, Clark, Messonnier et al. 2012, Klein, Bartlett et al. 
2012, Sheridan, Ware et al. 2012, Witt, Katz et al. 2012). After infant immunizations at 2, 
4 and 6 months, immunity wanes over time, resulting in adults and adolescents reservoirs 
of the disease (von Konig, Halperin et al. 2002). Although adolescents and adults are 
often the largest group infected, the burden of disease falls on unimmunized infants, for 
whom morbidity and mortality from infection is highest (Vitek, Pascual et al. 2003, 
Elliott, McIntyre et al. 2004, Theilen, Johnston et al. 2008). For this reason, strategies 
have been put in place to protect infants through booster immunizations for adolescents 
and adults who serve as reservoirs (Hethcote 1999, Mooi and de Greeff 2007). 
Significant advances in our understanding of the complex molecular mechanisms of B. 
pertussis pathogenesis, and have led to ongoing research for the development of 
improved pertussis vaccines.  
 
1.2 B. PERTUSSIS VIRULENCE FACTORS 
B. pertussis expresses over 20 virulence factors which aid in bacterial 
colonization and evasion of host immunity (Mooi 1988). Expression of the virulence 
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genes is modulated by a genetic locus which consists of two closely linked genes bvgA 
and bvgS (Beier, Fuchs et al. 1996). The BvgAS component system activates the 
virulence genes in response to environmental signals such as temperature and nutrients 
(Konig, Bock et al. 2002, Nakamura, Liew et al. 2006), and also controls phase variation 
to a non-virulent form with the loss of expression of the virulence factors (Deora, 
Bootsma et al. 2001). The expressed virulence factors fall into two main groups: adhesins 
and toxins. The adhesins are mostly found on the surface of the bacteria and are 
responsible for mediating bacterial attachment to the host. B. pertussis adhesins studied in 
detail include the filamentous hemagglutinin (FHA), fimbrae (FIM), pertactin (PRN) and 
the serum resistance protein (BrkA). The toxins on the other hand, have 
immunosuppressive properties to enhance bacterial colonization and include the pertussis 
toxin (PTx), the adenylate cylase toxin (ACT), tracheal cytotoxin (TCT) and the 
dermonecrotic toxin (DNT) (Locht 1999). Table 1 shows the virulence factors expressed 
by the three major Bordetella species. 
 
1.3 ACELLULAR PERTUSSIS (AP) VACCINES  
The whole cell pertussis (wP) vaccines which preceded the current acellular 
pertussis (aP) vaccines were made from killed whole cell suspensions of one or more 
strains of B. pertussis, and subsequently treated to reduce toxicity but maintain 
effectiveness (Organization 2007). However, immunization with wP vaccines raised 
safety concerns, due to local and systemic reactions such as convulsions and infrequently, 
neurological reactions (Trollfors 1984). A challenge in aP vaccine development was that 
the bacterium produces multiple virulence factors, none of which provided a clear 
correlate of protection (Robbins, Schneerson et al. 1998, Robbins, Schneerson et al. 
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2009). However, increased knowledge of the molecular mechanisms of Bordetella 
pathogenesis and immunity led to the development of aP vaccine (Sato, Kimura et al. 
1984), containing up to five of the virulence factors including PTx, FHA, PRN and 
fimbriae types 2 and 3 (FIM 2/3). 
 
Table 1.1: Virulence factors expressed by the three major Bordetella species.  
 
    B. pertussis    B. parapertussis     B. bronchiseptica 
________________________________________________________________________ 
Adhesins    
FHA    +   +   + 
PRN    +   +   + 
FIM    +   +   + 
Brk    +   Gene present
a
  Gene present
a
 
 
 
Toxins 
PTx    +   Gene present
b
   Gene present
b
 
ACT    +   +   + 
TCT    +   +   + 
DNT    +   +   + 
 
a
 – The gene for the serum resistance protein (Brk) is present in B. parapertussis and B. 
bronchiseptica; however it is not known whether they are expressed.  
b
 – The PTx gene is present in B. parapertussis and B. bronchiseptica, but 
transcriptionally silent due to the presence of mutations mostly in the promoter regions 
(Aricò and Rappuoli 1987, Locht 1999). Table adapted from (Locht 1999). 
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1.4 ANTIBODIES AGAINST AP VIRULENCE FACTORS 
The mechanisms underlying protection conferred by pertussis vaccines or natural 
infection is still an open issue due to the complexity of the range of pharmacological 
effects from the numerous toxins and adhesins produced by B. pertussis (Mills 2001). It 
is however known that both B and T cells provide protective immunity (Mills and 
Redhead 1993, Mills, Ryan et al. 1998, Leef, Elkins et al. 2000). Early studies in mice 
did not provide a clear role for antibodies in protection against B. pertussis. Antibody 
responses to B. pertussis in mice after respiratory challenge develop slowly and are 
detected at low levels, even after the bacteria are cleared (Mills, Barnard et al. 1993). 
However, results of passive immunization studies indicated antibodies against various B. 
pertussis virulence factors play a protective role against B. pertussis infection. Polyclonal 
pertussis immunoglobulin (P-IVIG), prepared from the sera of immunized human 
volunteers, passively protected mice against an aerosol challenge and also reversed 
disease symptoms (Bruss and Siber 1999). Phase I clinical trials with infants treated with 
P-IVIG also showed a significant reduction in the number and duration of coughing 
(Granstrom, Olinder-Nielsen et al. 1991). A larger clinical trial however showed no 
difference in the reduction of symptoms compared to a placebo, and was terminated early 
due to unavailability of the antibody product (Halperin, Vaudry et al. 2007), and was 
therefore inconclusive. House hold exposure studies have however also indicated that 
individuals with high serum antibody levels against PTx, PRN and FIM had lower 
incidence of severe pertussis (Cherry, Gornbein et al. 1998, Storsaeter, Hallander et al. 
1998). Children immunized with a one-component aP vaccine, with higher anti-PTx 
antibodies, have also been shown to be protected from development of severe pertussis 
(Taranger, Trollfors et al. 2000). Anti-FHA antibodies are also thought to contribute to 
protection (He, Viljanen et al. 1994), although the relative value in the absence of 
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antibodies against PRN and FIM is not clear (Cherry, Gornbein et al. 1998). These 
studies show a correlation between the levels of serum antibodies to individual virulence 
factors and protection against severe whooping cough infection.  
Significant differences have been observed in both the T and B cell immune 
responses generated after aP vaccination compared with wP vaccines or natural infection 
(Podda, Bona et al. 1995). Analysis of T cells in infants primed with aP vaccines, showed 
a Th2 skewed or mixed Th2/Th1 response, whereas wP vaccines or natural infection 
induced predominantly Th1/17 responses (Ross, Sutton et al. 2013). In addition, 
individuals immunized with aP vaccines are observed to have a higher magnitude of T 
cell and antibody responses with a slower rate of decay, compared to individuals with 
natural infection or primed with wP vaccines (Dalby, Petersen et al. 2010). Antibody 
responses to FHA, FIM and PRN in aP vaccines are higher in magnitude compared to 
responses to the wP vaccines or natural infection (Edwards, Meade et al. 1995, Berbers, 
van de Wetering et al. 2013). The anti-FHA and PRN antibodies however decline more 
quickly (Giuliano, Mastrantonio et al. 1998, Berbers, van de Wetering et al. 2013). Anti-
PTx antibody levels are variable depending on the aP vaccine (Edwards, Meade et al. 
1995), but may be lower in magnitude compared to natural infection (Berbers, van de 
Wetering et al. 2013). The decay kinetics of anti-PTx antibodies induced to aP vaccines 
also appear to be variable in comparison to natural infection. One study, suggests anti-
PTx levels may decline faster after aP vaccination (Berbers, van de Wetering et al. 2013), 
while another study suggests the contrary (Dalby, Petersen et al. 2010).  Serum antibody 
levels and the kinetics of antibody decay after aP vaccination therefore do not provide a 
complete picture of the protection from aP vaccine immunization still protects from 
severe disease.  In addition, some aP vaccines with lower efficacy may also induce high 
antibody levels (Greco, Salmaso et al. 1996, Gustafsson, Hallander et al. 1996, Olin, 
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Rasmussen et al. 1997), further suggesting not all the virulence factors in the aP vaccines 
contribute to protection against severe infection.  
 
1.5 OBJECTIVES OF THIS DISSERTATION 
 FHA and PTx are antigens included in almost all current aP vaccines. 
Both FHA and PTx induce an immune response sufficient for protection, however anti-
PTx antibodies correlate more with protection. Most studies assessing the efficacy of aP 
vaccines have used however serum titers as the primary means to measure an antibody 
response to a given antigen, while only a few have used ELISpot analysis to monitor 
antigen specific B cell populations (Stenger, Smits et al. 2010, Hendrikx, de Rond et al. 
2011, Hendrikx, Ozturk et al. 2011). While overall serum antibody titers are high in aP 
vaccinated individuals, serum ELISAs do not distinguish between high concentrations of 
weakly binding antibodies and low concentrations of tightly binding antibodies, or easily 
identify the spectrum of epitopes recognized by the polyclonal serum. Serum antibody 
studies have however provided a broad understanding of the quality of antibodies induced 
by infections versus acellular vaccines.  
Recent developments in isolation and analysis of monoclonal antibodies from 
single B cells (Meijer, Andersen et al. 2006, Tiller, Meffre et al. 2008) have provided 
great insights into antigen-specific antibody repertoires, facilitating identification of rare, 
neutralizing antibodies (Yu, Tsibane et al. 2008) and correspondingly, the epitopes 
recognized (Krause, Tsibane et al. 2011). For instance, the techniques of isolating 
monoclonal antibodies from polyclonal serum (Cheung, Beausoleil et al. 2012, Wine, 
Boutz et al. 2013) have been used to identify neutralizing antibodies against pathogens 
such as HIV (Zhu, O'Dell et al. 2012, Zhu, Ofek et al. 2013), 1918 influenza virus 
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(Wrammert, Smith et al. 2008, Yu, Tsibane et al. 2008, Krause, Tsibane et al. 2011). 
Single cell techniques therefore offer an opportunity to better understand the biochemical 
attributes of individual antibodies induced upon aP vaccination, and determination of the 
number of antibody sequence families responding to a given antigen. In addition, the 
ligand binding affinity and neutralization capacity of each antibody can be determined. 
Identified neutralizing antibodies also have the potential to be used for passive 
immunotherapy.   
In the next two chapters of this study, antibody responses to FHA and PTx after 
aP booster vaccination are characterized. Monoclonal antibodies derived from single B 
cells which responded to FHA and PTx were purified from transiently expressing CHO-
K1 cells.  The binding affinities to the antigens were characterized, the mechanisms of 
FHA and PTx neutralization evaluated, and the binding epitopes of the antibodies 
analyzed. This study, the first to provide insight into the anti-FHA and PTx antibody 
repertoire after pertussis vaccination, also identifies useful antibodies for further 
elucidation of the structure and function of these antigens.  In the third chapter of this 
thesis, the molecular mechanisms of neutralization of two potently neutralizing anti-PTx 
monoclonal antibodies, 1B7 and 11E6 are presented. Antibody binding to live B. 
pertussis, inhibition of PTx binding to a model receptor fetuin and effects on PTx 
trafficking in CHO-K1 cells were evaluated. Further understanding of the molecular 
mechanisms of 1B7 and 11E6 neutralization provides a platform for engineering or 
isolating such unique anti-PTx antibodies for passive immunization therapies. 
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Chapter 2: Characterization of antibodies from single B cells induced to 
the filamentous hemagglutinin (FHA) after acellular pertussis booster 
immunization. 
 
2.1 INTRODUCTION 
FHA, one of the first major B. pertussis virulence factors to be discovered (Arai 
and Sato 1976, Sato, Izumiya et al. 1981) is a large immunogenic antigen found both 
surface associated and secreted. FHA is first synthesized as a large ~370 kDa precursor 
from the fhaB gene (Delisse-Gathoye, Locht et al. 1990, Domenighini, Relman et al. 
1990), after which it undergoes extensive N-terminal (Jacob-Dubuisson, Buisine et al. 
1996, Lambert-Buisine, Willery et al. 1998) and C-terminal proteolytic processing to 
yield the ~220 kDa mature protein (Delisse-Gathoye, Locht et al. 1990, Domenighini, 
Relman et al. 1990), which is the major secreted product. Structurally, FHA has been 
shown to be a monomeric filamentous rod, about 50 nm in length with a globular end 
(Makhov, Hannah et al. 1994, Kajava, Cheng et al. 2001).    
Mature FHA is thought to have four binding domains responsible for B. pertussis 
adherence to receptors on host cells (Brennan, Hannah et al. 1991, Prasad, Yin et al. 
1993, Hannah, Menozzi et al. 1994). A heparin binding domain (HBD), located at the N-
terminal end of FHA (Hannah, Menozzi et al. 1994, Colombi, Horton et al. 2004), is 
involved in the carbohydrate dependent hemagglutination of red blood cells (Sandros and 
Tuomanen 1993, Menozzi, Mutombo et al. 1994), and binds receptors with sulfated 
glycoconjugates such as heparin which may be present on mucus secreting epithelial cells 
(Menozzi, Mutombo et al. 1994). The relevance of the HBD in the pathogenesis of B. 
pertussis infection is however unclear as it is not sufficient for adherence to epithelial 
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cells and macrophages, but appears to contain neutralizing epitopes sufficient for 
protection (Alonso, Reveneau et al. 2002).  
A second region comprising the tri-peptide residues 1097-1099, contains the 
amino acid sequence Arg-Gly-Asp (RGD) is involved in binding to integrins on 
macrophages and ciliated cells (Ishibashi, Claus et al. 1994, Ishibashi, Relman et al. 
2001). The RGD domain on FHA is involved in binding to the leukocyte response 
integrin/integrin-associated protein (LRI/IAP) complex and the integrin 
αMβ2/complement receptor 3 (CR3)/macrophage receptor 1 (Mac1) on macrophages and 
possibly other leukocytes, and enhances the attachment and invasion of B. pertussis 
(Saukkonen, Cabellos et al. 1991, Ishibashi, Claus et al. 1994).  The RGD domain on 
FHA also appears to be involved in binding to the epithelial integrin, α5β1, and enhancing 
bacterial invasion of human epithelial cells (Ishibashi, Relman et al. 2001). The RGD 
domain however does not appear to be crucial for colonization, as B. pertussis strains 
with an RAD mutation still maintain virulence  similar to parental strains (Ishibashi, 
Relman et al. 2001, Julio, Inatsuka et al. 2009).  
A third region close to the RGD sequence, the carbohydrate binding domain 
(CBD), is found within residues 1141-1279. The CBD binds to lactosylceramides, and B. 
pertussis strains with in-frame deletions of the CBD fail to adhere to macrophages and 
ciliated cells in-vitro (Prasad, Yin et al. 1993). Recently, a region within the C-terminus 
of the mature FHA (MCD), located ~500 amino acids at the end of the mature FHA has 
been implicated in B. pertussis adherence to epithelial cells and macrophages (Julio, 
Inatsuka et al. 2009). The MCD also contains neutralizing epitopes sufficient for 
protection (Knight, Huang et al. 2006). 
FHA mediates B. pertussis adherence to epithelial cells and macrophages in-vitro 
(Urisu, Cowell et al. 1986, Ishibashi, Relman et al. 2001) and is also required for 
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colonization of the trachea in-vivo (Jacob-Dubuisson, Buisine et al. 1996, Julio, Inatsuka 
et al. 2009). In addition to mediating adherence, FHA also has important 
immunomodulatory functions. FHA binding to the LRI/IAP complex on macrophages via 
its RGD domain upregulates CR3 binding activity (Ishibashi, Claus et al. 1994), while the 
interaction of the FHA RGD with the VLA-5 integrin on epithelial cells, upregulates 
ICAM-1 expression (Ishibashi and Nishikawa 2002, Ishibashi and Nishikawa 2003). 
FHA has also been shown to inhibit CD4
+
 T cell proliferation (Boschwitz, Batanghari et 
al. 1997) and induce apoptosis (Abramson, Kedem et al. 2001) or immunosuppressive 
effects (McGuirk and Mills 2000, McGuirk, McCann et al. 2002) on macrophages and 
dendritic cells. Due to its importance as an adhesin and immune-modulator, FHA is 
included in almost all currently licensed aP vaccines. 
Anti-FHA antibodies are thought to be protective (He, Viljanen et al. 1994) by 
blocking bacterial adhesion and promoting bacterial clearance (Sato, Izumiya et al. 1981). 
To better understand protection and the rapid waning of immunity induced by aP 
vaccines, we evaluated the quality of individual antibody responses to FHA after an adult 
booster immunization. The DNA from single B cells responding to FHA isolated from 
the adult volunteers cloned into expression vectors were kindly provided by 
Excelimmune Inc. The single B cells were isolated from adult volunteers immunized with 
a booster aP vaccine and DNA sequences corresponding to antibodies responding to each 
antigen extracted. The antibody sequences were cloned into mammalian expression 
vectors, and the fully human antibodies subsequently purified from CHO-K1 cell lines. 
Of the greater than 50 unique anti-FHA antibodies identified, six were selected for further 
characterization. The selected purified antibodies bound FHA with high affinity, were 
diverse in the germline sequence families, but appeared to recognize an immunodominant 
epitope. We identified two neutralizing, antibodies, B6, and H6 in an in-vitro 
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hemagglutination assay. B6 also inhibited B. pertussis binding to CHO-K1 epithelial 
cells, while H6 potently inhibited FHA binding to the macrophage CR3 receptor. All the 
tested antibodies bound whole B. pertussis cells suggesting they may be substrates for 
complement mediated killing of B. pertussis. This study, the first to provide insight into 
the anti-FHA antibody repertoire after pertussis vaccination, also identifies useful 
antibodies for further elucidation of the FHA structure and function and provides 
promising candidates for passive immunotherapy for whooping cough infection. 
 
 
2.2 MATERIALS AND METHODS 
2.2.1 Antibody plasmid DNA  
DNA plasmid vectors encoding antibody sequences corresponding to single B 
cells responding to FHA were kindly provided by Excelimmune, Inc. The B cells were 
isolated from two healthy adult volunteers on day 6 after  receiving a booster vaccination  
with the acellular pertussis vaccine, either Adacel, (Sanofi Pasteur, Lyon, France), or 
Boostrix (GlaxoSmithKline Biologicals, Rixensart, Belgium and Novartis Vaccines and 
Diagnostics, GmbH & Co. KG, Marburg, Germany. Subjects were recruited as part of 
their routine medical care.  All donors completed a uniform blood donor history 
questionnaire. An IRB approved consent form was obtained from each donor giving 
permission to collect their blood for research purposes.  
The single B cells responding to native FHA were then isolated using established 
methodologies as described below (Coronella, Telleman et al. 2000). The heavy and light 
chain antibody sequences provided were in either a one or two plasmid vector system 
(Table 2.1). The one plasmid system contained both the heavy or light chain in a single 
 14 
vector with a neomycin/kanamycin resistance cassette and other functional elements such 
as a ColE1 origin of replication, and a CMV promoter for high level protein expression in 
mammalian cells. The dual plasmid system was made up of two plasmids vectors, each 
containing either the heavy or light chain sequences with a neomycin/kanamycin 
resistance cassette and other functional elements such as a ColE1 origin of replication, 
and a CMV promoter. 
 
 
Table 2.1:  Plasmid vectors for expression of anti-FHA antibodies 
Heavy chain 
antibody 
Light chain antibody Plasmid Vector Antibody ID 
used in this study 
42.11.D4.22G2.VH  42.11.D4.23G2.K Single D4 
42.11.G2.22E4.VH 42.11.G2.23E4.K Single G2 
42.12.A9.22G6.VH  42.12.A9.23G6.K Single A9 
55.12.G10.34E2.VH 55.12.G10.32E4.K Single G10 
55.12.H2.34A3.VH 55.12.H2.32A5.K Single H2 
55.15.C12.34A5.VH 55.15.C12.32B7.K Dual C12 
55.15.E10.34E5.VH 55.15.E10.32G7.K Single E10 
55.16.H6.34D7.VH 55.16.H6.32A9.K Dual H6 
55.18.D12.34F8.VH 55.18.D12.32G10.K Single D12 
55.19.B6.34A9.VH 55.19.B6.32A11.K Dual B6 
55.19.C2.34G9.VH 55.19.C2.32E11.K Dual C2 
55.22.E7.34C11.VH 55.22.E7.33A1.K Single E7 
57.52.B5.1A1.VH 57.52.B5.1A1.K Single B5 
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2.2.2 Antibody screening 
2.2.2.1 Isolation of plasma cells, antibody cloning  
Isolation of plasma cells and antibody cloning were perfomed by excelimmune 
inc as described. Plasma B cells were enriched from PBMCs using a plasma cell isolation 
kit (Miltenyi-Biotech), labeled with antibodies (BioLegend) to CD19, CD38 and Kappa 
or Lambda light chains and single-cell sorted by FACS (BD FACSJazz). The single 
sorted B cells were then distributed into 96-well PCR plates containing reverse 
transcriptase buffer, RNase inhibitor (NEB) and primers for the heavy chain J region and 
both light chains (Kappa and Lambda). Reverse transcription was performed using the 
Superscript III reverse transcriptase (Invitrogen). The cDNA was divided and separate 
semi-nested PCRs were performed to produce VH (VDJ) and light chain (VLCL) antibody 
amplicons. For antibody expression, an IgG1 constant region was grafted onto the cloned 
VDJ sequences. Cognate pairing of antibodies was maintained and antibodies were 
transiently expressed under EF1alpha promoters in HEK293 mammalian cells (ATCC) in 
a 96 well format.  Transfection was achieved by polyethylenimine (Polysciences) using a 
standard transfection protocol. From the microplates, supernatants were removed and 
screened for antigen-antibody interactions in custom Luminex™ assays. 
 
2.2.2.2 Antibody-antigen screening 
Luminex™ MagPlex® microspheres were coated with antigens using an xMAP 
Antibody Coupling Kit according to the manufacturer’s instructions (Luminex 
Corporation). In brief, the desired number of microspheres were placed in a microtube, 
washed and activated for coupling using the activation buffer.  Sulfo-NHS was added, 
followed by EDC.  The microspheres were incubated for 20 minutes at room temperature 
 16 
on a rotator in the dark.  The microspheres were washed before coating conditions were 
added and microspheres were then incubated for 2 hours at room temperature while 
rotating.  The microspheres were then washed and placed in storage buffer (1% PBS, 1% 
BSA and 0.05% sodium azide).  For all washing steps, a DynaMag™ Magnet 
(Invitrogen) was used. Each Luminex™ MagPlex® microsphere received a single 
antigen for coupling.  For multiplexing, antigens were coupled to Luminex™ MagPlex® 
microspheres with unique spectral signatures. Antigens were purchased from List Labs 
and included Fimbriae 2/3, Pertactin, Pertussis Toxin (whole), Pertussis Toxin Protomer 
A and Pertussis Toxin Protomer B. Coupled beads were then used to perform the 
Antigen-Antibody assays.  The assay was run according to manufacturer’s instructions 
(Luminex).  Briefly, coupled microspheres were placed in wells of 96 well microplates 
and incubated with supernatants derived from transfected HEK293 cells for 30 minutes.  
The microplates were then washed with assay buffer (1X PBS pH 7.4 with 1% BSA) and 
a PE conjugated goat anti-FC antibody (Jackson ImmunoResearch) was added and 
incubated for another 30 minutes.  After incubation, the microplates were washed and 
resuspended in assay buffer. Microplates were then read in a Luminex FlexMap 3D.  
Reactivities were scored based on values of fold over background.   
 
2.2.3 Bacterial strains and growth conditions 
The Bordetella strains used were B. pertussis Tahoma I (ATCC# BAA-587), B. 
pertussis ΔFHA, a streptomycin resistant B. pertussis Tahoma I derivative lacking the 
structural gene for FHA,  D420, a recent clinical isolate of B. pertussis pertussis (from 
Eric Harvill, Penn State University), B. bronchiseptica strain RB50 (ATCC# BAA-588), 
and B. parapertussis strain 12822 (ATCC # BAA-589). The Bordetella strains were 
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grown on Bordet-Gengou agar supplemented with 15% sheep blood (BD Biosciences). 
Liquid cultures were grown from colonies on the plates which showed hemolysis due to 
production of the adenylate cyclase toxin (ACT), and indicative of the expression of the 
virulence genes. Cultures were grown in Stainer Scholte medium (Stainer and Scholte 
1970) with 1g/L of hepatikis (2,6-O-dimethyl-β-cyclodextrin) added for the production of 
FHA. Plasmid vectors for transient expression of antibodies in CHO-K1 cells were 
purified from the E. coli strain DH5α. Transformation of the antibody plasmid vectors 
into E. coli was done by electroporation. Cells successfully transformed were selected on 
2XYT plates containing ampicillin. 
 
2.2.4 Antigens and antibodies 
2.2.4.1 FHA 
Mature FHA produced by B. pertussis strain 165 was purchased from List 
Biological Laboratories, Inc. (Campbell, CA), or obtained through BEI Resources, 
NIAID, NIH. FHA from B. pertussis TahomaI strain, D420 strain (recent clinical isolate) 
or from B. bronchiseptica were purified from the  culture supernatant using heparin 
affinity chromatography as described (Menozzi, Gantiez et al. 1991). FHA concentrations 
were determined using a BCA assay using BSA as a standard. Purified FHA was stored 
in 50 mM Tris, pH 8, 500mM NaCl at -20
o
C. The FHA fragments 861-1655 (pMAL 83) 
and 1655 (pMAL 85) were generously provided by Dr. Camille Locht. Construction and 
expression of pMAL 83 and 85 have been previously described (Leininger, Bowen et al. 
1997). FHA fragments 1-435 and 1156-1295 the corresponding coding regions were 
amplified from B. pertussis TahomaI cells and cloned into the pMALc-5x vector (NEB) 
between the NdeI and HindIII restriction sites. The FHA 1-435 peptide fragment was 
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amplified using the forward primer 5’- aggaaccacatatgaacacgaacctgtacaggctggtctt - 3’ 
and reverse primer 5’- aagaactacagcaagcttcgacagcttgtccgccttgagg - 3’. The 1156-1295 
fragment was amplified using the forward primer 5’- 
aatcggacatatggctgccaaaggggacaagggcaagcc and reverse primer 5’ - 
gctaactaagcttgccgtccgagccgaccaggaa - 3’. Restriction sites are underlined. The pcr 
reactions contained 5% DMSO to enhance fragment amplification from the GC-rich B. 
pertussis genomic DNA. The amplified fragments were pcr purified (Qiagen purification 
kit), digested with the NdeI and HindIII restriction enzymes and ligated to the pMALc-5x 
vector, similarly digested and gel purified (Qiagen purification kit). 
 
2.2.4.2 Antibodies 
The antibodies were transiently expressed on a laboratory scale in adherent CHO-
K1 cells from mammalian plasmid DNA containing cDNA sequences of the antibody 
genes. The plasmid vectors were purified using a midiprep plasmid preparation kit 
(Qiagen). Concentration and quality of plasmid DNA were assessed by A260 
measurements on a nanodrop 2000 (ThermoScientific). Three confluent T-150 flasks 
containing adherent CHO-K1 cells were transfected with 150 µg of the plasmid DNA 
using Lipofectamine 2000 reagent (Life Technologies). After a total of three changes of 
complete antibody media media (DMEM media (Life Technologies) with 10% Ultra Low 
IgG FBS (Life Technologies) and 1X Penicillin/Streptomycin (Life Technologies)), the 
saved culture supernatants were pooled and concentrated by overnight precipitation with 
50% saturated ammonium sulfate. Antibodies were purified by protein A affinity 
chromatography as described after dialysis into sodium phosphate buffer pH 7.2, 150mM 
NaCl (Sutherland and Maynard 2009). Protein concentrations were determined by 
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absorbance at 280 nm on a nanodrop 2000 (Thermo Scientific) using an extinction 
coefficient of 1.4.  Antibody purity was verified with 12% SDS-PAGE gels stained with 
GelCode Blue (Pierce). Human intravenous pertussis immunoglobulin (P-IGIV) (Bruss, 
Malley et al. 1999) was obtained from the Massachusetts Public Health Biologic 
Laboratory. Polyclonal mouse anti-FHA antibody was obtained from NIBSC. HRP and 
fluorescent conjugated secondary antibodies were obtained from Southern Biotech and 
Thermoscientific respectively. The IgG3 anti-B. pertussis lipo-oligosaccharide (LOS) 
antibody (D26E) was obtained from Thermoscientific. 
 
2.2.5 Phylogenetic analyses 
The VH and Vĸ sequences of the isolated antibodies were mapped to the closest 
human germline VDJand VJ sequences respectively using NCBI/IgBLAST (Ye, Ma et al. 
2013). The human germline sequences from  NCBI/IgBLAST are obtained from the 
IMGT database (Lefranc, Giudicelli et al. 2005). To obtain the closest human germline 
sequence, we adapted the methodology of (Jayaram, Bhowmick et al. 2012) by selecting 
the sequence hit with the highest score. The score is determined after calculating the final 
points after adding points for each match and subtracting points for each mismatch (Ye, 
Ma et al. 2013). The germline sequences are presented in the form IGHV1-46*03. The 
first two variables IG represent an immunoglobulin. The next variable, H represents the 
genetic locus, (H, K or L). The next, V represents the type of gene segment (V D or J), 
the number after the gene segment, 1, represents the gene family. The subsequent 
number, 46, represents the individual gene, and the last two numbers, 03, correspond to 
the allele. The gene segment pairings (VDJ or VJ) for each genetic locus (H or K) were 
compared and the frequencies of pairing for the putative VDJ or VJ presented in a heat 
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map. The individual gene families and alleles were also analyzed by indicating the 
frequencies in a pie chart. Since the antibody isolation maintained the original pairing of 
the heavy and light chains, the full VH or Vĸ sequences were then aligned using 
Phylogeny.fr (Dereeper, Guignon et al. 2008) to generate phylogenetic trees. 
 
2.2.6 Thermal stability analysis 
Thermal stability of the purified antibodies was analyzed in an applied 
Biosystems ViiA 7s instrument. Three replicates of 100 µg/ml solutions of the antibodies 
were prepared in PBS using the protein thermal shift dye (Life Technologies) according 
to the manufacturer’s protocol. The antibodies were heated from 25oC to 90oC with a 
scanning rate of 1
o
C/min increments. To determine the melting temperature (Tm), the 
data was fit to a sigmoidal four parameter (4PL) non-linear regression model using Graph 
pad prism 5.  
 
2.2.7 Antigen specific responses 
2.2.7.1 Indirect ELISA assays 
High binding ELISA plates (Costar) were incubated overnight at 4
o
C with FHA at 
a concentration of 1 µg/ml in PBS, pH 7.4. All volumes were 50 µl/well unless otherwise 
stated. The plates were washed after each incubation step with wash buffer (PBS, pH 7.4 
+ 0.05% Tween-20) to remove any unbound proteins. Serially diluted antibodies prepared 
in blocking buffer, were added to the plates after blocking with 5% milk in wash buffer. 
Subsequently, HRP-conjugated anti-human Fc antibodies (Southern Biotech) diluted 
1:1000 were used to detect bound antibodies. The plates were developed with TMB 
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substrate (ThermoScientific) according to the manufacturer’s instructions and quenched 
with 1N HCl. Absorbances were read at 450 nm in a SpectraMax M5 instrument 
(Molecular Devices) using the SoftMax Pro v5 software. The relative binding affinities of 
antibodies to respective coated antigens were determined by estimation of the 
concentration of each antibody required to achieve 50% maximal binding at saturation 
(EC50). The EC50 values were determined from fitting the binding curves to the 4 
parameter logistic (4PL) non-linear curve model using the GraphPad Prism 5 software.  
 
2.2.7.2 Competition ELISA assays 
The ability of the antibodies to compete with a biotinylated competitor antibody 
for binding to overlapping was evaluated by a competition ELISA. The competitor 
antibody was biotinylated with 20 molar excess EZ-link Sulfo-NHS-LC-Biotin following 
the manufacturer’s instructions. Excess biotin was removed by dialysis against PBS 
overnight at 4
o
C. FHA was coated at 1 µg/ml overnight at 4
o
C. Serially diluted antibodies 
incubated with a constant concentration of a biotinylated competitor antibody were added 
to the coat of FHA. The biotinylated antibody was detected with streptavidin-HRP, and 
the reaction developed using TMB substrate as above. The concentration of antibody 
required to achieve 50% inhibition (IC50) was determined from fitting the binding curves 
to the 4 parameter logistic (4PL) curve model.  
 
2.2.7.3 Western blot 
To detect antibody epitopes on FHA, 5 µg of full length FHA from B. pertussis 
TahomaI was electrophoresed in a 7.5% gel and then transferred to a PVDF membrane at 
20V, 4
o
C overnight. The membranes were blocked with PBS + 5 % milk, washed with 
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PBS-tween, incubated with 25 µg of antibody, and subsequently with HRP-conjugated 
secondary antibodies. Binding to FHA was detected using a colorimetric TMB substrate 
kit (Fisher scientific).  
 
2.2.7.4 Surface Plasmon resonance 
A BIAcore 3000 instrument (GE Healthcare) was used to quantitatively measure 
the equilibrium binding affinity of selected antibodies from the anti-FHA repertoires. The 
antibodies were covalently coupled to CM5 chips (GE healthcare) using standard amine 
coupling with a 50/50 solution of 1-ethyl-3-[3-(dimethylamino) propyl] carbodiimide 
hydrochloride and N-hydroxysuccinimide, in 100 mM sodium acetate buffer (pH 5.0) to 
achieve ~1000 - 1600 response units. The reaction was then quenched with 1.0 M 
ethanolamine-HCl, pH 8.5. Samples of antigen at different concentrations in running 
buffer (HBS, pH 7.4 0.005% Tween) were run in duplicate over the chip at 30 µl/min, 
with injection and dissociation times of 3 and 5 min respectively.  A 30 s injection of 3.6 
M magnesium chloride 1 mM Glycine, pH 2 at 30 μL/min was used to regenerate the 
surface between antigen injections. The baseline was corrected by subtracting 
simultaneous runs over a second flow cell which had been coupled with an irrelevant 
human antibody. The on (kon) and off (koff) rates were estimated by globally fitting five 
different concentrations of antigen to the 1:1 Langmuir binding equation in the 
BIAevaluation v3.0 (Pharmacia Biosensor AB) software. The dissociation constant, KD, 
was determined from the ratio of the kon and koff. 
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2.2.7.5 Expression of antibody epitopes on whole B. pertussis 
The expression of anti-FHA epitopes on live B. pertussis were assessed as 
follows. Bacteria were harvested from cultures grown on Bordet Gengou agar, 
resuspended in PBS with 5% glycerol (PBSG), and the OD600/mL adjusted to 1. The cells 
were washed with PBS and then incubated with 1 µg of each antibody in 100 µL at room 
temperature. Bound antibodies were detected after washing with a 1:500 dilution of goat 
anti human Fc Alexa Fluor 647 conjugate or F(ab’)2 goat anti mouse Fc Alexa Fluor 488 
(Jackson Immunoresearch). 10 000 events per treatment were collected on a BD SLRII 
Fortessa flow cytometer. The cell associated fluorescence for a gated population of the 
cells was determined using the FlowJo_V10 software. An anti-Bordetella LOS mouse 
IgG3 antibody (D26E) (Thermoscientific) was used as a positive control. To detect D26E 
binding to B. pertussis, the antibody was incubated with the B. pertussis cells in PBS on 
ice. Bound antibody was detected after washing with a 1:50 dilution of goat anti mouse 
Fc Alexa Fluor 488 conjugate (Jackson Immunoresearch).  
 
2.2.8 In-vitro neutralization of FHA binding activities 
2.2.8.1 Inhibition of FHA mediated hemagglutination 
The ability of the anti-FHA antibodies to inhibit the FHA meidated 
hemagglutination of red blood cells (RBC) was analyzed as follows. Serially diluted 
antibodies were first prepared in a round bottom micro-titer plate. An amount of 0.5 µg of 
FHA was then added to each well and the mixture incubated at 25°C for 30 minutes. 
Sheep RBC was added to a final concentration of 0.5% and the total volume of the 
reaction topped up to 100 µl with PBS. The preparation was incubated at 25°C for 
approximately 3 hours. The lowest amount of antibody that could inhibit 
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hemagglutination caused by FHA was taken as the neutralizing dose. Up to 30 molar 
excess antibodies were tested for FHA neutralization. 
 
2.2.8.2 Inhibition of B. pertussis binding to CHO-K1 cells 
FHA binds epithelial cells or macrophages to mediate B. pertussis adherence to 
the host. We tested the ability of isolated monoclonal antibodies to inhibit B. pertussis 
binding to CHO-K1 cells using a modified form of the adherence assay (Hazenbos, van 
den Berg et al. 1994, Cotter, Yuk et al. 1998). B. pertussis cells were labeled with FITC 
(Thermoscientific) as previously described (Hazenbos, van den Berg et al. 1994) with 
minor modifications. 10
8
 cfu/mL of bacteria were incubated in a 100 µL solution of 1 
mg/ml of FITC in 100 mM carbonate buffer, pH 9.2. The labeling was carried out at 
room temperature for 30 minutes, after which the cells were washed three times with PBS 
to remove excess FITC. To assay for inhibition of adherence of Bp-FITC to CHO-K1 
cells, 1 x 10
6
 CHO-K1 cells were first allowed to adhere in 12-well plates for 1 hour at 
37
o
C, 5% CO2. The CHO cells were maintained in media without antibiotics (DMEM 
buffer with 10% FBS). The CHO cells were then incubated with the Bp-FITC in the 
presence of 25 µg/ml antibodies. The plates were spun down to promote contact between 
the bacteria and CHO cells, and incubated for another hour at 37
o
C.  Unbound bacteria 
were washed with PBS, after which the adherent cells were scraped off and resuspended 
in 500 µL FACS buffer (PBS + 2% FBS). Bound Bp-FITC cells were analyzed by flow 
cytometry using a BD SLRII Fortessa instrument. The analysis did not differentiate 
between bound and internalized B. pertussis. 
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2.2.8.3 Inhibition of FHA binding to the macrophage receptor CR3 
The ability of the antibodies to inhibit FHA binding to the macrophage 
complement receptor 3 (CR3, CD11b/CD18, αMβ2 integrin or Mac1) was evaluated in a 
competition ELISA. FHA binding to CR3 was first confirmed using an indirect capture 
ELISA. To assess inhibition of FHA binding to CR3, high binding ELISA plates (Costar) 
were coated overnight with CR3 at 1 µg/ml in PBS. The plates were then blocked with 
blocking buffer (2% PBS-BSA). The antibodies were then serially diluted, and incubated 
for 1 hour at room temperature in the presence of a constant concentration of 247 nM 
FHA. The antibody-FHA mixtures were then added to the CR3 coat. Bound FHA was 
detected with a polyclonal mouse anti-FHA mixture and a 1:1000 dilution of rabbit α 
mouse HRP-conjugated antibodies (Invitrogen). The plates were developed with TMB 
substrate and the absorbance at 450nm recorded. The absorbance were normalized to the 
highest in each data set and plotted using the GraphPad Prism 5 software.  
 
 
2.2.8.4 Complement mediated bactericidal activity 
The ability of the anti-FHA antibodies to induce complement mediated 
bactericidal activity was assessed. B. pertussis were grown on Bordet Gengou plates for 3 
days at 37
o
C. 3 x 10
5
 bacteria were then incubated with antibody in 20 µl for 30 minutes 
at 37
o
C in a 96-well round bottom plate. Antibody depleted complement was then added 
and the mixture incubated for another hour 37
o
C. PBS with 10 mM EDTA was added to 
stop the complement reaction, and serial dilutions plated on Bordet Gengou plates. The 
plates were incubated at 37
o
C and colony forming units determined after 3 days of 
growth to assess bactericidal activity. 
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2.3 RESULTS 
2.3.1 Vaccination with aP induces high numbers of B cells responding to native FHA 
From the FHA specific responses of the individual B cells isolated, greater than 
50 unique anti-FHA B cells were identified, compared to only 5 unique anti-PTx B cells. 
The higher number of B cells responding to FHA is consistent with previous reports of a 
higher magnitude of serum responses to FHA in comparison with variability in the anti-
PTx response (Berbers, van de Wetering et al. 2013). FHA is also normally secreted at 
much higher levels than PTx by B. pertussis. The high levels of secreted FHA may be 
important for promoting adherence of phase variants which may arise in vivo, and for 
neutralizing bactericidal antibodies when attached to the bacterial cell surface (Mooi 
1988). High FHA secretion by B. pertussis may also allow FHA to act as a decoy antigen 
by presenting epitopes which allow binding by anti-FHA antibodies without effectively 
neutralizing FHA activities. 
 
2.3.2 B cell responses to FHA after aP booster vaccination arise from discrete 
germline families 
There was significant similarity in the sequences forming the framework regions 
of the 13 antibody sequences analyzed. The sequences of the antibodies, aligned using 
ClustalOmega (Sievers, Wilm et al. 2011), indicated the framework regions of the 
antibody sequences exhibited the most similarity, with the biggest differences in the 
CDRs (not shown). From an NCBI/IgBLAST search of the isolated sequences of the 
variable heavy and light chains; potential germline sequences of the isolated antibodies 
were identified by selecting germline sequences in the IMGT database with the highest 
score. From the identified parental germline sequences, the anti-FHA antibodies had 
discrete parental clones, with a few antibodies sharing the same parental germline 
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sequences. Within both the variable light and heavy chain regions, the IgH and IgΚ V3 
gene segments were predominant, while the D3 gene segment of the heavy chain was the 
most utilized. The J5 gene segment occurred more in the heavy chain, while J1 and J2 
were used equally in the light chain (Figure 2.1). Initial studies of VDJ gene segment 
usage revealed pairing preferences exist among gene segments (Reth, Jackson et al. 
1986). Subsequently, Volpe and Kepler (Volpe and Kepler 2008) provided statistical 
analysis of preferred D-J gene segment pair preferences after analyzing almost 6500 
human immunoglobulin heavy chain genes. They showed that 5’D segments showed 
increased frequency of pairing with the 3’- most J segments. Furthermore, some 3’ D 
segments paired more frequently with the closest 5’ J segments (1 to 4). From their 
observations, they concluded multiple D-J rearrangements occur prior to the formation of 
a complete VDJ gene. Although we analyzed only 13 antibodies, we observed a few 
antibodies also showed pairing between the 5’ D segment and the 3’ J segment or vice 
versa. The small data set of antibodies characterized however limits the extent of analysis 
of pairing frequencies.  
 We also analyzed the sequences at the level of the genes and alleles (Figure 2.2). 
Within the heavy chain, the 43D*03 gene and allele combination in the V segment was 
the most represented. Also, the 19*01 and 26*01 in the D segment, and the 5*02 in the J 
segment were most utilized. Within the light chain, the 20*01 and 1*01 combinations 
were most utilized in the V and J gene segments respectively. The number of mutations 
in the amino acids of the isolated sequences compared to the putative parental germline 
sequences ranged from 5 to 34 within the V regions. The D and J regions on the other 
hand, had few changes with 0 to 4 mutations compared to the putative germline 
sequences (Tables 2.2 and 2.3). Since the antibody isolation maintained the original 
pairing of the heavy and light chains, the full VH or Vĸ sequences were then aligned 
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using Phylogeny.fr. The phylogenetic tree generated after combining the full VH and VL 
sequences also suggested the antibodies descended from discrete germline families 
(Figure 2.3). This study is the first to provide insight into the anti-FHA antibody 
repertoire after pertussis vaccination. The sequence information obtained during the 
formation of anti-FHA antibodies in the immune repertoire can potentially be used to 
guide efforts to generate stable and/or humanized antibodies for in-vivo therapeutic use.  
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Figure 2.1: VDJ gene family usage of the anti-FHA heavy and light chains. 
Each panel represents the number of unique VDJ patterns existing in the heavy and light 
chains of the thirteen isolated anti-FHA antibody sequences. The color legend shows the 
number of antibodies with the corresponding VDJ genes. The white space represents 
absent VDJ recombination types in the repertoire. 
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Figure 2.2: Gene and allele family usage of the isolated anti-FHA antibodies. 
Genes and alleles are shown in the pie chart in the a*b format. The number and percentage of antibodies represented is 
indicated below each gene and allele used. 
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Table 2.2: VDJ germline family usage of the isolated anti-FHA antibody light chains. 
Antibody Chain Germline V Germline D Germline J Mismatches 
D4.K Light IGKV1-9*01 - IGKJ4*01  12,0 
A9.K Light IGKV3-20*01 - IGKJ1*01  11,1 
G10.K Light IGKV3-20*01 - IGKJ1*01  9,0 
H2.K Light IGKV3-20*01 - IGKJ5*01  9,1 
C12.K Light IGKV3-20*01 - IGKJ2*01  9,0 
E10.K Light IGKV3-20*01 - IGKJ1*01  12,1 
H6.K Light IGKV3-15*01 - IGKJ3*01  21,1 
D12.K Light IGKV3-20*01 - IGKJ2*01 9,0 
B6.K Light IGKV3-20*01 - IGKJ2*01  12,0 
C2.K Light IGKV4-1*01 - IGKJ4*01  13,0 
E7.K Light IGKV3-15*01 - IGKJ3*01  23,1 
B5.K Light IGKV1-39*01,IGKV1D-39*01 - IGKJ2*02  34,2 
G2.K Light IGKV3-20*01 - IGKJ1*01  5,0 
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Table 2.3: VDJ germline family usage of the isolated anti-FHA antibody heavy chains. 
Antibody Chain Germline V Germline D Germline J Mismatches 
D4.VH Heavy IGHV3-30-3*03,IGHV3-30*04 IGHD6-19*01 IGHJ5*02 18,1,1 
A9.VH Heavy IGHV4-59*01 IGHD3-9*01 IGHJ4*02  20,0,0 
G10.VH Heavy IGHV3-30-3*01 IGHD6-19*01 IGHJ6*02  18,0,1 
H2.VH Heavy IGHV5-10-1*03 IGHD5-24*01  IGHJ2*01  18,0,1 
C12.VH Heavy IGHV3-43D*01 IGHD1-26*01  IGHJ5*02 23,0,0 
E10.VH Heavy IGHV1-46*03 IGHD6-19*01  IGHJ4*02  7,0,0 
H6.VH Heavy IGHV3-30*02 IGHD3-10*02  IGHJ1*01  25,0,0 
D12.VH Heavy IGHV3-43D*01 IGHD1-26*01 IGHJ5*02  23,0,0 
B6.VH Heavy IGHV3-43D*01 IGHD1-26*01  IGHJ5*02  24,0,0 
C2.VH Heavy IGHV4-39*01 IGHD3-3*02  IGHJ5*02  21,0,0 
E7.VH Heavy IGHV3-30*02 IGHD3-10*02  IGHJ1*01  25,0,0 
B5.VH Heavy IGHV4-30-4*01 IGHD3-10*01  IGHJ4*02  24,0,1 
G2.VH Heavy IGHV3-30*18 IGHD2-15*01  IGHJ6*02  21,0,4 
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Figure 2.3: Phylogenetic tree of isolated anti-FHA antibodies. 
The phylogenetic tree was constructed from the VH and Vk gene sequences of the isolated anti-FHA antibodies using 
phylogeny.fr. The tree shows the diversity of germline families of the antibodies. The length of a branch is proportional to the 
number of mutations in the antibody compared to a putative germline. 
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2.3.3 Antibody expression and stability 
To select anti-FHA antibodies for further characterization, the thirteen anti-FHA 
antibodies were screened for specific activity, estimated as the ratio of FHA binding to 
expression levels (Fig 2.4 A). Six isolates with varying FHA specific activity, which are 
representative of different phylogenetic families were subsequently purified for further 
characterization (Fig 2.4 B). The different antibodies exhibited low expression levels in 6 
well culture plates, ranging from 0.01 to 0.37 µg/mL (Table 2.4, column 2). Typical 
yields for therapeutic antibodies are in the range of g/L after optimization (Wurm 2004). 
The low yields of these antibodies on the laboratory scale may be due to low transfection 
efficiency in the 6-well plate format, or to inherently poor expressing strains due to the 
DNA sequence. Although D12, G10, H2 and H6 exhibited the lowest expression levels 
from the 6-well plate format, their expression levels did not correlate with expression 
levels from T-150 flasks. Yields obtained for these antibodies from T-150 flasks were 
approximately 2 µg/mL (not shown). From a therapeutic standpoint, relevant low 
expressing antibodies may need further engineering for increased expression levels. 
Further studies on improving yields can be done by testing different transfection 
conditions and/or expressing the antibodies in suspension cultures in bioreactors. 
Antibodies selected by phage display appear to express better, and may indicate a 
methodological bias for selection of inherently better folding antibodies. Yields of 
relevant antibodies from this study could therefore be improved significantly through in-
vitro sequence engineering to select for better expressing variants (Mason, Sweeney et al. 
2012).  
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Figure 2.4: Selection and purification of anti-FHA antibodies. 
A) Specific activity of anti-FHA antibodies. Binding of antibodies to FHA from crude culture supernatant after transient CHO 
cell expression was monitored using an FHA capture ELISA. The antibody concentrations in the crude culture supernatant 
were determined using an Fc capture ELISA with irrelevant monoclonal antibody as a standard to estimate the antibody 
concentrations. The specific activity was determined from the ratio of FHA binding (A450nm) to the estimated concentration 
of antibody. Antibodies marked with * were selected for further characterization. B)  Gel electrophoresis of selected purified 
antibodies in reduced and non-reduced conditions. Molecular weights (MW) in kDa of the standard are indicated. The antibody 
heavy and light chains are at the expected sizes of ~50 and 25 kDa respectively in reducing conditions. In non-reducing 
conditions, the antibody sizes are ~150 kDa. 
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To examine the thermal stability of the selected anti-FHA antibodies, the 
antibodies were heated fro-m 25
o
C to 90
o
C in the presence of the protein thermal shift 
dye (Life Technologies). The melting temperature (Tm) was determined from fitting the 
fluorescence data normalized to the maximum and minimum fluorescence. The six anti-
FHA antibodies also exhibited diverse thermal stability profiles (Figure 2.5) with melting 
temperatures ranging from 64.45 ± 0.04 to 74.38 ± 0.06 (Table 2.4). During development 
of antibodies for therapeutic use, antibodies with superior biophysical properties such as 
high thermostability are selected Relevant antibodies identified in this study with low 
stability can be engineered for increased thermostability. 
 
 
Figure 2.5: Melting temperature profile of selected purified anti-FHA antibodies.  
The anti-FHA antibodies, each at a concentration of 100 µg/ml, were heated up to 90
o
C 
in PBS with the protein thermal shift dye. The Tm was determined from fitting the data to 
a sigmoidal four parameter logistic (4PL) non-linear regression model after normalizing 
the data to the maximum and minimum fluorescence. Data after the maximum 
fluorescence are not shown. 
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Table 2.4: Expression levels and stability of anti-FHA antibodies 
Antibody  Expression level (µg/ml) Melting temperature, Tm (
o
C) 
A9 0.14 ± 0.005 70.89 ± 0.02 
B6 0.37 ± 0.05 67.36 ± 0.03 
D12 0.02 ± 0.01 64.45 ± 0.04 
G10 0.06 ± 0.01 73.11 ± 0.05 
H2 0.03 ± 0.002 74.19 ± 0.04 
H6 0.03 ± 0.0004 74.38 ± 0.06 
 
 
2.3.4 Purification of FHA from Bordetella sp. 
High yields of up to 80 mg/L have been reported for FHA purified from different 
strains of B. pertussis using various chromatographic techniques (Sato, Cowell et al. 
1983, Wong and Skelton 1989, Ozcengiz, Kilinc et al. 2004). The interaction of B. 
pertussis FHA with the glycoconjugate heparin is one of the techniques exploited for its 
purification. Using heparin affinity chromatography as described (Menozzi, Gantiez et al. 
1991), FHA from two strains of B. pertussis (the recent clinical isolate D420 and the 
classical strain TahomaI) and B. bronchiseptica strain RB50 were purified. The FHA 
from B. pertussis and B. bronchiseptica were electrophoretically similar with B. 
bronchiseptica FHA running slightly larger due to its slightly larger nucleotide sequence 
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as previously reported (Jacob-Dubuisson, Kehoe et al. 2000, Inatsuka, Julio et al. 2005). 
The yields of FHA in this study from the heparin affinity were approximately 80-fold 
lower than reported using ionic or hydrophobic interactions (Sato, Cowell et al. 1983, 
Wong and Skelton 1989, Ozcengiz, Kilinc et al. 2004) (Table 2.5).  FHA from B. 
parapertussis could also not be purified by heparin affinity. The apparent lack of affinity 
of B. parapertussis FHA with heparin is consistent with the inability of heparin to inhibit 
B. parapertussis binding to  epithelial cells, in contrast to B. pertussis (van den Akker 
1998). 
 
Table 2.5: Yields of FHA from Bordetella sp. using heparin affinity chromatography 
Bordetella strain Estimated FHA yields (mg/L) 
B. pertussis strain D420  
(recent clinical isolate) 
4.32 ± 3.09 
B. pertussis strain TahomaI 2.84 ± 1.59 
B. bronchiseptica strain RB50 0.73 ± 0.01 
B. parapertussis strain 12822 ND 
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2.3.5 B. pertussis anti-FHA antibodies after aP booster immunization bind FHA 
with high affinity  
To assess the binding of the antibodies to the respective antigens, indirect ELISAs 
were used to assess the apparent binding affinities, based on the concentration of 
antibody resulting in 50% of the maximum signal also called the 50% effective 
concentration (EC50). The anti-FHA antibodies exhibited nM binding affinity to purified 
FHA from different strains of B. pertussis (Table 2.6, columns 2-4). There were however 
differences in the estimated affinities, with H6 showing the lowest affinity for FHA. 
Surface plasmon resonance (SPR), the industry standard for determination of binding 
affinities was then used to determine the on (kon) and off (koff) rates of the B6 and H6 
anti-FHA antibodies (Figure 2.6). The affinities determined from antibody binding to B. 
pertussis strain D420 FHA, showed B6 had a Kd of 0.19 ± 0.04 nM, approximately six-
fold higher affinity than H6, with a Kd of 1.27 ± 0.05 (Table 2.6, column 4). The 
estimated affinities are both consistent with expected affinities in the range of 10-0.1 nM 
for antibodies in the circulating immune repertoire (Foote and Eisen 1995).  
Other Bordetella species such as B. bronchiseptica and B. parapertussis also 
cause whooping cough, although B. parapertussis is better able to successfully infect and 
cause disease in immunocompromised humans (Watanabe and Nagai 2004). FHA is one 
of the common virulence factors produced by the Bordetella strains, in addition to 
pertactin, adenylate cyclase toxin, tracheal cytotoxin and dermonecrotic toxin (Mattoo, 
Foreman-Wykert et al. 2001). The FHA proteins produced by B. bronchiseptica strain 
RB50 and B. parapertussis strain 12822, are very similar to that of B. pertussis strain 
TahomaI, with internal variations in sequence (Kloos, Mohapatra et al. 1981, Parkhill, 
Sebaihia et al. 2003) and are important for adherence and invasion of a variety of cells 
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lines in-vitro (Ewanowich, Sherburne et al. 1989, van den Akker 1998, Ishibashi, Relman 
et al. 2001, Julio, Inatsuka et al. 2009).  
The apparent binding affinities (EC50) were compared for the six anti-FHA 
antibodies to purified FHA from two strains of B. pertussis (TahomaI – laboratory B. 
pertussis strain; D420 – recent B. pertussis clinical isolate), and one strain of B. 
bronchiseptica (strain RB50). The B. pertussis anti-FHA antibodies similarly bound FHA 
from B. bronchiseptica with high nM affinity (Figure 2.7, Table 2.6, column 5). This 
agrees with reports that anti-FHA antibodies in B. pertussis induced serum cross react 
with B. bronchiseptica (Goebel, Zhang et al. 2009). The B6 antibody however showed 
reduced affinity to B. bronchiseptica FHA, suggesting its epitope may not be fully 
conserved in B. bronchiseptica FHA. FHA from B. parapertussis could however not be 
purified by heparin affinity. The apparent lack of affinity of B. parapertussis FHA with 
heparin is consistent with the inability of heparin to inhibit B. parapertussis binding to  
epithelial cells, in contrast to B. pertussis (van den Akker 1998). Binding of the six B. 
pertussis anti-FHA monoclonal antibodies was therefore assessed to whole cell cultures 
or cell culture supernatant of B. parapertussis using an indirect ELISA. The binding 
affinities to whole cells were in the range of 0.005 to 0.11 nM, (Table 2.6, column 6). 
The estimates of the affinities may however not be definite due to the longer time need to 
generate the signal in the ELISAs. The H2 and H6 antibodies however appeared to show 
more specific binding compared to the other four antibodies to the B. parapertussis 
culture supernatant (not shown).  Polyclonal antibodies to B. pertussis FHA and other 
antigens have also been shown to weakly cross-react with B. parapertussis bacterial 
suspensions although the two FHA proteins may be immunologically distinct (Khelef, 
Danve et al. 1993). The slightly stronger binding of H2 and H6 to B. parapertussis 
culture supernatant would also be consistent with their major binding epitopes being on 
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the C-terminus of FHA (discussed below). B. pertussis and B. parapertussis share 85.7% 
and 87.5% sequence identity and similarity respectively. The C-terminus of B. 
parapertussis FHA however most closely resembles B. pertussis FHA, since the N-
terminus of B. parapertussis FHA has additional sequences. 
 
 
Figure 2.6: Biacore sensograms for B6 and H6 binding to B. pertussis D420 FHA.  
The A) B6 and B) H6 antibodies were immobilized on a CM5 chip to a level of ~900 and 
1600 RU respectively. B. pertussis strain D420 FHA was then injected at the indicated 
concentrations at a flow rate of 30 µL/min. Baseline correction was performed by 
subtracting simultaneous runs over a second flow cell with an isotype control protein 
immobilized.  The antibody binding affinity (Kd) was determined from the ratio of the 
off-rate (koff) to the on-rate (kon), after globally fitting the binding curves to the 1:1 
Langmuir model in the BIAevaluation v3.0 software.   
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Figure 2.7:  Binding affinity of the selected anti-FHA antibodies to purified FHA from B. pertussis and B. bronchiseptica 
FHA.  
Purified FHA from the Bordetella sp. indicated was coated at a concentration of 1 µg/mL. Serially diluted antibodies were 
added to FHA coat and binding detected with HRP conjugated anti-human Fc antibodies after TMB substrate development. 
Binding curves were fit to the four parameter logistic (4PL) non-linear equation using GraphPad prism 5 to estimate EC50 
values. The EC50 are shown as log10 of the estimated mean values. The ELISAs were repeated at least twice with similar 
results. Error bars represent the standard error of the mean from replicate experiments. 
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Table 2.6: Estimated affinities for anti-FHA antibodies binding to FHA from major to Bordetella species. 
Antibody 
EC50, nM ± SE 
B. pertussis strain 
165 
EC50, nM ± SE 
B. pertussis strain 
TahomaI 
EC50, nM ± SE 
(Kd, nM ± SE) 
B. pertussis strain 
D420 
EC50, nM ± SE 
B. bronchiseptica 
strain RB50 
EC50, nM ± SE 
B. parapertussis strain 
12822
+
 
A9 0.07 ± 0.02 0.06 ± 0.01 0.01 ± 0.004 0.02 ± 0.002 0.003± 0.001 
B6 0.16 ± 0.06 0.03 ±0.01 
0.01 ± 0.005 
(0.19 ± 0.04) 
0.19 ± 0 0.003± 0.002 
D12 0.08  ± 0.03 0.01 ± 0.004 0.006 ± 0.002 0.03 ± 0.002 0.003 ± 0.002 
G10 0.27 ± 0.05 0.03 ± 0.006 0.02 ± 0.003 0.03 ± 0.003 0.005 ± 0.004 
H2 0.05 ± 0.02 0.02 ± 0.006 0.01 ± 0.005 0.02 ± 0.002 0.03 ± 0.03 
H6 0.30 ± 0.05 0.13 ± 0.01 
0.11 ± 0.05 
(1.27 ± 0.05) 
0.37 ± 0.002 0.004 ± 0.17* 
+
 - EC50 determined from antibodies binding to whole B. parapertussis cells. 
* - Determined from one ELISA with two replicates. The other EC50 are from at least two independent experiments each with 
two replicates.
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2.3.6 Neutralizing anti-FHA antibodies after aP vaccination inhibit B. pertussis FHA 
mediated binding activities 
FHA has multiple binding specificities, with at least three binding domains 
responsible for B. pertussis adherence to host cells. FHA interacts with glycoconjugates 
on the surface of eukaryotic cells (Brennan, Hannah et al. 1991, Prasad, Yin et al. 1993) 
to mediate attachment. The FHA mediated hemagglutination of red blood cells (RBC) 
involves FHA binding to surface glycoconjugates and is inhibited by glycoconjugates 
such as heparin (Menozzi, Mutombo et al. 1994). This suggests inhibition of FHA 
mediated hemagglutination may directly correlate with inhibition of FHA binding and 
subsequently B. pertussis adhesion to host cells. Of the six selected anti-FHA antibodies, 
B6 and H6 were able to inhibit FHA mediated hemagglutination (Figure 2.8A). H6 more 
potently inhibited hemagglutination at an antibody:FHA molar ratio of 0.97 ± 0.31, while 
B6 inhibition was at a ratio of 20.5  ± 5.08 (Figure 2.8B). The rest of the antibodies tested 
did not inhibit hemagglutination up to 30 molar excess concentrations. Leininger et al. 
(Leininger, Bowen et al. 1997) identified two immunodominant domains on FHA 
recognized by antibodies in sera from infants immunized with either aP or wP vaccines or 
from patients with pertussis disease. Leininger et al. also observed that some antibodies 
that bound the C-terminal domain, more potently neutralized the FHA mediated 
hemagglutination of RBC. On the other hand, some antibodies which recognized the N-
terminus of FHA weakly inhibited the hemagglutination. The more potent ability of H6 to 
inhibit FHA mediated hemagglutination therefore indicated its epitope may be closer to 
the C-terminal domain of FHA, while the weaker inhibition of hemagglutination by B6 
indicated its epitope lies closer to the N-terminus. Elucidation of the B6 and H6 epitopes 
would therefore supplement knowledge about the relationship of the structure of FHA 
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and how this relates to hemagglutination. This information would also lead to better 
understanding of the FHA mediated adherence of B. pertussis to cells in-vivo. 
 
 
 
Figure 2.8: Inhibition of FHA mediated hemagglutination of RBC.  
A) B6 and H6 anti-FHA antibodies inhibit FHA mediated hemagglutination. FHA was 
added to the serially diluted antibodies and the mixture incubated at 25°C for 30 minutes. 
Sheep RBC was added to a final concentration of 0.5% and the total volume of the 
reaction topped up to 100 µl with PBS. The lowest amount of antibody that could inhibit 
hemagglutination caused by FHA was taken as the neutralizing dose. The rest of the anti-
FHA antibodies tested did not inhibit FHA hemagglutination up to 30 M excess. B) 
Molar neutralization of FHA mediated hemagglutination. 
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FHA mediates B. pertussis adhesion to and invasion of epithelial cells in-vitro 
(Tuomanen and Weiss 1985, Urisu, Cowell et al. 1986, van den Berg, Beekhuizen et al. 
1999, Ishibashi, Relman et al. 2001, Ishibashi and Nishikawa 2002). Anti-FHA 
antibodies have also been shown to be important for inhibiting the attachment of B. 
pertussis to mammalian cells in-vitro (Sato, Izumiya et al. 1981, Tuomanen, Zapiain et al. 
1984, van den Berg, Beekhuizen et al. 1999). To assess the relevance of the isolated anti-
FHA antibodies in inhibiting B. pertussis binding to epithelial cells, FHA binding to 
CHO-K1 epithelial cells was first confirmed in a FACS assay. FHA was found to bind to 
CHO-K1 cells in a dose dependent manner (Figure 2.9A) and also increased the 
adherence of B. pertussis to the CHO-K1 cells when added exogenously (Not shown). 
The ability of five of the selected anti-FHA antibodies were then tested for inhibition of 
B. pertussis binding to CHO-K1 epithelial cells. Using B. pertussis conjugated to FITC, 
and an MOI of approximately 100, B6 was found to inhibit binding to the CHO-K1 cells 
(Figure 2.9B). B6 may therefore bind an epitope sufficient for inhibition of B. pertussis 
binding to CHO-K1 epithelial cells. FHA interaction with glycoconjugates and integrins 
on the surface on epithelial cells is thought to be important for B. pertussis adhesion 
(Menozzi, Gantiez et al. 1991, Menozzi, Mutombo et al. 1994, Ishibashi, Relman et al. 
2001) and B6 may inhibit these interactions. Further characterization of the B6 epitope 
showed it binds strongly bound an N-terminal fragment of FHA. An N-terminal epitope 
of B6 is also in agreement with the study by Leininger which identified neutralizing N-
terminal antibodies which weakly inhibit FHA mediated hemagglutinatoin (described 
below). A previous study also identified an antibody to the N-terminus of FHA which 
inhibited B. pertussis binding to epithelial cells (Leininger, Probst et al. 1993). More in 
depth analysis of the B6 epitopes would therefore contribute to information on the 
functional binding site of FHA to epithelial cells. 
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Figure 2.9: Inhibition of B. pertussis adhesion to CHO-K1 epithelial cells.  
A) Biotinylated FHA binds to CHO-K1 epithelial cells in a dose dependent manner. Dilutions of biotinylated FHAwere added 
to CHO-K1 cells. Bound FHA was detected with PE conjugated streptavidin and assessed by flow cytometry.  B) Anti-FHA 
antibodies inhibit B. pertussis adhesion to CHO-K1 epithelial cells. CHO-K1 epithelial cells were incubated with B. pertussis 
cells conjugated to FITC (Bp-FITC) at an MOI of 100 in 12-well culture plates. To assess inhibition of binding, 2.5 µg of the 
antibodies were pre-incubated with Bp-FITC. Bound B. pertussis cells after washing were detected by flow cytometry after 
scraping the cells off. The assays were repeated twice except for H6, and error bars represent the standard error of the mean 
from replicate experiments. H6 inhibition of Bp-FITC binding was performed once due to limited antibody.
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In addition to binding to epithelial cells, FHA also mediates B. pertussis adhesion 
to host macrophages by interacting with integrins such as the macrophage CR3 receptor 
(Relman, Tuomanen et al. 1990, Ishibashi, Claus et al. 1994). FHA binding to the soluble 
CR3 receptor was confirmed in a capture ELISA (Figure 2.10A). The ability of the anti-
FHA antibodies to inhibit FHA binding to soluble CR3 was then assessed in a 
competition ELISA assay. H6 more potently inhibited the interaction of FHA with CR3, 
however, the other antibodies tested also weakly inhibited FHA binding to CR3 (Figure 
2.10B). The absorbance at 450nm was normalized to the highest absorbance in each data 
set to account for the amplified signal observed in the samples with antibody added. The 
amplified signal in samples with antibody added relative to the no antibody control may 
have been due to non-specific binding of other antibodies in the secondary GαR HRP 
antibody to the human antibodies. Other tested secondary antibodies exhibited non-
specific inhibition of FHA binding. 
Initial studies implicated the FHA RGD motif in mediating the interaction of FHA 
with CR3 to enhance B. pertussis attachment to macrophages (Ishibashi, Claus et al. 
1994). Further studies using variants of B. pertussis containing an RAD amino acid 
substitution at the RGD motif, suggests the RGD motif may only play a partial role in 
mediating B. pertussis attachment to macrophages in-vivo (Hellwig, Hazenbos et al. 
1999). B. pertussis attachment to host macrophages via the interaction of FHA with CR3 
may however allow internalization of the bacteria which may serve as a reservoir, and 
prolong clinical manifestations of the disease (Ishibashi, Claus et al. 1994, Hellwig, 
Hazenbos et al. 1999). Disruption of the FHA-CR3 interaction by neutralizing anti-FHA 
antibodies may therefore be useful for reducing bacterial persistence. Further in-vitro and 
in-vivo studies are therefore needed to assess the role of antibodies like H6 in reducing B. 
pertussis entry and survival in CR3 bearing cells such as macrophages.  
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Figure 2.10: Inhibition of FHA binding to the macrophage CR3 receptor 
A) FHA binding to the macrophage CR3. FHA was serially diluted and added to a coat of 
CR3 at 1 µg/ml. Bound FHA was detected using polyclonal mouse anti-FHA antibody 
and goat-anti-mouse HRP. The control wells had no CR3 coated to detect non-specific 
binding of FHA to the coat. B) Antibody mediated inhibition of FHA binding to CR3. 
Serially diluted antibodies with a constant concentration of 247 nM FHA were added to a 
coat of CR3 at 1 µg/ml. Bound FHA was detected using polyclonal mouse anti-FHA 
antibody and a polyclonal rabbit anti-mouse HRP secondary. The absorbance at 450nm 
was normalized to the highest absorbance in each data set to account for amplified signal 
observed in the samples with antibody added compared to the no antibody control. 
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2.3.7 Anti-FHA antibodies after aP vaccination recognize immunodominant epitopes 
in the N and C terminus of FHA 
The 220kDa active form of FHA is derived from a large 370 kDa precursor, with 
further proteolytic breakdown products which are thought to play different roles during 
infection (Domenighini, Relman et al. 1990). Domenighini et al (Domenighini, Relman et 
al. 1990) have suggested a scheme for the proteolytic digest of FHA from its precursor 
utilizing immunoblot analysis and sequencing of the FHA fragments. The ~150 doublet, 
125, 75 and 58 kDa fragments are attributed to the C-terminus of FHA, while the 98 kDa 
fragment is attributed to the N-terminus. Studies have subsequently shown that the C-
terminal ~500 amino acid end of FHA designated as the type I region, is 
immunodominant after either immunization or infection with B. pertussis (Leininger, 
Bowen et al. 1997, Piatti 1999). Neutralizing antibodies induced to the type I region FHA 
strongly inhibit FHA mediated hemagglutination (Leininger, Bowen et al. 1997). A 
second immunogenic domain in FHA, located in the N-terminus, designated as the type II 
region, was also identified by Leininger et al. (Leininger, Bowen et al. 1997). 
Neutralizing antibodies induced to the type II region however exhibited a weaker 
inhibition of FHA mediated hemagglutination. The more potent inhibition of FHA 
mediated hemagglutination by H6, and weaker inhibition by B6 gave an indication that 
H6 binds the C-terminus, while B6 binds the N-terminus.   
Using a western blot, we directly assessed binding of the antibodies to the FHA 
fragments produced after SDS gel electrophoresis. The A9, B6, D12, and G10 anti-FHA 
antibodies strongly recognized smaller FHA fragments in the blot, as well as larger 
precursor forms of FHA (Figure 2.11). Recognition of the ~150 kDa doublet attributed to 
the C terminal portion of FHA would be consistent with results that suggest the C 
terminal end of FHA is immunodominant after vaccination or disease, and suggests these 
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antibodies may have linear elements to their epitopes. However, these antibodies also 
appeared to recognize an ~100 kDa fragment, which could be the designated N-terminal 
fragment (Domenighini, Relman et al. 1990). The results of the hemagglutination assay 
putatively assigning B6 to the N-terminus was therefore conflicting with the ability of B6 
to recognize fragments attributed to both the N and C-termini. 
 
 
Figure 2.11: Western blot analysis of binding of the isolated anti-FHA antibodies to 
FHA fragments.  
An amount of 5µg of FHA from B. pertussis was electrophoresed in a 7.5% gel and 
transferred to a PVDF membrane under standard conditions. Strips of PVDF containing 
FHA were incubated with the anti-FHA antibodies and binding to the FHA fragments 
detected with a secondary HRP conjugated antibody. The blots were developed with a 
chromogenic substrate 
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To further clarify the regions on FHA bound by the isolated antibodies, we assessed 
binding to recombinant FHA fragments produced using the pMAL-c expression system 
in E. coli (Figure 2.12). The use of the 861-1655 (pMAL 83) and 1655-2111 (pMAL 85) 
fragments have been previously described (Leininger, Bowen et al. 1997). The 1-435 and 
1156-1295 fragments were generated in this study. The A9, B6, D12 and G10 antibodies 
bound the 1-435 fragment with high affinities in the range of 0.1-0.36 nM. These 
antibodies however bind more tightly to full length FHA with affinities in the range of 
0.01-0.06 nM, suggesting a loss affinity to the 1-435 fragment. This result suggests the 
epitopes of A9, B6, D12 and G10 are located close to the N-terminus, but their epitopes 
may span amino acids not included in the 1-435 fragment. Further studies using longer 
recombinant FHA fragments are therefore needed to assess the full binding epitopes of 
these antibodies.  None of the antibodies bound the 861-1655 fragment which contains 
the RGD sequence (Saukkonen, Cabellos et al. 1991, Ishibashi, Claus et al. 1994) nor the 
1156-1295 fragment which is within the carbohydrate binding domain (Prasad, Yin et al. 
1993). A9, B6, D12 and G10 however also very weakly recognized the 1655-2111 
fragment located in the C-terminus of the mature FHA (Table 2.7). The strong reactivity 
of the A9, B6, D12 and G10 antibodies to the N-terminal 1-435 fragment, and weak 
reactivity with the C-terminal 1655-2111 fragment in the ELISAs was therefore 
consistent with the observation of binding to both N and C terminal fragments in the 
immunoblot. Cross reactivity of antibodies to both the N- and C-termini of FHA has also 
been previously observed (Leininger, Bowen et al. 1997), and suggests the antibodies 
may have secondary binding epitopes.  
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Figure 2.12: Recombinant FHA fragments used to probe the antibody binding epitopes. 
A) Schematic of recombinant FHA fragments for antibody epitope mapping. The open 
box represents the complete ~3590 amino acid open reading frame (ORF) of the 
precursor FHA. The putative end of the ORF to form the mature 220 kDa FHA is 
indicated. Hatched smaller boxes represent the recombinant FHA fragments produced as 
MBP fusions in E. coli. Amino acid residue numbers are indicated. B) Representative 
ELISA for antibodies binding to the FHA 1-435 fragment. Serially diluted antibodies 
were added to a coat of the purified FHA fragment. Bound antibodies were detected with 
a polyclonal anti-human Fc HRP antibody. 
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Table 2.7: Reactivity of isolated antibodies with recombinant FHA fragments. 
 
Antibody/FHA 
fragment 
1-435  861-1655  
(pMAL 83) 
1156-1295 1655-2111  
(pMAL 85) 
A9 ++ (0.36) ± - ± 
B6 +++ (0.36) ± - ± 
D12 +++ (0.29) ± ± ± 
G10 ++ (0.14) - - - 
H2  - ± - + (0.01) 
H6  - ± - + (0.07) 
P-IVIG + + ± ++ 
Polyclonal 
mαFHA 
+ + ± +++ (0.8) 
Reactivity was graded as very strong (+++), strong (++), weak (+), equivocal (±) or 
negative (-) based on the intensity of the ELISA signal and ability to reach saturation at 
the highest concentration tested. The estimated affinities (EC50) for antibodies which 
exhibited saturating binding curves are indicated in parentheses. pMAL 83 and 85 kindly 
provided by Dr. Camille Locht. 
 
 
The secondary binding epitopes may be because of repeat sequences present in 
FHA. The first repeat region (R1) consists of about 38 tandem copies of a 19-residue 
repeat, located approximately at the N-terminal end of FHA. Next to the R1 region, is a 
smaller repeat region similar to R1 designated B1 (Makhov, Hannah et al. 1994, Jacob-
Dubuisson, Kehoe et al. 2000, Kajava, Cheng et al. 2001). Antibodies to FHA have also 
been identified which recognize an amino acid sequence repeat in the R1 and B1 regions 
(Leininger, Bowen et al. 1997).  The second repeat region (R2) consists of 13 tandem 
copies of a 19-residue repeat, and is located approximately at the C-terminal end of FHA 
(Makhov, Hannah et al. 1994, Jacob-Dubuisson, Kehoe et al. 2000, Kajava, Cheng et al. 
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2001). Next to R2, is the B2 region, also containing similar repeat sequences. Further 
studies using peptide scanning analysis can therefore be used to identify specific 
sequences to which the antibodies bind. The ability of the A9, B6, D12, G10 and H2 anti-
FHA antibodies to recognize the SDS denatured B. pertussis TahomaI FHA fragments in 
the western blot also suggests these antibodies may recognize chemically modified forms 
of FHA. This is because the toxins in aP vaccines are stabilized by addition of cross-
linkers such as glutaraldehdye or formalin,  a process which can change the physical and 
immunological properties of the proteins (Nencioni, Volpini et al. 1991). 
While H2 weakly recognized the FHA fragments in the western blot, H6 did not 
recognize any of the FHA fragments in the immunoblot, suggesting the H6 epitope may 
be conformational, or it only recognizes the native form of FHA. H2 and H6 also 
recognized the 1655-2111 fragment with affinities of approximately 0.02 and 0.07 nM 
respectively. The estimated binding affinities for H2 and H6 binding the 1655-2111 
fragment were similar to binding the full length FHA (Table 2.7), indicating their primary 
epitopes lie close to the C-terminus. The polyclonal mαFHA also strongly bound the 
1655-2111 fragment with an estimated affinity of 0.8 nM. The strong binding therefore 
suggested most of the antibodies in the polyclonal preparation predominantly bound the 
C-terminal end of FHA. There was a marked reduction in the absorbance at saturation for 
H2 and H6 compared to the polyclonal mαFHA binding to the 1655-2111 fragment (not 
shown). In ELISAs with the full length FHA, H2 and H6 reach high absorbance at 
saturation, similar to the polyclonal mαFHA. This suggested while the primary epitopes 
of H2 and H6 may be close to the C-terminus, they may also have other secondary 
epitopes on FHA. We also used a competition ELISA with biotinylated H6 to assess 
whether the antibodies compete with H6 for similar epitopes. The antibodies weakly 
competed with H6 binding for to FHA, suggesting an overlap in their epitopes, however, 
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H2 and the polyclonal m α FHA inhibited H6 binding the most (Figure 2.13), further 
suggesting H2 and H6 may share a primary epitope in close proximity.  The strong 
competition with polyclonal m α FHA further indicates the H2 and H6 epitopes are closer 
to the C-terminus.  
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Figure 2.13: Competition of binding of the anti-FHA antibodies with biotinylated H6.   
Representative ELISA for inhibition of biotinylated H6 binding to FHA. Serially diluted 
anti-FHA antibodies were incubated with a constant concentration of biotinylated H6 
anti-FHA. Bound biotinylated H6 was detected with streptavidin-HRP.  
 
 
 
The lack recognition of FHA fragments in the western blot by H6 could be due to 
the presence of conformational epitopes at/close to the C-terminus. The C-terminal 
domain is thought to have globular structure (Makhov, Hannah et al. 1994, Mazar and 
Cotter 2006), and may therefore present conformational epitopes which not detected in 
immunoblots due to linearization from the SDS. Alternatively, a conformational epitope 
may be formed by the N- and C-termini. The current model of FHA topology and 
maturation hypothesizes that prior to the secretion of mature FHA, the C-terminal domain 
of the precursor FHA remains intracellular to allow the mature C-terminus to achieve its 
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proper conformation. FHA therefore would initially form a hairpin which would bring the 
N- and C-termini close together (Mazar and Cotter 2006, Noël, Mazar et al. 2012).  
 
2.3.8 Anti-FHA antibodies after aP vaccination bind Bordetella whole cells  
FHA is both secreted and surface bound, and surface bound FHA is relevant for 
B. pertussis adhesion (Arico, Nuti et al. 1993), while the secreted FHA may help in the 
dispersal of bacteria (Coutte, Alonso et al. 2003). The presence of FHA on the surface of 
B. pertussis however has implications for antibody mediated bactericidal activity by 
opsonization of bacteria and/or complement mediated lysis (Aase, Herstad et al. 2011). A 
FACS assay was therefore used to assess whether the epitopes of the isolated anti-FHA 
antibodies are exposed on surface bound FHA molecules on the bacteria. Significant 
binding of the antibodies was detected to whole cell B. pertussis compared to an 
irrelevant antibody control (Figure 2.14). Irrelevant control antibodies and the secondary 
fluorescent antibodies did not show binding to B. pertussis. This result is consistent with 
the detection of monoclonal anti-FHA antibodies to surface bound FHA on B. pertussis 
(Coutte, Alonso et al. 2003). The six B. pertussis anti-FHA antibodies also showed 
binding to B. bronchiseptica and B. parapertussis whole cells in the FACS assays (B. 
parapertussis not shown). Binding of the anti-FHA antibodies to the Bordetellae however 
was detected only when the antibodies were incubated with the bacteria in buffer 
containing 5% glycerol at room temperature. In modified assays where the antibodies 
were incubated with B. pertussis on ice in PBS without glycerol, we detected minimal 
binding to B. pertussis. No significant binding of the antibodies was detected to a strain 
of B. pertussis with the FHA gene deleted, indicating the observed binding was specific 
to surface exposed FHA (not shown).  In control assays, we however detected binding of 
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the anti-B. pertusiss lipo-oligosaccharide (LOS) antibody (D26E), to B. pertussis, B. 
bronchiseptica and B. parapertussis (not shown). A further control testing only 
secondary antibodies binding to the Bordetellae showed no binding. Cross reactivity of B. 
pertussis anti-LOS antibodies to B. bronchiseptica lipopolysaccharide (LPS) has been 
reported. Western blot analysis however suggests the LPS of B. pertussis and B. 
parapertussis are serologically distinct (Amano, Fukushi et al. 1990, Archambault, 
Rondeau et al. 1991, Martin, Peppler et al. 1992). The LPS of Porphyromonas gingivalis 
shows glycerol conjugates and derivatives are present within the structure (Paramonov, 
Aduse-Opoku et al. 2009). The cross reactivity we observed for D26E binding the B. 
parapertussis in glycerol may therefore have been due to the glycerol present in the 
buffer modifying the LPS structures of B. parapertussis to make it more similar to that of 
B. pertussis and B. bronchiseptica. In the absence of glycerol, D26E did not bind to B. 
parapertussis (Independent assay from lab colleague, Xianzhe Wang). 
Antibodies against surface exposed antigens on B. pertussis have been reported to 
promote phagocytosis (Hellwig, Rodriguez et al. 2003, Aase, Herstad et al. 2011), and 
anti-FHA antibodies are sometimes thought to be bactericidal (Weiss, Patton et al. 2004). 
We therefore assessed whether the anti-FHA antibodies induced to aP vaccination were 
capable of inducing bactericidal activity. Serum from a baboon recovering from B. 
pertussis infection had the highest bactericidal activity. Compared to the serum, or the 
absence of antibodies, the B6, H2 and H6 antibodies were however not significantly 
bactericidal. The lack of significant bactericidal activity may be because only a few 
available molecules may be available for complement mediated lysis, due to the efficient 
secretion of FHA (Weiss, Patton et al. 2004). In addition, B. pertussis expresses the BrkA 
(Bordetella resistance to killing) protein (Barnes and Weiss 2001), which inhibits 
complement mediated bactericidal killing. 
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Figure 2.14: Anti-FHA antibody binding to intact B. pertussis TahomaI whole cells and bactericidal activity.  
A) Representative FACS plot of H2 anti-FHA antibody binding to whole B. pertussis cells. B. pertussis cells grown on Bordet 
Gengou plates were scraped and resuspended to 1 OD600/mL. The cells were washed and incubated with 1 µg of the antibodies 
in PBS with 5% glycerol. Bound antibodies were detected with fluorescently labeled secondary antibodies and analyzed by 
flow cytometry. B) Percentages of fluorescent Bordetella cells after labeling with the B. pertussis anti-FHA antibodies. Using 
the FlowJo_V10 software, % fluorescent cells were determined for a gated population of the cells using unlabeled B. pertussis 
as a negative control. Data represent the average of at least two independent experiments. Error bars represent the standard 
error of the mean. C) Complement bactericidal activity. 3 x 10
5
 cfu B. pertussis in the presense of 10% antibody depleted 
serum was incubated with 25 µg/ml of the indicated antibodies or 25% serum from an infection baboon for an hour. Dilutions 
of bacteria were spread on Bordet Gengou blood agar plates and colonies counted after 3 days of growth at 37
o
C. The results 
represent the average and standard error of two experiments.
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2.4 DISCUSSION 
In this study, the spectrum of antibodies isolated from single plasmablast cells 
from recently vaccinated adult volunteers was analyzed. Pertussis still remains a vaccine 
preventable disease in industrialized countries in spite of high vaccine coverage. 
Understanding the immunologic mechanisms underlying enhanced protection against 
pertussis infection is important for development of next generation vaccines with 
enhanced efficacy. Greater than 50 unique anti-FHA antibodies were recovered from the 
single B cells, compared to only 5 anti-PTx antibodies (Chapter 3).  The higher frequency 
of anti-FHA antibodies compared to anti-PTx antibodies is consistent with a strong anti-
FHA serum response after aP vaccination (Berbers, van de Wetering et al. 2013). The 
higher magnitude of the anti-FHA immune response may be because of the efficient 
secretion of this adhesin by B. pertussis compared to the other virulence factors. Secreted 
FHA may be important for promoting adherence of phase variants which may arise in 
vivo (Mooi 1988) or for spreading the bacteria from micro-colonies after initial 
colonization (Coutte, Alonso et al. 2003).  
There was significant similarity in the sequences forming the framework regions 
of the 13 antibody sequences analyzed. The biggest differences in the sequences were not 
surprisingly in the CDRs.  Analysis of putative germline families showed the antibodies 
descended from different germline sequence families, suggesting the B cells responding 
were oligoclonal, with somatic hypermutations resulting in the identified antibodies with 
very similar framework regions. This result is similar to antibodies isolated B cells 
responding to the influenza virus, where the authors noted each individual antibody clone 
arose from different phylogenetic lineages, and suggested multiple clad members exist to 
provide antibodies that respond to drift variant virus epitopes that occur quickly in the 
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rapidly mutating influenza virus. (Krause, Tsibane et al. 2011). Similarly diverse, and 
high-affinity anti tetanus antibodies have been isolated from volunteers immunized with 
the tetanus toxoid (Meijer, Andersen et al. 2006). The oligoclonal nature of the B cell 
response to B. pertussis FHA may provide plasticity to respond to the large complex 
antigen.  The small data set of antibodies characterized in this study however limits the 
extent of analysis of diversity. The isolated antibodies all exhibited high affinity to FHA, 
with diversity in the expression levels, stability and epitopes. The affinities of B6 and H6, 
estimated to be 0.19 and 1.27 nM respectively by SPR analysis, are consistent with 
affinities of 0.1-10 nM for antibodies in the circulating immune repertoire (Foote and 
Eisen 1995). 
Two anti-FHA antibodies, B6 and H6, were identified which neutralized the in-
vitro FHA mediated hemagglutination of red blood cells (RBC).  FHA mediated 
hemagglutination and binding to epithelial cells in-vitro can be inhibited by sulfated 
glycoconjugates such as heparin, and the heparin binding site is located in the N-terminus 
of FHA (Menozzi, Gantiez et al. 1991, Menozzi, Mutombo et al. 1994). The ability of B6 
and H6 to inhibit FHA mediated hemagglutination therefore suggested these antibodies 
may block the interaction of B. pertussis with glycoconjugates on the surface of host 
cells. Using recombinant FHA fragments, we found that B6 as well as A9, D12 and G10 
preferentially bound an N-terminal fragment with high affinity, but also weakly bound 
other fragments. H6 on the other hand bound the C-terminal fragment more strongly, 
with indications that it may also have other secondary epitopes. Only B6 however 
prevented the attachment of B. pertussis to CHO-K1 epithelial cells in-vitro. A previous 
study also identified an antibody to the N-terminus of FHA which inhibited B. pertussis 
binding to epithelial cells (Leininger, Probst et al. 1993). In mice, immunization with an 
N-terminal recombinant FHA fragment (Fha44) protected against challenge with B. 
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pertussis, indicating the N-terminus of FHA contains protective epitopes for inhibiting 
bacterial adherence to epithelial cells. Fha44 by itself however was not sufficient for 
adherence to epithelial cells and macrophages, although it contains the complete heparin 
binding domain. Additionally, Fha44 could not replace FHA during colonization of the 
respiratory tract (Alonso, Reveneau et al. 2002).  
The C-terminal ~500 amino acids on the other hand is more immunodominant 
after immunization or infection (Delisse-Gathoye, Locht et al. 1990, Leininger, Bowen et 
al. 1997, Wilson, Siebers et al. 1998), and appears very relevant for adherence and 
inducing protection (Knight, Huang et al. 2006, Julio, Inatsuka et al. 2009). Recent 
studies with B. bronchiseptica have also indicated the C-terminus of FHA is what is 
surface exposed during secretion (Mazar and Cotter 2006), in contrast to a previous 
model suggesting the N-terminus emerges first (Jacob-Dubuisson, Buisine et al. 1996). 
Information obtained from studies of B. bronchiseptica FHA is thought to be directly 
related to B. pertussis FHA since the two proteins are similar at the sequence level, and 
may be functionally interchangeable (Julio, Inatsuka et al. 2009). An extensive analysis 
of serum responses after natural infection showed that antibodies induced to FHA 
predominantly bind the C-terminus, while aP vaccination induces antibodies 
predominantly to the N-terminus (Leininger, Bowen et al. 1997). Our observation that 4 
out of the 6 characterized monoclonal antibodies preferentially bound the N-terminus is 
therefore consistent with the results by Leininger et al, indicating that aP vaccination 
induces anti-FHA antibodies predominantly to the N-terminus. The immunodominance of 
the N-terminus after aP vaccination may be because FHA is tethered to the bacterium 
during maturation. After secretion, the N-terminus may be more accessible, as such; the 
use of soluble FHA in aP vaccines may therefore predispose the formation of antibodies 
to the more accessible N-terminus. We suggest that B. pertussis may also secrete FHA at 
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such levels to present decoy non-neutralizing epitopes. Further studies are therefore 
needed to further define the epitopes recognized by the neutralizing antibodies to aid in 
the design of relevant recombinant FHA fragments which can be included in improved aP 
vaccines. 
Tested antibodies were also competent at inhibiting FHA binding to the 
macrophage CR3 receptor, with H6 being the most potent. FHA mediates B. pertussis 
binding to human monocytes, macrophages (Relman, Tuomanen et al. 1990, Ishibashi, 
Claus et al. 1994) and epithelial cells (Ishibashi, Relman et al. 2001). Entry and survival 
of B. pertussis within the host macrophages is thought constitute a reservoir for 
transmitting infection (Steed, Setareh et al. 1991, Friedman, Nordensson et al. 1992). 
Antibody mediated reduction of FHA binding to the CR3 receptor may therefore directly 
reduce B. pertussis invasion and persistence. FHA also exhibits immunosuppressive 
effects on macrophages and dendritic cells by upregulating CR3 binding activity . The 
CR3 complement receptor 3 (αMβ2 integrin; CD11/CD18) is also the receptor for another 
B. pertussis virulence factor, the adenylate cyclase toxin (ACT) (Guermonprez, Khelef et 
al. 2001, Wang and Maynard 2014). ACT binding allows translocation of its catalytic 
domain into the cellular cytosol to increase intracellular cAMP levels and inhibit the anti-
bacterial responses (Confer and Eaton 1982). FHA mediated adherence of B. pertussis to 
macrophages may therefore facilitate delivery of ACT to the target cells (Zaretzky, Gray 
et al. 2002) allowing it to exert immunosuppressive effects (Henderson, Inatsuka et al. 
2012).  Antibody mediated reduction of FHA binding to the CR3 receptor may therefore 
additionally inhibit FHA and ACT mediated immunosuppression. 
Although studies have suggested FHA antibodies provide protection (Storsaeter, 
Hallander et al. 1990, Shahin, Amsbaugh et al. 1992, He, Viljanen et al. 1994), possibly 
by reducing B. pertussis adherence (Sato, Izumiya et al. 1981), there is some debate about 
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whether FHA is sufficient for protection against B. pertussis infection in-vivo (Oda, 
Cowell et al. 1984, Cherry, Gornbein et al. 1998, Storsaeter, Hallander et al. 1998). In a 
vaccine efficacy trial, there appeared to be no correlation between anti-FHA antibodies 
induced to the aP vaccines and protection in the absence of antibodies to PTx and PRN 
(Cherry, Gornbein et al. 1998). Our in-vitro studies indicated that neutralizing anti-FHA 
antibodies may be able to reduce bacterial adherence as previously reported (Sato, 
Izumiya et al. 1981, Knight, Huang et al. 2006). Recent studies in baboons have however 
suggested aP vaccination protects against toxin mediated effects, but does not prevent 
transmission (Warfel, Zimmerman et al. 2014). Surface exposed antigens on B. pertussis 
could serve as targets for antibody mediated bactericidal activity by opsonization of 
bacteria and/or complement mediated lysis (Aase, Herstad et al. 2011). Of the antigens in 
currently licensed aP vaccines, FHA, PRN and FIM, which are outer membrane proteins, 
are more likely to serve as targets for bactericidal activity. Anti-PRN antibodies have 
been shown to be bactericidal in-vitro (Weingart, Keitel et al. 2000) and in mice (Gotto, 
Eckhardt et al. 1993). FHA on the other hand is both secreted and also loosely associated 
with the bacterial outer membrane. Although the anti-FHA antibodies were found to be 
competent to bind to surface bound FHA on B. pertussis, preliminary experiments 
suggest there may not be a significant bactericidal effect of the anti-FHA antibodies. This 
may be because of the efficient secretion of resulting in only a few available molecules 
for complement lysis (Weiss, Patton et al. 2004). In addition, B. pertussis expresses the 
BrkA (Bordetella resistance to killing) protein (Barnes and Weiss 2001), which inhibits 
the complement mediated bactericidal killing. Although B. pertussis appears to be killed 
specifically via the antibody dependent classical pathway (Barnes and Weiss 2003), B. 
pertussis has been shown to bind to the host inhibitor factor H, C4b binding proteins 
(Amdahl, Jarva et al. 2011) and C1-esterase inhibitor (Marr, Luu et al. 2007) to escape 
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complement mediated killing via both the alternative and classical pathways. Anti-FHA 
antibody mediated bactericidal mechanisms may therefore not be sufficient for clearing 
bacteria. Other surface exposed antigens and/or T-cell mediated bactericidal activity may 
be the predominant mechanism for clearing B. pertussis.  
Low in-vivo protection by FHA may also be because FHA by itself may reduce 
the protective Th1 responses by apoptosis of activated Th1 cells (Boschwitz, Batanghari 
et al. 1997, McGuirk and Mills 2000, Abramson, Kedem et al. 2001, McGuirk, McCann 
et al. 2002, Öhman, Willén et al. 2005). However the formulation of the vaccine may 
increase the FHA induced apoptosis of Th1 cells. Like most vaccines, aP vaccines are 
formulated with alum as the adjuvant. It has however been demonstrated that alum 
preferentially promotes Th2 cells (Lambrecht, Kool et al. 2009) whereas the more 
protective Th1/17 responses from by wP vaccines or natural infection may be induced by 
other types of adjuvants (Ross, Sutton et al. 2013). Protective immunity to an 
experimental aP vaccine containing PTx and FHA was demonstrated to be enhanced by 
replacing alum with a different adjuvant such as CpG (Ross, Sutton et al. 2013) which 
promotes the induction of Th1 cells (Hemmi, Takeuchi et al. 2000). Additionally, 
secondary infections may reduce the effective immune responses of the aP vaccines. It 
has been demonstrated that co-infection with Fasciola hepatica suppresses the protective 
Th1 responses against B. pertussis (Brady, O'Neill et al. 1999). Prevention and treatment 
of such secondary infections may also improve the immune responses to aP vaccines. 
The limited efficacy of anti-FHA antibodies may also be a reflection of reduced 
immunologic properties retained by FHA after chemical treatment in vaccines from 
different manufacturers. In one study, formalin treated FHA or its antibodies appeared to 
be less protective unless administered with pertussis toxoid or its antibodies (Sato and 
Sato 1984). Chemical treatment has been shown to reduce immunogenicity of PTx, a 
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major virulence factor in current aP vaccines (Nencioni, Volpini et al. 1991, Fowler, 
Byron et al. 2003). Further studies may therefore be needed to assess the immunogenicity 
of chemically treated FHA in current aP vaccines. Although different binding domains 
have been attributed to separate regions on the mature FHA, the C-terminal end of mature 
FHA (MCD) has been recently recognized as being critical for B. pertussis adherence and 
colonization (Julio, Inatsuka et al. 2009).  A recombinant FHA fusion protein of the 
MCD has also been shown to be immunogenic and protective (Knight, Huang et al. 
2006). Recombinant FHA fragments containing protective epitopes which would require 
less stabilizing agents may therefore be suitable candidates for inclusion in new aP 
vaccines. 
FHA is a common antigen produced by all the major Bordetella strains which 
infect humans.  Previous studies with serum containing anti-FHA antibodies have shown 
that B. pertussis induced serum cross reacts with B. bronchiseptica (Goebel, Zhang et al. 
2009) and B. parapertussis (Khelef, Danve et al. 1993) FHA. The isolated B. pertussis 
anti-FHA monoclonal antibodies also recognized FHA from the three major Bordetella 
species. B. pertussis FHA also bound B. bronchiseptica FHA with high nM affinity, and 
also bound B. parapertussis whole cells. While immunization with purified B. pertussis 
FHA appears to be sufficient for protection against B. bronchiseptica infection in mice 
(Goebel, Zhang et al. 2009), it is not protective against B. parapertussis colonization 
(Khelef, Danve et al. 1993). aP vaccination is even thought to enhance B. parapertussis 
infection (Long, Karanikas et al. 2010). Interestingly, immunization with whole B. 
pertussis appears to be cross protective against B. parapertussis infection. This suggests 
B. pertussis antigens not included in the current acellular vaccines may confer cross 
protection against B. parapertussis. It has been suggested that the cross reaction of anti B. 
pertussis FHA, but lack of cross-protection against B. parapertussis infection is because 
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the FHA from the two species are immunologically distinct. Of the six antibodies 
characterized, four appeared to have their major binding sites within the N-terminus of 
FHA. Although B. pertussis and B. parapertussis share 85.7% and 87.5% sequence  
identity and similarity respectively, the N-terminus of B. parapertussis FHA is more 
distinct, with the presence of additional sequences. The antibodies to the N-terminus of B. 
pertussis may therefore only bind weakly to the N-terminus of B. parapertussis FHA, and 
may not be fully protective.  Further studies are therefore needed to assess the role of 
antibodies to the C-terminus of FHA in inducing cross-protection. 
The type of immune response generated B. pertussis infection may additionally be 
required for cross protection. B. pertussis cross-protection with B. parapertussis appears 
to be T-cell mediated (Feunou, Bertout et al. 2010). Nasal vaccination with attenuated B. 
pertussis which induces a predominantly Th1/17 response appears adequate for cross-
protection against B. parapertussis in mice (Watanabe and Nagai 2001, Mielcarek, 
Debrie et al. 2006, Feunou, Bertout et al. 2010). Natural infection and wP vaccination 
also induces a predominantly Th1/17 response, whereas infants primed with aP vaccines 
have a Th2 skewed or mixed Th2/Th1 response (Ross, Sutton et al. 2013). aP vaccine 
antigens which generate a Th1/17 biased immune response may therefore be useful to 
induce cross-protection against B. parapertussis.  
 
2.5 CONCLUSIONS 
The single cell approach utilized for understanding the humoral response to FHA 
after aP vaccination, as opposed to analysis of serum responses, shows antibodies 
induced to FHA after aP immunization arise from diverse germline sequences, and bind 
with high nM affinity. Neutralizing antibodies reduced bacterial adherence to CHO-K1 
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epithelial cells or the leukocyte CR3 receptor in-vitro. While natural infection induces 
antibodies predominantly to the C-terminus of FHA, aP vaccination induces antibodies 
predominantly to the N-terminus. The tested anti-FHA antibodies were also all competent 
to bind whole B. pertussis cells, but did not appear to induce significant bactericidal 
activity. To improve upon current aP vaccines, the inclusion of protective recombinant 
FHA fragments may reduce the induction of antibodies to non-neutralizing epitopes. 
Neutralizing anti-FHA monoclonal antibodies identified in this study may have 
prophylactic potential and are useful reagents for characterizing functional domains of 
FHA.  
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Chapter 3: Quality and diversity of antibodies isolated from single B 
cells induced to the pertussis toxin (PTx) after acellular pertussis 
booster immunization. 
 
3.1 INTRODUCTION 
PTx is a 105kDa extracellular toxin and colonizing factor produced only by B. 
pertussis. The closely related species, B. bronchiseptica and B. parapertussis which 
cause a milder form of whooping cough in humans, contain a transcriptionally silent PTx 
operon due to mutations mostly in their promoter regions (Aricò and Rappuoli 1987). 
PTx belongs to the AB5 class of toxins, which are characterized by a catalytically active 
A subunit and a receptor binding B subunit. The initial classifications of the AB type 
toxins were based on sequence homology and catalytic activity. However, more toxins 
were added to the group as more crystal structures of these toxins were solved, revealing 
a high degree of structural homology, and has offered great insight into the mechanisms 
of these toxins (Beddoe, Paton et al. 2010). The crystal structure of PTx determined to 
2.9 Å resolution (Stein, Boodhoo et al. 1994), shows significant homology with other 
bacterial toxins such as the cholera toxin, the E. coli labile toxin and the shiga toxin 
(Figure 3.1.1). 
 The single A subunit (S1) of PTx with a molecular weight (MW) of 26 026 kDa, 
contains the catalytic site for the toxic ADP-ribosyltransferase activity. The B pentamer 
consists of four non-covalently linked subunits, S2 (MW 21 925 Da), S3 (MW 21 873 Da), 
S4 (MW 12 059 Da) and S5 (MW 11 013 Da) in a molar ratio of 1:1:2:1 respectively. The 
B oligomer contains recognition domains responsible for binding host cell surface 
receptors for internalization of the toxic S1 subunit. Independent of the toxic ADP-
ribosyltransferase activity of the S1 subunit, the B oligomer also displays non-enzymatic 
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toxicity including cellular agglutination, T cell activation and mitogenicity (Tamura, 
Nogimori et al. 1983, Nencioni, Pizza et al. 1991, Schneider, Weiss et al. 2007), and 
intercellular transfer of membrane proteins and lipids (Millen, Schneider et al. 2013). 
 
 
Figure 3.1: Crystal structures of bacterial AB5 toxins.  
A) Bordetella pertussis toxin B) Cholera toxin, C) E. coli heat-labile enterotoxin D) 
Shiga toxin. The enzymatically active A subunit is green for the four toxins shown with 
the receptor binding B pentamer in distinct colors for the different subunits. 
 
Early in infection, PTx targets resident cells in the lung tissue such as alveolar 
macrophages and epithelial cells to aid in colonization of the respiratory tract (Carbonetti, 
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Artamonova et al. 2003). PTx binds to cell surface receptors via its B subunit, undergoes 
receptor-mediated endocytosis, followed by retrograde transport from the Golgi to the 
endoplasmic reticulum (ER).  Within the ER, reduction of a disulfide bond in S1 and an 
ATP-induced conformational change in the B subunit, results in release of the S1 subunit 
from the holotoxin (Hazes, Boodhoo et al. 1996).  Unfolded S1 is then transported into 
the cytoplasm possibly by a Sec61 dependent pathway (Hazes and Read 1997). Within 
the cytosol, the S1 subunit catalyzes the ADP-ribosylation of some membrane-associated 
Gi/o proteins, disrupting G-protein function (Katada and Ui 1982, Katada, Tamura et al. 
1983, Meade, Kind et al. 1984, Meade, Kind et al. 1984, Schaeffer and Weiss 2001, 
Kirimanjeswara, Agosto et al. 2005). PTx toxicity results in inhibition of neutrophil 
recruitment and altered circulation of mononuclear phagocytes, thus aiding in the evasion 
of bacterial opsonization by monocytes (Kirimanjeswara, Agosto et al. 2005, Andreasen 
and Carbonetti 2008). In addition to inactivating neutrophils and macrophages, PTx also 
confers a colonization advantage for B. pertussis by suppressing antibody responses to 
resist antibody mediated clearance (Vogel, Klein et al. 1985).  
In mice, neutralizing anti-PTx antibodies elicited after immunization or 
administered passively are protective by reducing in-vivo PTx induced toxicity such as 
leukocytosis and histamine sensitization. Neutralizing anti-PTx antibodies are even able 
to reverse disease when administered as treatment in mice (Sato, Sato et al. 1987, Sato 
and Sato 1990). Studies in humans have also shown high anti-PTx antibodies in serum 
after household exposure (Cherry, Gornbein et al. 1998, Storsaeter, Hallander et al. 1998) 
or immunization (Taranger, Trollfors et al. 2000), correlate with lower incidence of 
severe pertussis. When present in aP vaccines however, immune responses to PTx do not 
appear to be dependent on its concentration, instead, the immunogenicity may be 
influenced by antigen derivation and formulation (Nencioni, Volpini et al. 1991, 
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Edwards, Meade et al. 1995, Fowler, Byron et al. 2003). The PTx responses after aP 
vaccination also tend to be lower than that to other components of the vaccine such as 
FHA or PRN with a faster decay rate (Edwards, Meade et al. 1995, Berbers, van de 
Wetering et al. 2013). In addition, aP vaccination induces lower neutralizing serum 
antibody titers to either the A or B subunit (Sutherland, Chang et al. 2011). 
In this study, five anti-PTx antibodies isolated from single B cells after aP booster 
vaccination were characterized. The low frequency of B cells to PTx is consistent with 
low serum anti-PTx antibodies after aP vaccination. However, since the presence of high 
titers of neutralizing anti-PTx antibodies correlates with protection after exposure to B. 
pertussis, aP vaccines need to induce higher neutralizing anti-PTx antibodies through the 
use of the more immunogenic genetically modified PTx (PTg) (Rappuoli 1999), or 
formulate the vaccines with adjuvants which boost the PTx response.  The isolated 
antibodies appeared to be derived from unique putative parental germline sequences. 
They also strongly bind unique epitopes on PTx with affinities in the range of 0.05 ± 0.03 
to 0.3 ± 0.08 nM. The antibodies also similarly recognized genetically modified PTx 
(PTg) with high affinity. Antibody D8 potently neutralized PTx activity in an in-vitro 
CHO cell neutralization assay, while the rest of the antibodies were either weakly 
neutralizing or non-neutralizing. D8 and another antibody, A12, also inhibited PTx 
binding to a model receptor, fetuin, suggesting they may both block PTx-receptor 
interactions. The inability of A12 to inhibit PTx toxicity in the CHO assay however raises 
questions about the use of this assay for in-vitro identification of neutralizing anti-PTx 
antibodies. This study, the first to provide insight into the anti-PTx antibody repertoire 
after pertussis vaccination, also identifies useful antibodies for further elucidation of PTx 
function and provides promising candidates for passive immunotherapy for whooping 
cough infection. 
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3.2 MATERIALS AND METHODS 
3.2.1 Antibody plasmid DNA  
DNA plasmid vectors encoding antibody sequences corresponding to the single B 
cells responding to PTx were also kindly provided by Excelimmune Inc. The single B 
cells were isolated from healthy adult volunteers as described for anti-FHA antibody 
isolation (Chapter 2).  The anti-PTx heavy and light chain antibody sequences were 
provided in a one vector system which contained the heavy and light chain sequences 
(Table 3.1). The plasmid vectors contained a neomycin/kanamycin resistance cassette and 
other functional elements such as a ColE1 origin of replication, and a CMV promoter for 
high level protein expression in mammalian cells.  
 
 
Table 3.1:  Plasmid vectors for expression of anti-PTx antibodies 
Heavy chain 
antibody 
Light chain antibody Plasmid Vector Antibody ID used in 
this study 
42.18.E12.24F10.VH 42.18.E12.25D10.K Single E12 
55.12.A8.33A8.VH  55.12.A8.33G4.K Single A8 
55.15.H5.33C9.VH 55.15.H5.37C11.K Single H5 
55.17.D8.33A10.VH 55.17.D8.33E5.K Single D8 
42.12.A12.24G9.VH 55.17.D8.33E5.K Single A12 
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3.2.2 Bacterial strains 
The Bordetella strain used in this study was the B. pertussis Tahoma I strain 
(ATCC # BAA-587) grown on Bordet-Gengou agar supplemented with 15% sheep blood 
(BD Biosciences). Plasmid vectors for transient expression of antibodies in CHO-K1 
cells were purified from the E. coli strain DH5α. Transformation of the antibody plasmid 
vectors into DH5α was by electroporation. Cells successfully transformed were selected 
on 2XYT plates containing ampicillin. 
 
3.2.3 Antigens and antibodies 
3.2.3.1 PTx 
Native PTx (in glycerol or lyophilized) or genetically modified PTx (PTg) was 
purchased from List Biological Laboratories, Inc. (Campbell, CA). Native PTx was also 
obtained through BEI Resources, NIAID, NIH: B. pertussis Toxin, Salt-free, NR-31826.  
A soluble, truncated version of the PTx S1 subunit, PTx-S1-220 expressed using the 
pAK400 plasmid was purified from E. coli as described (Sutherland and Maynard 2009).  
3.2.3.2 Antibodies 
The anti-PTx antibodies were transiently expressed on a laboratory scale by 
protein A/G affinity chromatography as described for purification of the anti-FHA 
antibodies (Chapter 2). Human intravenous pertussis immunoglobulin (P-IGIV) (Bruss, 
Malley et al. 1999) was obtained from the Massachusetts Public Health Biologic 
Laboratory. The previously characterized murine anti-PTx neutralizing antibodies, 1B7 
and 11E6 (Sato, Sato et al. 1987, Sato and Sato 1990) were purified as described 
(Sutherland and Maynard 2009). Humanized versions of 1B7 and 11E6 with similar 
affinity and epitope specificity as the parent murine antibodies were purified from the 
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culture media of stably transfected CHO cells by Catalent (Somerset, NJ) (Nguyen et al., 
2014. In review). HRP and fluorescent conjugated secondary antibodies were obtained 
from Southern Biotech and Thermoscientific respectively.  
 
3.2.4 Phylogenetic analyses 
The DNA sequences of the isolated anti-PTx antibodies were analyzed similar to 
the analyses done for the anti-FHA antibodies (Section 2.2.5). Briefly, NCBI/IgBLAST 
was used to map the VDJ or VJ sequences of each VH or Vĸ respectively to the closest 
human germline sequence from the IMGT database by selecting the hit with the highest 
score. The score is determined after adding points for each match and subtracting points 
for each mismatch (Ye, Ma et al. 2013). The gene segment pairings (VDJ or VJ) for each 
genetic locus (H or K) were compared.  The frequencies of pairing for the putative VDJ 
or VJ are presented as a heat map. The individual gene families and alleles were also 
analyzed by indicating the frequencies in a pie chart. To compare the full VH or Vĸ, the 
sequences of the isolated antibodies were aligned using Phylogeny.fr (Dereeper, Guignon 
et al. 2008) to generate phylogenetic trees.  
 
3.2.5 Thermal stability analysis 
Thermal stability of the purified antibodies was analyzed as described for the anti-
FHA antibodies (Chapter 2). Briefly, three replicates of 100 µg/ml solutions of the 
antibodies were prepared in PBS using the protein thermal shift dye (Life Technologies) 
according to the manufacturer’s protocol. The antibodies were heated from 25oC to 90oC 
with a scanning rate of 1
o
C/min increments. The melting temperature (Tm) was 
determined from fitting the fluorescence data normalized to the maximum and minimum 
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fluorescence. The data was fit to a sigmoidal four parameter (4PL) non-linear regression 
model using Graph pad prism 5. For antibodies which exhibited complex melting paths, 
the temperatures at 10% of the maximum fluorescence, defined as the Tonset temperature, 
or the average of the minimum and maximum fluorescence, Taverage was determined. 
 
3.2.6 Antigen specific responses 
3.2.6.1 Indirect ELISA assays 
Indirect capture ELISAs were performed as described for FHA (Chapter 2) with 
the following modifications. PTx holotoxin final concentration wase 1 µg/ml. PTx A-
subunit and PTx B-subunit final concentrations were 0.25 µg/ml and 0.85 µg/ml 
respectively. Briefly, serially diluted antibodies were added to the plates after blocking 
with 5% milk in wash buffer. Subsequently, HRP-conjugated anti-human Fc antibodies 
(Southern Biotech) diluted 1:1000 were used to detect bound antibodies. The plates were 
developed with TMB substrate (ThermoScientific) and quenched with 1N HCl. 
Absorbances were read at 450 nm in a SpectraMax M5 instrument (Molecular Devices) 
using the SoftMax Pro v5 software. The relative binding affinities of antibodies to 
respective coated antigens were determined by estimation of the concentration of each 
antibody required to achieve 50% maximal binding at saturation (EC50). The EC50 values 
were determined from fitting the binding curves to the 4 parameter logistic (4PL) non-
linear curve model using the GraphPad Prism 5 software.  
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3.2.6.2 Competition ELISA assays 
The ability of the antibodies to compete with competitor antibody for binding to 
PTx was evaluated by a competition ELISA as described for FHA (Chapter 2) with the 
following modifications. The competitor antibody was either a biotinylated or a murine 
antibody. Due to low concentrations, the anti-PTx antibodies were biotinylated with 1000 
or 5000 molar excess EZ-link Sulfo-NHS-LC-Biotin following the manufacturer’s 
instructions. Functional binding of the biotinylated antibodies to PTx was confirmed. The 
biotinylated antibody was detected with streptavidin-HRP, while the murine antibodies 
were detected with a polyclonal goat-anti-mouse antibody preparation.  
 
3.2.6.3 Simultaneous binding of antibody to PTx bound to fetuin 
Fetuin was used as model soluble receptor to detect antibodies bound to a PTx-
fetuin complex using a method adapted from (Kenimer, Kim et al. 1989). High binding 
ELISA plates (Costar) were coated with 50 µL/well of 10 µg/mL fetuin (Sigma) at in 
PBS. After overnight incubation at 4˚C, the plates were blocked with 50 µL/well 
blocking buffer (PBS + 5% BSA) at room temperature for 1 hour. Plates were washed 
three times in wash buffer (PBS, + 0.05% Tween-20) after each incubation step. Serially 
diluted PTx was then added to the fetuin coat and incubated further overnight. Antibodies 
at a concentration of 1 µg/ml antibody were then added and incubated for 1 hour at room 
temperature. Anti-human Fc HRP (Jackson Immunoresearch) was added at a 1:1000 
dilution in wash buffer and incubated at room temperature for another hour. Signal was 
developed using the TMB Substrate Kit (Thermo-Scientific), the reaction stopped with 
1N HCl, and the plate read using a SoftMax Pro v5 (Molecular Devices) at 450 nm. All 
plated volumes were 50 µL/well.  
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3.2.6.4 Western blot 
To detect antibody epitopes on PTx subunits, 0.5 µg PTx was first boiled for 2 
minutes in reducing SDS buffer to dissociate PTx into its constituent subunits. PTx was 
then electrophoresed in a 12% gel, and then transferred to a PVDF membrane at 20V, 
4
o
C overnight. The membranes were blocked with PBS + 5 % milk, washed with PBS-
tween, incubated with 25 µg of antibody, and subsequently with HRP-conjugated 
secondary antibodies. Binding to PTx subunits was detected using a colorimetric TMB 
substrate kit (Fisher scientific). 
 
3.2.6.5 Expression of antibody epitopes on whole B. pertussis 
The expression of anti-PTx epitopes on live B. pertussis was determined as for 
FHA (Chapter 2). Briefly, B. pertussis harvested from 3 day cultures grown on Bordet 
Gengou agar, were resuspended in PBS with 5% glycerol (PBSG), to an OD600/mL of 1 
after washing with PBS. The cells were then incubated with 1 µg of each antibody in 100 
µL at room temperature. Bound antibodies were detected after washing with a 1:500 
dilution of goat anti human Fc Alexa Fluor 647 conjugate (Jackson Immunoresearch). 10 
000 events per treatment were collected on a BD SLRII Fortessa flow cytometer. The cell 
associated fluorescence for a gated population of the cells was determined using the 
FlowJo_V10 software.  
 
3.2.7 In-vitro neutralization of PTx activities 
3.2.7.1 Inhibition of PTx mediated CHO cell clustering 
A CHO neutralization assay was used to determine the molar neutralizing 
concentration of the isolated anti PTx human antibodies to PTx induced CHO cell 
 79 
clustering. CHO-K1 cells (ATCC, Manassas, VA) were grown in DMEM media 
supplemented with 10% fetal bovine serum (complete medium) and 1X 
penicillin/streptomycin and maintained at 37C with 5% CO2 in a jacketed incubator. 
Serial two-fold dilutions of each antibody were prepared in complete DMEM media 
leaving 25 μl in all the wells. Next, 25 μl of a constant concentration of 5 pM PTx was 
added and the complex incubated for 30 minutes at 37C. A volume of 100 µl of 
trypsinized CHO cells at 1.5 x 10
5
 cells/ml was then added to the PTx-1B7 solution, and 
the cells scored 24 hours later. Clustering due to PTx toxicity was scored from 0 to 3 as 
follows; 0 (no clustering), 1 (a few clusters/equivocal), 2 (positive clustering), 3 
(maximum/complete clustering). Concentrations of antibodies were tested to find the 
molar concentration able to relieve PTx mediated clustering. Up to 500 000 molar excess 
antibodies were tested for neutralization of PTx mediated CHO cell clustering. 
 
3.2.7.2 Inhibition of PTx binding to fetuin, a model receptor 
PTx binds to receptors on host lung resident cells, is internalized and transported 
to the cytosol to exert its toxic effects. While the receptors for PTx are still unknown, 
PTx has specificity for sialylated glycoprotein conjugates such as fetuin, transferrin and 
haptoglobin (Heerze and Armstrong 1990). Using fetuin as a model receptor, the ability 
of the anti-PTx antibodies to inhibit PTx binding to fetuin in a competition ELISA was 
investigated. Fetuin was coated overnight at 4
o
C, at a concentration of 10 µg/ml in PBS. 
The next day, the plates were blocked with PBS-BSA(5%). Serially diluted antibodies 
with a constant concentration of 0.79 nM PTx were incubated overnight at 4
o
C. Bound 
PTx was detected with a home-made mixture of three murine antibodies to PTx (1B7, 
11E6 and 7F2) at 0.1 µg/mL. The mouse antibodies were detected using HRP-conjugated 
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goat-anti mouse antibodies and the plates developed with TMB. The absorbances were 
read at 450nm and analyzed using Graphpad prism 5.     
 
 
3.3 RESULTS 
3.3.1 A low frequency of B cells respond to native PTx after aP vaccination 
From the antigen specific responses of the individual B cells isolated, only 5 anti-
PTx antibodies were identified, compared to the >50 anti-FHA antibodies (Chapter 2). 
The high number of B cells responding to FHA is consistent with serological data of a 
strong antibody response to FHA after infection or immunization with whole cell vaccine 
(Thomas, Ashworth et al. 1989, Berbers, van de Wetering et al. 2013). The low numbers 
of B cells responding to native PTx may be due to the immunosuppressive nature of PTx, 
which naturally acts to inhibit the primary antibody response by inhibiting lymphocyte 
proliferation (Vogel, Klein et al. 1985), thus allowing B. pertussis to colonize the host 
more easily. Additionally, reduced immunogenicity of PTx from chemical detoxification 
for the aP vaccine formulation may also contribute to the lower numbers of B cells 
responding to PTx. Since the screening used native PTx, while the vaccine uses 
chemically detoxified PTx, B cells responding to only native epitopes on PTx may have 
been preferentially isolated, thus underestimating the overall response to PTx. 
  
3.3.2 Phylogenetic analysis of isolated anti-PTx antibodies 
The sequences of the 5 anti-PTx antibodies isolated were analyzed 
phylogenetically. From an NCBI/IgBLAST sequence search, potential germline 
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sequences of the heavy and light chains were identified by selecting germline sequences 
in the IMGT database with the smallest e-value. Within the heavy chain sequences, two 
of the antibodies utilized the IgH V3, one utilized IgH V1, and another utilized the IgH 
V4 family. Within the light chain sequences, IgΚ V1 was used by two of the antibodies, 
and the other three used the IgK V3 family. Only the D1 and D3 gene families were used 
by the heavy chains, with D3 being more predominant. The heavy chain also utilized the 
J4-6 family while the light chain used J1-4 (Figure 3.2). Although a very small subset of 
anti-PTx antibodies were isolated, the pairing of the VDJ also showed paring preferences 
among the gene segments, with the 5’ D segments showing increased frequency of 
pairing with the 3’- most J segments as previously suggested (Volpe and Kepler 2008).  
At the gene and allele level, we observed unique families were utilized by the V gene 
segments of the heavy and light chains, as well as the D segment of the heavy chains. The 
6*02 gene and allele combination was utilized twice with the J gene segments of the 
heavy chain, while the rest of the three antibodies utilized other unique gene and alleles. 
For the light chain, the 4*01 gene and allele combination was utilized by three of the 
antibodies, while the other two, utilized other unique genes and allele combinations 
(Figure 3.3). The five isolated anti-PTx antibodies therefore appeared to each descend 
from unique germline sequences. Overall, the number of mutations in the amino acids of 
the isolated antibodies compared to the putative parental germline sequences ranged from 
11 to 24 in the V gene segment. The D and J regions on the other hand, had few changes 
with 0 to 2 mutations compared to the putative germline sequences (Table 3.2). 
Combining the full VH and VL sequences to form a phylogenetic tree also indicated the 
antibodies descended from unique germline families with A12 and E12 potentially 
descending from (Figure 3.4). 
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Figure 3.2: VDJ germline usage of the heavy and light chains of the five anti-PTx antibodies. 
 
Each panel represents the number of unique VDJ patterns existing in the heavy and light chains of the five isolated anti-PTx 
antibody sequences. The color legend shows the number of antibodies with the corresponding VDJ genes. The white space 
represents absent VDJ recombination types in the repertoire. 
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Figure 3.3: Gene and allele family usage of the isolated anti-PTx antibodies. 
Genes and alleles are shown in the pie chart in the a*b format. The number and percentage of antibodies represented is 
indicated below each gene and allele used. 
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Table 3.2: Anti-PTx antibody gene diversity
Antibody Heavy/Light V D J Mismatches 
A12.K Light IGKV3-11*01 - IGKJ4*01 11,1 
E12.K Light IGKV3-20*01 - IGKJ4*01 22,2 
A8.K Light IGKV1-17*01 - IGKJ1*01  12,2 
H5. K Light IGKV1D-33*01,IGKV1-
33*01 
- IGKJ4*01  11,0 
D8.K Light IGKV1-39*01,IGKV1D-
39*01 
- IGKJ2*01  11,2 
A12.VH Heavy IGHV3-11*06 IGHD3-9*01  IGHJ6*03  11,0,2 
E12.VH Heavy IGHV3-23*04 IGHD3-3*01  IGHJ4*02  12,0,1 
A8.VH Heavy IGHV1-18*01 IGHD3-3*02  IGHJ6*02  19,0,1 
H5.VH Heavy IGHV4-61*01 IGHD3-10*01  IGHJ6*02  24,0,2 
D8.VH Heavy IGHV1-69*06, IGHV1-69*14 IGHD1-26*01 IGHJ5*02 13,0,0 
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Figure 3.4: Phylogenetic tree of isolated anti-FHA antibodies. 
The phylogenetic tree was constructed from the VH and Vk gene sequences of the 
isolated anti-PTx antibodies using phylogeny.fr. The tree shows the diversity of germline 
families of the antibodies. The length of a branch is proportional to the number of 
mutations in the antibody compared to a putative germline. 
 
 
3.3.3 Antibody expression and stability 
The isolated human anti-PTx antibodies were expressed in adherent CHO-K1 
cells using Lipofectamine 2000 (Life Technologies) following the manufacturer’s 
instructions. Expression levels of the anti-PTx antibodies in 6 well culture flasks ranged 
0.01 to 1.32 µg/mL (Table 2). A12 and D8 had the lowest expression levels of 0.26 ± 
0.04 and 0.01 ± 0.003 µg/ml respectively. The two antibodies were however the most 
interesting in terms of neutralization of PTx binding to a model receptor, fetuin (Section 
3.3.6). The purified antibodies (Figure 3.5) were stable with melting temperatures 
ranging from 54.41 ± 0.03 to 74.29 
o
C (Table 3.3). For A12, A8 and H5 which exhibited 
complex melting paths, the Taverage and Tonset temperatures as defined were determined. 
The complex unfolding of A12, A8 and H5 may reflect differences in stability of the 
variable regions. The D8 antibody which was potently neutralizing in the in-vitro CHO 
clustering assay, exhibited the least stable melting temperature. From a therapeutic 
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standpoint, the A12 and D8 antibodies may therefore need further engineering for 
increased expression levels and stability (D8). 
 
 
Figure 3.5: Purity and stability of purified anti-PTx antibodies.  
A) SDS-PAGE of purified anti-PTx antibodies. Each well contained 1 µg of protein 
boiled for two minutes under reducing or non-reducing conditions. B) Melting 
temperature profile of purified anti-PTx antibodies. Each antibody at a concentration of 
100 µg/ml, was heated up to 90
o
C in PBS with the protein thermal shift dye. The Tm was 
determined from fitting the data to a sigmoidal four parameter logistic (4PL) non-linear 
regression model after normalizing the data to the maximum and minimum fluorescence. 
Data after the maximum fluorescence are not shown.
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Table 3.3: Expression levels and stability of anti-PTx antibodies 
Antibody ID 
 
Expression level (µg/ml) Melting temperature, Tm (
o
C) 
A12 0.26 ±  0.04 69.76^, 8.47
# 
 
 
  
E12 1.26 ±  0.05 64.07 ± 0.01 
A8 1.32 ±  0.13 63.68^, 7.25
#
  
D8 0.01 ±  0.003 54.41 ± 0.03 
H5 0.9 ±  0.14 74.29^, 8.95
#
  
 
^ - Taverage: Average of the maximum and minimum temperature of unfolding. 
# - Tonset: 10% of mean maximum temperature for the unfolding curve. 
 
 
3.3.4 Anti-PTx antibodies after aP vaccination recognize unique epitopes with high 
affinity 
The isolated anti-PTx antibodies exhibited strongly bound PTx as well as 
genetically modified PTx (PTg) with high affinities <0.5 nM (Figure 3.6, Table 3.4). PTg 
has two amino acid substitutions (R9K and E129G) in the enzymatically active S1 
subunit and has been proposed as a replacement for chemically detoxified PTx in current 
acellular vaccines due to its reduced toxicity but high immunogenicity (Nencioni, Pizza 
et al. 1990). The binding affinities of D8 and H5 to PTx or PTg appeared to remain intact 
without significant changes. Since PTg has the amino acid changes in the S1 subunit, the 
lack of change in the affinities of these two antibodies to PTg is consistent with their 
epitopes being primarily on the B-oligomer (epitope specificities discussed in next 
paragraph). On the other hand, the affinity of E12 to PTg appeared to be slightly 
improved, while the affinities of A12 and A8 were slightly reduced about 2-fold 
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compared to native PTx. The epitope of A8 appears to lie primarily on the S1 subunit, 
however the slightly reduced affinity of A8 binding to PTg, suggests the amino acid 
changes in PTg may slightly perturb the A8 binding site. The A12 epitope, although 
Previous reports of antibody binding to PTx or PTg also observed affinities which either 
improved or remained intact (Ibsen 1996). For the antibodies with improved affinities, 
the author suggested the amino acid changes may make the epitope more accessible 
leading to the enhanced binding.  
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Figure 3.6: Binding affinity of the isolated anti-PTx antibodies to native PTx and 
genetically modified PTx (PTg).  
Serially diluted antibodies were added to purified PTx coated at 1 µg/mL. Antibody 
binding was detected with HRP conjugated anti-human Fc antibodies and TMB substrate 
development. The estimated binding affinity (EC50) was determined after fitting the 
binding curves to the four parameter logistic (4PL) model using GraphPad prism 5. The 
ELISAs were repeated at least twice in duplicate. Error bars represent the standard error 
from replicate experiments. The murine 1B7 and 11E6 were used as controls.  
* 
* 
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* Humanized versions of 1B7 or 11E6 
The epitope specificities of the isolated antibodies were then assessed by subunit 
ELISAs. Two of the anti-PTx mAbs, A8 and E12, bound a recombinant version of the 
PTx S1-subunit, S1-220, with affinities of 0.05 ±0.03 and 0.02 ± 0.006 nM respectively 
(Figure 3.7 A, Table 3.4). The full length PTx S1 subunit has 235 amino acid residues, 
but is more difficult to express due to the presence of a hydrophobic C-terminal tail 
(Sutherland and Maynard 2009). A PTx S1-219 truncated version maintains the ADP-
ribosyltransferase catalytic activity of the full length PTx S1 (Krueger and Barbieri 
1994), while a PTx S1-220 version has better expression levels (Sutherland and Maynard 
2009). The PTx S1-220 recombinant version has also been shown previously to maintain 
the binding affinity of a previously characterized anti S1-antibody, 1B7 (Sutherland and 
Maynard 2009). We observed high binding of A8 and E12 to the A subunit similar to 
binding the holotoxin, with affinities of 0.05 ± 0.03 and 0.02 ± 0.006 nM. The results 
indicate the PTx S1-220 truncation does not affect the E12 and A8 binding, and their 
epitopes lie primarily on the S1 subunit. Two of the anti-PTx antibodies, D8 and H5, also 
bound the B-subunit of PTx with affinities of 0.78 ± 0.22 and 0.11 ± 0.05 nM (Figure 3.7 
B, Table 3.4). D8 and H5 therefore maintained high sub nM affinity to the B-oligomer 
suggesting their epitopes lie primarily on the B-pentamer.  However, the approximately 7 
and 5 fold decrease in affinities of D8 and H5 respectively for binding to the B oligomer 
indicated their epitopes may be stabilized by the presence of the S1 subunit, or they may 
have weak interactions with the S1 subunit. The binding affinities of the antibodies with 
specificity for the S1 subunit or the B-oligomer were comparable to the affinities of the 
previously characterized S1 or B-oligomer antibodies, 1B7 and 11E6 respectively. For 
the A12 antibody however, we observed loss of binding to either the A or B subunit in 
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the subunit ELISAs, suggesting the A12 epitope may span an interface on the A and B 
subunits, or it may be stabilized by the presence of the other subunit.  
The ability of the antibodies to detect linear epitopes on the PTx subunits using 
western blots was also used to further analyze the epitope specificity of the antibodies. 
PTx dissociates into its component five subunits under the denaturing conditions of SDS-
PAGE. Western blots confirmed A8 and E12 recognize an ~26 kDa fragment, most likely 
the A subunit of PTx (Figure 3.7 C). E12 and A8 also recognized a smaller band less than 
25kDa. A previously characterized antibody, 11E6, which binds the S2 and S3 subunits 
of 21.93 kDa and 21.83 kDa respectively, did not recognize the smaller fragment, 
suggesting it is more likely a processed form of the S1 subunit.  In addition, another 
previously characterized antibody, 1B7, which binds the S1 subunit of ~26 kDa, 
recognized the same two bands in the western blot, suggesting the smaller band may be a 
processed form of the S1 subunit. Binding of A12, D8 and H5 antibodies to the PTx 
subunits was not detectable on the western blot. The lack of binding of D8 and H5 is 
likely due to insensitivity of the technique to detect subunits of the B oligomer. The 
difficulty of western blotting for detecting antibodies to the PTx-B oligomer has been 
previously demonstrated (Lynn, Burnette et al. 1994). Higher concentrations of PTx in 
western blots which increases the sensitivity of the detection of the B oligomer (Lynn, 
Burnette et al. 1994) were however not tested due to cost limitations. A12 showed a loss 
of binding to either the A or B subunit in the subunit ELISAs, suggesting the A12 epitope 
may span an interface on the A and B subunits, or it may be stabilized by the presence of 
the other subunit. The lack of A12 binding to the S1 subunit in the western blot also 
supports the indication that its epitope may be conformational. 
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Table 3.4: Binding affinities of the isolated anti-PTx antibodies to the native PTx or its 
subunits, and to genetically modified PTx (PTg). 
 
Antibody PTx EC50, 
nM ± SE 
PTg EC
50
, 
nM ± SE 
PTx S1-220 
EC
50
, nM ± SE 
PTx B-oligomer 
EC
50
, nM ± SE 
A12 0.10 ± 0.03 0.18 ± 0.02 ND ND 
E12 0.13 ± 0.006 0.05 ± 0.02 0.05 ± 0.03 ND 
A8 0.15 ± 0.003 0.3 ± 0.08 0.02 ± 0.006 ND 
D8 0.14 ± 0.04 0.11 ± 0.08 ND 0.78 ± 0.22 
H5 0.02 ± 0.01 0.06± 0.03 ND 0.11 ± 0.05 
Mouse 
1B7 
0.06 ± 0.01* 0.07 ± 0.03 0.008 ± 0.002* ND 
Mouse 
11E6 
0.17 ± 0.03* 0.06  ± 0.007  ND 1.18 ± 0.19 
P-IVIG 4.26 ± 1.27 1.05 ± 0.04 9.39 ± 1.67 ND 
PTg- genetically modified PTx with the 9K/129G amino acid substitutions in the S1 
subunit (Burnette, Cieplak et al. 1988, Pizza, Covacci et al. 1989). 
PTx S1-220 – A truncated variant of the PTx S1 subunit (Sutherland and Maynard 2009). 
* Humanized antibody (Nguyen et al. In review). 
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Figure 3.7: Epitope specificity of the isolated anti-PTx mAbs.  
Representative ELISA plots for antibody binding to the A) PTx-A and B) PTx B subunits. A truncated form of the PTx-A 
subunit, PTx S1-220, or the B-oligomer was coated in ELISA plates. Serially diluted antibodies were added to the plates after 
blocking and detected with goat-anti-human Fc HRP antibody. C) Immunoblots of the antibodies binding to PTx after 
electrophoresis under reducing and denaturing conditions. 
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The epitopes of the isolated anti-PTx antibodies were further analyzed by 
comparison with two previously characterized neutralizing antibodies 1B7 and 11E6. The 
epitope of 1B7 was previously shown to be primarily on the A subunit of PTx (Sato, Sato 
et al. 1987, Sato and Sato 1990), and recent analysis suggest it may also span the B 
subunit (Sutherland and Maynard 2009).  The 11E6 epitope on the other hand, is on the 
S2 and S3 subunits in the B pentamer of PTx (Sato, Sato et al. 1987, Rambow-Larsen and 
Weiss 2004). The ability of the anti-PTx antibodies to inhibit 1B7 or 11E6 binding to 
PTx was then assessed in a competition ELISA. In the 1B7 competition, A12 weakly 
inhibited 1B7 binding to PTx with an IC50 of 0.39 ± 0.15 µM (Figure 3.8 A). The other 
four antibodies however did not appear to inhibit 1B7 binding to PTx. The ability of A12 
to weakly compete with 1B7 for binding to PTx suggests an overlap in their epitopes. 
Alternatively binding of one may affect weakly affect the conformation needed for 
binding of the other. In the 11E6 competition, none of the five isolated antibodies 
inhibited binding to PTx, suggesting they bind unique epitopes not overlapping with that 
of 11E6 (Figure 3.8 B).  
Competition between the five antibodies for binding to PTx was also assessed 
using biotinylated forms of the antibodies incubated with unlabeled antibody. 
Biotinylated A8 inhibited unlabeled A8 and E12 binding to PTx (Table 3.5), indicating 
A8 and E12 may share a similar epitope. The rest of the antibodies however did not 
inhibit each other’s binding to PTx, suggesting they bind unique epitopes. Competition 
between biotinylated D8 and the rest of the antibodies was not tested due to low express 
yields and ineffective biotinylation of D8. Further studies are ongoing to define the 
epitopes of the S1-subunit antibodies using yeast display libraries with mutations in the 
S1 subunit. 
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Figure 3.8: Representative competition ELISAs for epitope specificity of the isolated antibodies with the previously 
characterized antibodies, 1B7 and 11E6.  
A constant concentration of the murine A) 1B7 or B) 11E6 was incubated with serially diluted human antibodies. The antibody 
mixtures were then added to PTx coated at 1 µg/ml. Bound murine 1B7 or 11E6 was detected using a polyclonal goat-anti-
mouse HRP antibody. The inhibition curves were fit to the 4PL non-linear model using GraphPad prism 5 to estimate the 
concentration needed to achieve 50% inhibition (IC50). 
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Table 3.5: Competition of the isolated anti-PTx antibodies for binding to similar epitopes on PTx. 
Antibody Human 
A12 
Human 
E12 
Human 
A8 
Human 
D8 
Human 
H5 
Humanized 
1B7 
Humanized 
11E6 
Biotin 
A12 
+ - - - - + - 
Biotin 
E12 
- + + - - - - 
Biotin 
A8 
- + + - - + - 
Biotin 
D8 
- - - + - - - 
Biotin 
H5 
- - - - + - - 
Mouse 
1B7 
+ - - - - + - 
Mouse 
11E6 
- - - - - - + 
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3.3.5 D8 anti-PTx antibody potently neutralizes PTx mediated CHO cell clustering 
In the presence of PTx, CHO cells grow in a clustered morphology (Hewlett, 
Sauer et al. 1983), due to the toxicity of the A-subunit catalyzed ADP-ribosyltransferase 
activity (Burns, Kenimer et al. 1987). In the presence of neutralizing antibodies, the 
clustered CHO cell morphology is rescued to the normal elongated non-clustered 
phenotype [25]. Neutralization of CHO cell clustering is therefore a simple in-vitro assay 
commonly used to assess the in-vivo toxicity of the A-subunit. Of the five antibodies, 
only D8 potently neutralized PTx mediated CHO cell toxicity, approximately 10-fold 
better than the previously characterized neutralizing anti-PTx antibodies, 1B7 and 11E6 
(Sato, Sato et al. 1987) or the polyclonal anti-PTx preparation (P-IVIG) (Bruss, Malley et 
al. 1999) (Figure 3.9, Table 3.6). 
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Figure 3.9: Molar neutralization of PTx mediated CHO cell clustering. 
Serial dilutions of the antibodies were pre-incubated with a constant concentration of 
PTx. The PTx-antibody complexes were then added to CHO cells in 96 wells and 
clustering scored 24 hours later. The molar concentration of antibody needed to 
neutralize PTx mediate CHO cell clustering was determined from the concentration 
amount of antibody required to change the clustering score from 1 to 0. 
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Table 3.6: Molar neutralization of PTx mediated CHO cell clustering. 
Antibody Neutralizing ratio (molar [Ab: PTx]) 
A12 > 500 000 
E12   ~100 000 
A8 ND 
D8 313 ± 77 
H5  ~100 000  
m1B7 3750 ± 1250 
m11E6 1875 ± 625 
P-IVIG 2813  ±1263 
ND – not determined. 
 
3.3.6 A12 and D8 anti-PTx antibodies inhibit PTx binding to a PTx model receptor, 
fetuin 
While the in vivo target receptors for PTx are unknown, in vitro it promiscuously 
binds proteins with terminal sialylated oligosaccharide sequences. These are found on 
glycoproteins such as transferrin, haptoglobin and fetuin, making these useful model 
receptors for in vitro studies, including co-crystallization (Heerze and Armstrong 1990). 
The ability of the anti-PTx antibodies to inhibit PTx-receptor interactions was therefore 
tested in an inhibition assay using fetuin as a model receptor. The IC50 values were 
determined from fitting the inhibition curves to the four parameter logistic (4PL) model 
in GraphPad prism 5. The potently neutralizing antibody in the CHO clustering assay, 
D8, was able to inhibit PTx binding to fetuin with an IC50 of 1.31 ± 0.54 nM. The 
neutralizing antibody A12 which showed almost no neutralization in the CHO assay 
however also showed inhibition of PTx binding to fetuin with an IC50 of 1.86 ± 0.31 nM. 
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A12 and D8 were however approximately 10-fold less potent at inhibiting PTx binding to 
fetuin compared to the previously characterized B subunit antibody 11E6. A12 and D8 
were also approximately 5-fold less potent at inhibiting PTx binding to fetuin compared 
to the previously characterized A subunit antibody 1B7 (Figure 3.10, Table 3.7). A12 and 
D8 were however approximately 7-fold more potent than the polyclonal pertussis 
immunoglobulin (P-IVIG) (Table 3.7).  The other three antibodies, A8, E12 and H5 also 
appeared to weakly inhibit PTx binding to fetuin, however the inhibition was not 
significant compared to an irrelevant antibody. IC50 values were therefore not determined 
for these antibodies.  
 
 
Figure 3.10: Competition ELISA for inhibition of PTx binding to soluble fetuin.  
Serially antibodies with a constant concentration of 0.79 nM PTx were added to ELISA 
plates with fetuin coated at 10 µg/ml. Bound PTx was detected using a mixture of three 
murine anti-PTx antibodies at 0.1 µg/ml. Inhibition of PTx binding by E12 A8 and H5 
were not significant compared to an irrelevant antibody.  IC50s were determined from 
fitting the curves to the 4PL model using GraphPad prism 5. 
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Table 3.7: IC50 values for inhibition of PTx binding to fetuin.  
Antibody IC50, nM ± SE 
A12 1.86 ± 0.31 
E12 ND 
A8 ND 
D8 1.31 ± 0.54 
H5 ND 
1B7
*
 0.26 ± 0.05 
11E6
*
 0.11 ± 0.07 
P-IVIG 13.87 ± 3.1 
ND – not determined. 
*
 – humanized version 
 
Fetuin and other glycoconjugates with terminally sialylated oligosaccharides are 
thought to closely resemble PTx receptors on host cells. The results from the PTx 
mediated CHO clustering assay and fetuin inhibition suggests that A12 may block PTx 
interactions with receptors containing glycoconjugates resembling fetuin. Fetuin has also 
been indicated to be unable to block PTx intoxication of CHO cells (Armstrong and 
Peppler 1987, Tuomanen, Towbin et al. 1988), further suggesting that the PTx receptors 
on CHO cells may not be representative of PTx receptors in humans. Other studies have 
also indicated that the CHO cell clustering assay does not correlate with other in-vivo 
assays for detecting residual PTx activity in detoxified aP vaccines (Kataoka, Toyoizumi 
et al. 2002). In addition, the murine monoclonal antibody, 1B7, with a high CHO cell 
neutralization titer has been found to be potently neutralizing in-vivo (Sato and Sato 
1990). The CHO cell neutralization assay alone may therefore be limited in identifying 
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and fully assessing in-vitro efficacy of the isolated anti-PTx antibodies. Addition of other 
in-vitro assays such as the ELISA for inhibition of PTx binding to model receptors may 
be more practical. 
To assess whether the inhibition PTx binding to fetuin by A12 and D8 was due to 
antibody binding at the fetuin binding site, we assessed whether the antibodies could 
simultaneously bind to PTx already bound to fetuin. We found that A12 and D8 were 
competent to bind to PTx already bound to fetuin (Figure 3.11). E12 and A8 almost 
completely lost binding to PTx already bound to fetuin, while H5 exhibited markedly 
reduced binding.  The polyclonal P-IVIG was also competent to bind PTx already bound 
to fetuin. This result suggests the primary epitopes recognized by A12 and D8 remain 
accessible when PTx is bound to fetuin. Alternatively, A12 and D8 may have secondary 
binding sites which are not affected after PTx is bound to fetuin.  E12, A8 and H5 on the 
other hand which exhibited loss of binding to PTx bound to fetuin, may either bind close 
to the fetuin binding site, or the conformation of PTx after binding fetuin may be altered 
such that it inhibits their binding.  
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Figure 3.11: Simultaneous binding of antibodies to PTx bound to fetuin receptor. 
Serially diluted PTx was added to a coat of fetuin, after which a constant concentration of 
antibodies was added. Bound antibodies were detected using secondary goat-anti-mouse 
HRP antibody. Error bars indicated are the standard error of the mean. 
 
 
3.3.7 Anti-PTx antibodies bind whole B. pertussis 
PTx is a secreted B. pertussis toxin, but may be transiently associated with the 
bacterial surface during secretion (Farizo, Huang et al. 2000, Farizo, Fiddner et al. 2002). 
Binding to the whole bacteria was assessed by incubating the antibodies with live B. 
pertussis, followed by washing, signal development with a fluorescent secondary 
antibody conjugate and analysis by flow cytometry. Binding of the anti-PTx antibodies to 
live B. pertussis was detected (Figure 3.12). There was lower binding of the anti-PTx 
antibodies to B. pertussis compared to the polyclonal P-IVIG and a control anti-FHA 
antibody, H2. Expression of anti-PTx antibody epitopes on the whole bacteria suggests 
some molecules of PTx could possibly serve as targets for antibody mediated bactericidal 
 102 
activity since antibodies against surface exposed antigens on B. pertussis are reported to 
promote phagocytosis (Hellwig, Rodriguez et al. 2003, Aase, Herstad et al. 2011). 
Moreover, PTx has also been implicated in bacterial adherence in-vivo (Tuomanen and 
Weiss 1985, van't Wout, Burnette et al. 1992) , as such, anti-PTx antibodies recognizing 
surface bound PTx may be able to block relevant interactions needed for bacterial 
adherence. Further studies would be needed to evaluate the role of anti-PTx antibodies in 
bacterial adherence.
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Figure 3.12: Detection of anti-PTx antibody epitopes on B. pertussis TahomaI cell surface.  
A) Representative FACS plot of antibody binding to whole B. pertussis cells. B. pertussis cells grown on Bordet Gengou plates 
were scraped and resuspended to 1 OD600/mL. The cells were washed and incubated with 1 µg of the antibodies in PBS with 
5% glycerol. Bound antibodies were detected with fluorescently labeled anti-human Alexa Fuor 647 secondary antibody and 
analyzed by flow cytometry. B) Percentages of fluorescent Bordetella cells after labeling with the anti-PTx antibodies. Using 
the FlowJo_V10 software, % fluorescent cells were determined for a gated population of the cells using unlabeled B. pertussis 
as a negative control. Data represent the average of two independent experiments. The error bars represent the standard error of 
the mean. 
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3.4 DISCUSSION 
In this study, 5 antibodies isolated from single plasmablast cells responding to 
PTx after adult booster aP vaccination were characterized. Of the numerous virulence 
factors produced by B. pertussis, PTx is a major antigen which  may mediate most of the 
symptoms associated with severe pertussis infection (Pittman 1984, Weiss, Hewlett et al. 
1985) and induces a humoral response sufficient for protection (Granstrom, Granstrom et 
al. 1985). High levels of neutralizing anti-PTx antibodies correlate with protection 
against severe disease in  humans (Cherry, Gornbein et al. 1998, Storsaeter, Hallander et 
al. 1998, Storsaeter, Hallander et al. 2003), and neutralizing antibodies administered 
passively are able to alleviate and even reverse disease symptoms in mice (Sato, Sato et 
al. 1987).  
The lower frequency of anti-PTx antibodies isolated compared to anti-FHA 
antibodies (Chapter 2) is consistent with a lower anti-PTx serum response after aP 
vaccination (Berbers, van de Wetering et al. 2013). A ten-fold difference in the frequency 
of anti-PTx antibodies may be the result of the immunosuppression due to residual active 
in the vaccine, reduced immunogenicity of PTx in the vaccine, or the presence of 
memory B cells biasing new responses. PTx in aP vaccines are detoxified by chemical 
modification, a process which can change the physical and immunological properties of 
the toxin (Nencioni, Volpini et al. 1991). While natural infection induces high titers of 
antibodies recognizing native or genetically modified PTx, acellular vaccines produce 
higher titers of antibodies recognizing detoxified PTx (Sutherland, Chang et al. 2011). 
The lower anti-PTx responses observed may possibly be because of reduced 
immunogenicity of PTx from chemical detoxification processes and that only antibodies 
recognizing only the native conformation of PTx were isolated. Genetically modified PTx 
(PTg) with the 9K/129G amino acid substitutions in the catalytic S1 subunit of PTx has 
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reduced toxicity (Nencioni, Pizza et al. 1990), therefore requires less chemical treatment 
for stabilization, and is therefore a viable alternative to chemically detoxified PTx in 
acellular pertussis vaccines. 
In addition to inactivating neutrophils and macrophages, PTx confers an 
additional colonization advantage for B. pertussis by suppressing antibody responses to 
resist antibody mediated clearance (Vogel, Klein et al. 1985). Proteomic analysis of B. 
pertussis clinical isolates associated with the 2010 California state pertussis outbreak, 
showed isolates with reduced pertactin (PRN) activity, but increased PTx S1 production  
(Williamson, Moura et al. 2015). A previous study in the Netherlands also identified B. 
pertussis strains with increased PTx S1 production due to a novel allele in the PTx 
promoter (Mooi, van Loo et al. 2009). The higher secreted amounts of PTx S1 by current 
circulating B. pertussis strains have been suggested that vaccination may have driven 
selection of such strains to lead to increased virulence (Mooi, van Loo et al. 2009, 
Williamson, Moura et al. 2015). As such, the lower frequency of anti-PTx antibodies 
recovered may be a direct result of increased anti-S1 toxicity resulting in lower anti-PTx 
antibody responses. That the isolated anti-PTx antibodies also bound PTg with high nM 
affinity, further suggests PTg is therefore clearly a compelling replacement for PTx in 
new acellular vaccines, since it has reduced toxicity, induces neutralizing anti-PTx 
antibodies, (Nencioni, Pizza et al. 1990) and are similarly recognized by anti-PTx 
antibodies. 
On the other hand, the subjects from whom the B cells were isolated for this study 
were adults who may have been immunized with the whole cell vaccine as infants, or 
been exposed to infection. While the number of memory B cells responding to pertussis 
antigens is lower than for other antigens such as tetanus (Hendrikx, Ozturk et al. 2011), 
the presence of memory B cells, could bias future immune responses. As such, the low 
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anti-PTx response isolated from subjects may alternatively and/or additionally be a bias 
of only a few B cells responding to the PTx antigen due to previous vaccinations or 
infections. 
Many studies have identified anti-PTx antibodies with different epitope 
specificities and neutralization capacities (Anwar, Ashworth et al. 1987, Sato, Sato et al. 
1987, Schou, Au-Jensen et al. 1987, Kenimer, Kim et al. 1989, Kim, Burnette et al. 1989, 
Lang, Ganss et al. 1989, Sato, Sato et al. 1990, Halperin, Issekutz et al. 1991, Halperin, 
Issekutz et al. 1991, Sato, Sato et al. 1991). Such studies have shown that not only the 
catalytic A-subunit is immunogenic (Raupach and Schmidt 1994) but that the B-subunit 
also contains protective epitopes (Arciniega, Shahin et al. 1991, Nencioni, Pizza et al. 
1991). In analysis of serum responses to PTx, the B-subunit antibodies are however more 
readily identified with ELISAs using the purified B oligomer, than from recognition of 
the individual B subunits in western blots (Lynn, Burnette et al. 1994). Specific 
protective epitopes to antigens in aP vaccines may be used as serological correlates of 
immunity to pertussis infection. Two potently neutralizing epitopes recognized by the 
antibodies, 1B7 and 11E6 may be used as anti-PTx correlates of protection. The 
protective 1B7 and 11E6-like epitopes, more often induced after natural infection, than 
after vaccination with aP vaccines, are also more susceptible to chemical modification 
(Sutherland, Chang et al. 2011). The combination of results from the subunit ELISAs, 
western blots and competition ELISAs demonstrated the isolated antibodies bind unique 
epitopes. A8 and E12 possibly share a similar epitope, or epitopes in close proximity on 
the S1 subunit, while D8 and H5 primarily bound the B-oligomer. The A12 epitope was 
however elusive, since it bound neither the truncated S1 subunit alone, nor the B-
oligomer. The epitope of A12 may however overlap the potently neutralizing 1B7 
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epitope. Conversely, none of the antibodies appeared to compete with the neutralizing 
11E6 epitope.  
Although the A12 antibody was not neutralizing in the CHO assay, it is of interest 
first because its epitope appears to overlap with the previously characterized anti-PTx S1-
subunit antibody, 1B7 and secondly, it was able to inhibit PTx binding to fetuin. 1B7 is 
also less potent than 11E6 in the CHO clustering assay, but is more potently neutralizing 
in-vivo (Sato, Sato et al. 1987, Sato and Sato 1990), and also inhibits PTx binding to 
fetuin. Fetuin and other glycoconjugates have been shown to contain the carbohydrate 
groups on receptors recognized by PTx (Heerze and Armstrong 1990). However, as a 
model receptor, fetuin does not block the intoxication of CHO cells by PTx (Tuomanen, 
Towbin et al. 1988). The weak neutralization of PTx mediated CHO cell clustering by 
A12, but an ability to inhibit PTx binding to fetuin suggests the types of glycoconjugates 
on PTx receptors on CHO cells may be different from the glycoconjugates on fetuin to 
which PTx binds. The potent neutralization of PTx toxicity by 1B7 in mice (Sato, Sato et 
al. 1987, Sato and Sato 1990) and baboons (Nguyen et al. 2014, in prep), further suggests 
CHO cell receptors may not fully represent relevant receptors on host cells. Recent 
epitope mapping has suggested the epitope of 1B7 may span the A/B interface 
(Sutherland and Maynard 2009). Such A/B anti-PTx antibodies are interesting because 
purified recombinant S1 subunit by itself appeared incapable of inducing protective 
antibodies in mice (Nicosia, Bartoloni et al. 1987), and the B oligomer alone induced 
immunity that was less potent than protection induced to the holotoxin (Nencioni, Pizza 
et al. 1991), suggesting that more potent protective epitopes involve both the A-subunit 
and B-oligomer. Further characterization of antibodies spanning the A/B interface can 
additionally guide efforts in the development of recombinant PTx in next generation aP 
vaccines.  
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The B-oligomer antibody, D8, was also interesting because it potently neutralized 
PTx toxicity in the in-vitro CHO neutralization assay. D8 was approximately 10-fold 
more potent in the CHO assay than the previously characterized B-oligomer antibody, 
11E6 (Sato, Sato et al. 1987, Sato and Sato 1990). While the S1 subunit is thought to 
have one main neutralizing epitope (Cieplak, Burnette et al. 1988), the B-oligomer may 
have multiple neutralizing epitopes due to having four different subunits. D8 may bind a 
unique neutralizing epitope, different from the 11E6 epitope, since it did not compete 
with 11E6 for binding to PTx. From the receptor inhibition assay, it appears the 
mechanism of D8 neutralization is by inhibiting PTx interaction with the CHO cell 
receptors. It must be noted however that D8 inhibition of PTx binding to fetuin, was less 
potent than 11E6.  
Previous analysis of monoclonal antibodies binding PTx has suggested at least 
four non-overlapping epitopes on PTx (Bartoloni, Pizza et al. 1988, Cieplak, Burnette et 
al. 1988, Kenimer, Kim et al. 1989, Kim, Burnette et al. 1989). The anti-PTx antibodies 
in this study provide more reagents for elucidating both neutralizing and non-neutralizing 
PTx epitopes which can be used to further define serological correlates of PTx immunity. 
Neutralizing antibodies identified in this study after confirmation of in-vivo efficacy are 
also potentially useful for passive immunization therapies. 
 
 
 
3.5 CONCLUSIONS 
The single cell characterization of the humoral response to PTx, indicates only a 
few B cells may be induced to PTx after aP vaccination. We suggest the frequency of 
anti-PTx antibodies may be the result of immunosuppression due to residual active PTx 
after dextoxification, reduced immunogenicity of PTx in the booster vaccine, or the 
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presence of memory B cells biasing new responses. Antibodies induced to native PTx are 
diverse and recognize epitopes on either the A or B subunits with high affinity. The anti-
PTx antibodies also recognize genetically modified PTx (PTg) with amino acid changes 
in the catalytic A-subunit. PTg would require less chemical treatment for detoxification, 
and with reduced toxicity is therefore a viable alternative to chemically detoxified PTx in 
acellular pertussis vaccines. We identified a neutralizing anti B-subunit antibody which 
may inhibit PTx binding to cell surface receptors to prevent internalization and 
subsequent toxicity.  We also identified an antibody, A12 with an elusive epitope which 
inhibited PTx binding to a model receptor. A12 also competed with a previously 
characterized neutralizing antibody, 1B7, which has a unique protective epitope. Such 
rare neutralizing antibodies may be useful as serological correlates of protection during 
development of next-generation vaccines and for passive immunization strategies for 
pertussis. 
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Chapter 4: In-vitro neutralization mechansims of two potently 
neutralizing anti-PTx antibodies, 1B7 and 11E6.  
 
4.1 INTRODUCTION 
Of the numerous virulence factors produced by B. pertussis, PTx is thought to be 
a major antigen which elicits a humoral response sufficient for protection (Granstrom, 
Granstrom et al. 1985). Mice lacking PTx genes have reduced virulence (Weiss, Hewlett 
et al. 1985) and neutralizing anti-PTx antibodies administered passively are able to 
alleviate and even reverse disease symptoms in mice (Sato, Sato et al. 1987). Due to its 
immunogenicity and clear role as a major protective antigen, several anti-PTx antibodies 
have been generated and characterized for subunit specificity and protection in in vitro 
and in vivo assays (Sato, Ito et al. 1984, Sato, Sato et al. 1987, Schou, Au-Jensen et al. 
1987, Sato and Sato 1990, Halperin, Issekutz et al. 1991). Through extensive mouse 
studies, rare highly neutralizing anti-PTx antibodies have been isolated and characterized. 
Antibodies recognizing neutralizing epitopes are thought to either block the binding of 
the B-oligomer to the cell surface receptors or block catalysis of the A subunit (Sato, Sato 
et al. 1987, Kaslow, Schlotterbeck et al. 1990). Two antibodies in particular, named 1B7 
and 11E6, have proven to be neutralizing in in-vitro assays and exhibit synergistic effects 
when administered together (Sato and Sato 1990). In addition to demonstrating protection 
in a series of in vitro assays, 1B7 and 11E6 were able to protect mice prophylactically 
and even therapeutically, reversing disease symptoms when administered days after 
infection (Sato, Ito et al. 1984).  
The epitope recognized by 1B7 was initially mapped near the S1 catalytic site, 
based on a series of experiments with truncated toxin variants (Bartoloni, Pizza et al. 
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1988, Cieplak, Burnette et al. 1988). Although the mechanism of neutralization is 
unknown, the ability of 1B7 to inhibit the ADP-ribosyltransferase (ADPR) activity of 
PTx in-vitro, suggests 1B7 blocks S1 subunit-mediated catalytic activity (Sato, Ito et al. 
1984, Kaslow, Schlotterbeck et al. 1990, Kaslow, Schlotterbeck et al. 1991). However, no 
correlation has been shown between high in-vitro anti ADPR activity and in-vivo 
neutralizing activity of anti-S1 antibodies (Sato, Sato et al. 1991). In addition, purified S1 
by itself is unable to induce protective antibodies in mice (Nicosia, Bartoloni et al. 1987, 
Bartoloni, Pizza et al. 1988); suggesting neutralizing anti-S1 antibodies may inhibit PTx 
activity independently of the S1 catalytic site. Furthermore, the S1 subunit-mediated 
catalytic activity occurs in the cytosol after PTx undergoes retrograde trafficking as an 
ER escape route to bypass degradation   (Hazes and Read 1997, Worthington and 
Carbonetti 2007).  
To traffic the retrograde pathway, PTx first binds a cellular receptor with 
carbohydrate moieties via its B-oligomer (Heerze and Armstrong 1990, Heerze, Chong et 
al. 1992), undergoes receptor-mediated endocytosis to enter the early/recycling 
endosomes, followed by retrograde transport through the Golgi and the endoplasmic 
reticulum (ER) (Xu and Barbieri 1996, el Baya, Linnermann et al. 1997, Plaut and 
Carbonetti 2008). Within the ER, release of the PTx S1 subunit is dependent upon 
reduction of a disulfide bond in S1 by the presence of a reducing potential and protein 
disulfide isomerase (PDI), and an ATP-induced conformational change in the B subunit 
(Burns and Manclark 1986, Hazes, Boodhoo et al. 1996). Although the molecular details 
of the membrane translocation step for subsequent transport of the S1-subunit out of the 
ER into the cytosol remains unclear, it is thought to involve the Sec61 channel (Hazes 
and Read 1997). Retrotranslocation from the ER, across the Sec61 channel for entry into 
the cytosol, has been implicated for ricin, shiga and cholera toxins (Simpson, Roberts et 
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al. 1999, Schmitz, Herrgen et al. 2000, Yu and Haslam 2005) and demonstrated to be 
exploited by certain viruses for host immune evasion (Wiertz, Tortorella et al. 1996).  
Within the cytosol, the S1 subunit catalyzes the transfer of the ADP-ribosyl moiety from 
NAD to membrane-associated Gi/o proteins, disrupting G-protein function (Figure 4.1) 
(Katada and Ui 1982, Katada, Tamura et al. 1983, Burns, Kenimer et al. 1987). 
 
 
 
Figure 4.1: PTx retrograde trafficking and cell toxicity. 
After binding a cellular receptor 1), PTx traffics retrogradely from the early endosomes 
2) through the Golgi 3), to the endoplasmic reticulum 4). Within the ER, ATP and a 
reducing environment facilitate the unfolding of the S1 subunit, from where it is 
translocated to the cytoplasm. In the cytoplasm, the S1 subunit catalyzes the transfer of 
the ADP moiety from NAD to membrane associated G-proteins 5). The inactivated G-
proteins 6) are unable to inhibit activated 7) adenylyl cylase which forms cAMP from 
ATP, leading to increased cellular cAMP concencentrations.   
Figure adapted from (Sutherland and Maynard 2009). 
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Considering the complexity of the retrograde transport mechanism of PTx and a 
requirement for unfolding of the S1 subunit for translocation potentially through the 
sec61 pore, it is not clear that 1B7 can directly have access to the PTx catalytic site after 
trafficking of the large immune complex through the retrograde organelles to reach the 
highly reductive and proteolytic cytosol to impact catalysis.  Detailed epitope mapping 
using computational docking and site-directed mutagenesis, has specified the 1B7 unique 
epitope to lie primarily on the S1 subunit, and possibly interacting with S4 subunit 
(Sutherland and Maynard 2009), suggesting 1B7 may neutralize PTx toxicity without 
trafficking retrogradely.  The epitope of 11E6 on the other hand, found on the S2 and S3 
subunits (Sato, Sato et al. 1987, Sato, Sato et al. 1990, Rambow-Larsen and Weiss 2004) 
is thought to directly inhibit PTx binding to receptors (Sato, Sato et al. 1987).  
In this study, the mechanisms of 1B7 and 11E6-mediated PTx neutralization were 
further characterized. Using FACS analysis, binding of 1B7 and 11E6 to live B. pertussis 
was detected, demonstrating their epitopes are exposed on B. pertussis, possibly during 
PTx secretion. 1B7 and 11E6 however showed no significant opsonophagocytic activity, 
indicating that these antibodies directly interfere with the toxin’s activities after secretion. 
1B7 with its epitope on the S1 subunit was competent to bind receptor bound PTx. 11E6 
with two binding sites, one on either the S2 or S3 subunits was also able to bind receptor 
bound PTx Both antibodies however inhibited PTx binding to a model receptor, although 
it was expected only 11E6 would be able to do so. 1B7 effects on PTx trafficking in 
CHO-K1 cells were also analyzed to assess the possibility of 1B7 intracellular 
neutralization. Remarkably, although PTx can simultaneously bind both 1B7 and a model 
receptor, 1B7 appears to inhibit PTx internalization, and instead most of PTx remains at 
the cellular membrane. This suggests the epitope of 1B7 on the A/B interface impacts the 
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interaction of PTx with receptors to affect internalization or intracellular trafficking steps 
of the holotoxin.  
PTx in current acellular pertussis vaccines is chemically detoxified, a process 
which damages the protective epitope on the S1-subunit recognized by 1B7 and 11E6 
(Nencioni, Volpini et al. 1991, Sutherland, Chang et al. 2011). Destruction of such 
neutralizing epitopes results in lower protective antibody titers upon vaccination with aP 
vaccines than upon actual infection (Sutherland, Chang et al. 2011).  The induction of 
such rare and unique epitopes, induced mostly after B. pertussis infection, is a goal for 
future pertussis vaccines and their corresponding antibodies have potential for use in 
passive immunotherapy.  
 
 
 
4.2 MATERIALS AND METHODS 
4.2.1 Antigens and antibodies 
PTx (holotoxin) in glycerol was purchased from List Biological Laboratories, Inc. 
(Campbell, CA) or obtained through BEI Resources, NIAID, NIH.  A soluble, truncated 
version of the PTx S1 subunit, PTx-S1-220 was expressed and purified from the pAK400 
plasmid in E. coli, as described previously (Sutherland and Maynard 2009). The 
expression and purification details for full length murine 1B7 has been described 
previously (Sutherland and Maynard 2009). Humanized 1B7 and 11E6 versions of the 
murine monoclonal antibodies, with similar affinity and epitope specificity as the parent 
murine antibodies, were purified from CHO cells using protein A and anion 
chromatography by Catalent (Somerset, NJ) (Nguyen et al., 2014. In review). Purification 
of the human anti-PTx antibodies A8 and D8, specific for the A and B subunits 
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respectively is described in Chapter 3. Isotype control antibodies (IgG1 and IgG2a) were 
purchased from Santa Cruz Biotech or R&D systems. Commercial fluorescent secondary 
antibodies used are indicated. 
 
4.2.2 Antibody binding to whole B. pertussis  
The expression of PTx-epitopes on live B. pertussis was analyzed by indirect 
immunofluorescence using flow cytometry as previously described in Chapters 2 and 3 
(Aase, Herstad et al. 2007). The bacteria were grown for 72 hours on Bordet-Gengou, 
harvested and washed, and adjusted to an OD600/mL of 1 in PBS with 5% glycerol 
(PBSG). The bacteria were incubated with 1 µg of each antibody in 100 µL at room 
temperature and bound antibodies detected after washing with a 1:500 dilution of goat 
anti human Fc Alexa Fluor 647 conjugate (Jackson Immunoresearch). 10 000 events per 
treatment were collected on a BD SLRII Fortessa flow cytometer. The cell associated 
fluorescence for a gated population of the cells was determined using the FlowJo_V10 
software. 
 
4.2.3 Opsonophagocytic activity of PTx-specific antibodies 
Opsonophagocytic activity (OPA) performed by the Aase group, was measured as 
a respiratory burst, as previously described (Aase, Herstad et al. 2007). Briefly, 
hybridoma cell supernatants of anti-PTx antibodies 1B7 or 11E6, pooled anti-pertussis 
antibodies from vaccinated volunteers (P-IVIG), or purified monoclonal antibodies 
against PorA protein of Neisseiria meningitidis (Michaelsen, Kolberg et al. 2004) were 
diluted twofold in HBSS/BSA (2 mg/ml). Live B. pertussis (105/06), were used as 
targets, and dihydrorhodamine 123 (Invitrogen) primed PMNs from a donor 
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heterozygous for the FcgammaRIIa allotype were used as effector cells. 
Dihydrorhodamine 123 was used as a probe for respiratory burst. Human serum (10 %) 
was used as complement source, after being passed through a protein G column (HiTrap 
protein G HP; GE Healthcare, Oslo, Norway) to remove antibodies.  
 
4.2.4 CHO neutralization assay 
A CHO neutralization assay was used to determine the concentration of 1B7 
which rescues CHO cells from PTx induced clustering. CHO-K1 cells (ATCC, Manassas, 
VA) were grown in complete DMEM media (DMEM supplemented with 10% fetal 
bovine serum and 1X penicillin/streptomycin). The cells were grown and maintained at 
37 C with 5% CO2 in a jacketed incubator. The working cell concentration of 1.5 x 10
4
 
cells/96 well was first determined from a preliminary cell concentration series. The 
working concentration of PTx was determined from a preliminary toxin concentration 
series to find the lowest concentration resulting in complete CHO cell clustering. 
Clustering due to PTx toxicity was scored from 0 to 3 as follows; 0(no clustering), 1(a 
few clusters/equivocal), 2(positive clustering), 3(maximum/complete clustering). A PTx 
concentration of 0.25ng/ml (150µl culture volume) was determined to be the minimum 
concentration causing maximum clustering with a score of 3. A test dose of 1.05ng/ml 
PTx (150µl culture volume) (approximately four times higher than the minimum PTx 
dose showing a score of 3) was used to allow maximum clustering to be observed and 
reduce PTx lot-to-lot variability. To determine the neutralizing concentration of 1B7 and 
11E6, serial two-fold dilutions of antibody were prepared in complete DMEM media 
leaving 25 µl in all the wells. Next, 25 µl of PTx was added to all wells and the complex 
incubated for 30 minutes at 37˚C. CHO cells were trypsinized and diluted to 1.5 x 105 
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cells/ml in complete media. 100 µl of cells were added to the PTx-antibody solution to 
achieve the final cell concentration of 1.5 x 10
4
 total cells/96 well.   
 
4.2.5 ELISAs 
4.2.5.1 Indirect PTx ELISA 
Indirect capture ELISAs to assess the binding affinity and epitope specificity to 
the PTx holotoxin or subunits were performed as described in Chapter 3 with no 
modifications. PTx holotoxin final concentration was 1 µg/ml. PTx A-subunit and PTx 
B-subunit final concentrations were 0.25 µg/ml and 0.85 µg/ml respectively.  
 
4.2.5.2 Simultaneous binding of 1B7 and 11E6 to PTx 
Simultaneous binding of 1B7 and 11E6 to PTx was evaluated in a capture ELISA.  
High binding ELISA plates were coated with 1 µg/ml of the humanized versions of 1B7 
or 11E6. After blocking with PBST-milk, serial dilutions of PTx were added and 1 µg/ml 
of the murine parental versions of 1B7 or 11E6 added. Binding of the murine antibody 
was detected with a goat-anti-mouse HRP. The plates were developed using TMB and 
quenched with 1N HCl.  
 
4.2.5.3 Simultaneous binding of antibody PTx bound to fetuin 
As described in section 3.2.6.3, fetuin was used as model soluble receptor to 
detect antibodies bound to a PTx-fetuin complex using a method adapted from (Kenimer, 
Kim et al. 1989). High binding ELISA plates (Costar) were coated with 50 µL/well of 10 
µg/mL fetuin (Sigma) at in PBS. After overnight incubation at 4˚C, the plates were 
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blocked with 50 µL/well blocking buffer (PBS + 5% BSA) at room temperature for 1 
hour. Plates were washed three times in wash buffer (PBS, + 0.05% Tween-20) after each 
incubation step. Serially diluted PTx was then added to the fetuin coat and incubated 
further overnight. Antibodies at a concentration of 1 µg/ml antibody were then added and 
incubated for 1 hour at room temperature. Anti-human Fc HRP (Jackson 
Immunoresearch) was added at a 1:1000 dilution in wash buffer and incubated at room 
temperature for another hour. Signal was developed using the TMB Substrate Kit 
(Thermo-Scientific), the reaction stopped with 1N HCl, and the plate read using a 
SoftMax Pro v5 (Molecular Devices) at 450 nm. All plated volumes were 50 µL/well.  
  
4.2.6 Competition ELISA assays 
4.2.6.1 Antibody competition for binding to PTx 
The ability of 1B7 and 11E6 to compete for binding to PTx was evaluated by a 
competition ELISA as described for the human anti-PTx antibodies (Chapter 3). Briefly, 
the humanized 1B7 and 11E6 were biotinylated, and serial dilutions of the non-
biotinylated 1B7 or 11E6 competitor antibody incubated with a constant concentration 
the biotinylated antibody. The biotinylated antibody was detected after incubation of the 
antibody mixtures on a coat of PTx, using streptavidin-HRP, and the reaction developed 
using TMB substrate as described above.  
 
4.2.6.2 Antibody Inhibition of PTx binding to fetuin 
Using fetuin as a model receptor, the ability of 1B7 and 11E6 to inhibit PTx 
binding to fetuin in a competition ELISA was investigated as described for the human 
anti-PTx antibodies in Chapter 3. Briefly, fetuin coated overnight at 4
o
C, at a 
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concentration of 10 µg/ml in PBS was blocked the next day with PBS-BSA (5%). 
Serially diluted antibodies with a constant concentration of 0.79 nM PTx were incubated 
overnight at 4
o
C. Bound PTx was detected with a home-made mixture of three murine 
antibodies to PTx (1B7, 11E6 and 7F2) at 0.1 µg/mL. The mouse antibodies were 
detected using HRP-conjugated goat-anti mouse antibodies and the plates developed with 
TMB. The absorbances were read at 450nm and analyzed using Graphpad prism 5. The 
relative ability of the antibodies to inhibit PTx binding to fetuin was determined by 
estimation of the concentration of each antibody required to achieve 50% maximal 
binding at saturation (IC50). 
 
4.2.7 PTx intracellular trafficking via immunofluorescence microscopy 
Coverslips were seeded with at 5 x 10
5
 CHO cells/ ml in a 6 well plate and 
allowed to grow for 48 hours.  To visualize the early endosomes and Golgi, 3 µg of 
Rab5-GFP plasmid DNA or 50 µL of CellLight
TM
 Golgi-GFP Bacman 2.0 (Invitrogen) 
respectively were transfected into CHO cells grown on covers slips in a 6 well a day prior 
to the PTx trafficking assay. All samples were washed twice with PBS prior to further 
processing. The cells were then incubated in blocking buffer (serum and antibiotic-free 
DMEM media containing 2 mg/mL BSA, and 1µg/ml of an irrelevant murine IgG1 
antibody) at 37˚C with 5% CO2 for an additional 30 min. To visualize PTx trafficking, 
cells were incubated with 100µl of 10 nM PTx at 37
o
C 5% CO2 for varying times (15 
minutes to 4 hours). At select time points, the cells were washed with PBS and fixed with 
4% paraformaldehyde for 20 min at room temperature. After fixation, the cells were 
washed with PBS three times, permeabilized with PBS containing 0.1% Triton X-100 for 
30 minutes at room temperature and subsequently blocked with blocking buffer for 1 hr 
at 37˚C.  PTx was detected using 100µl of 0.5 µg/mL of a human monoclonal anti-PTx 
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antibody to the A subunit (A8) or to the B subunit (D8) in blocking buffer at 37˚C for 1 
hour or at 4
o
C overnight in humid conditions.  The endoplasmic reticulum was detected 
after PTx intoxication and fixing by primary antibody labeling to the ER-resident protein 
PDI using 100µl of anti-rabbit PDI (Sigma-Aldrich) at a 1:1000 dilution and detected 
with 100µl of 1:1000 anti-rabbit-IgG-Alexa488 (Molecular Probes). Next, the cells were 
washed three times with PBS and secondary antibody labeling done with 100µl of 1:1000 
dilutions of anti-human-IgG-AlexaFluor 594 (Molecular Probes) in blocking buffer in the 
dark at 37˚C for 1 hr.  After three final washes with PBS, the coverslips were mounted on 
slides using a drop of DAPI-fluoromount-G (SouthernBiotech, Birmingham, AL). To 
examine the effects of 1B7 on PTx trafficking, PTx was pre-incubated with 1000 or 
10,000-fold molar excess of 1B7 at 37˚C for 30 min prior to incubation with cells on at 
37˚C with 5% CO2. Imaging was performed with a Zeiss Axiovert fluorescent 
microscope (Carl Zeiss, Inc) and AxioVision software or a Leica SP2 AOBS confocal 
microscope (Leica, Bannockburn, IL). Images were enhanced by adjusting brightness and 
contrast using the ImageJ software (http://rsbweb.nih.gov/ij). 
 
 
4.3 RESULTS 
4.3.1 1B7 and 11E6 bind to live B. pertussis but may not induce opsonophagocytic 
activity  
Prior to secretion of PTx, the S1 subunit localizes to the outer membrane of the 
bacterium to serve as a nucleation site for assembly with the B oligomer to form the 
holotoxin (Pizza, Bugnoli et al. 1990, Farizo, Huang et al. 2000, Farizo, Fiddner et al. 
2002). Antibodies against surface exposed antigens on B. pertussis are reported to 
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promote phagocytosis (Hellwig, Rodriguez et al. 2003, Aase, Herstad et al. 2011). If 
either the 1B7 or 11E6 epitopes on PTx is transiently expressed on the bacterial cell 
surface during secretion, then antibodies could mediate opsonization of bacteria and/or 
complement-dependent lysis.   
To determine whether 1B7 and 11E6 are able to bind whole bacteria, the 
antibodies were incubated with live B. pertussis, followed by washing and signal 
development with a fluorescent secondary antibody conjugate and analysis by flow 
cytometry. Binding of 1B7 and 11E6 to live bacteria was detected, whereas a human 
polyclonal immunoglobulin preparation, which includes antibodies recognizing multiple 
pertussis antigens, showed strong binding (Figure 4.2).  
This result suggests the 1B7 and 11E6 epitopes are exposed during PTx secretion 
and therefore suggested that PTx may serve as a target for killing of B. pertussis through 
opsonophagocytic (OPA) or complement activity. In collaboration with Audun Aase, 1B7 
and 11E6 were tested for OPA activity. A polyclonal immunoglobulin preparation (P-
IVIG) and convalescent serum (KjHa) both revealed high OPA activity, however, no 
OPA activity was observed when 1B7 or 11E6 was incubated with live B. pertussis strain 
105/06 (Figure 4.3). 
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Figure 4.2: 1B7 and 11E6 binding to whole B. pertussis.  
A) Representative FACS plot of 1B7 antibody binding to whole B. pertussis cells. B. pertussis cells grown on Bordet Gengou 
plates were scraped and resuspended to 1 OD600/mL. The cells were washed and incubated with 1 µg of the antibodies in PBS 
with 5% glycerol. Bound antibodies were detected with fluorescently labeled anti-human Alexa Fuor 647 secondary antibody 
and analyzed by flow cytometry. B) Percentages of fluorescent Bordetella cells after incubation with the indicated antibodies. 
Using the FlowJo_V10 software, % fluorescent cells were determined for a gated population of the cells using unlabeled B. 
pertussis as a negative control. Data represent the average of two independent experiments. The error bars represent the 
standard error of the mean. 
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These results are in agreement with previous data showing that while polyclonal 
serum containing antibodies to PTx, FHA and pertactin (PRN) from vaccinated 
individuals exhibit binding to whole B. pertussis (Weingart, Keitel et al. 2000, Hellwig, 
Rodriguez et al. 2003, Aase, Herstad et al. 2011), opsonophagocytic activity is mostly 
due to anti-PRN antibodies (Gotto, Eckhardt et al. 1993, Hellwig, Rodriguez et al. 2003) 
and possibly anti-FHA antibodies (Aase, Herstad et al. 2011). Antibody-mediated 
complement killing of bacteria also requires a complex of the antigen on the surface of 
the bacteria with complement-fixing antibody (Weiss, Patton et al. 2004). Since PTx is 
mostly secreted, there may only be a few PTx molecules on the surface of the bacteria to 
mediate complement bactericidal activity.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3: Opsonophagocytic activity of anti-pertussis antibodies. 
Serially diluted antibodies were incubated with live B. pertussis and added to (DHR) 
primed peripheral mononuclear cells. The mixture was incubated in the presence of 10% 
IgG depleted human serum. Respiratory burst was measured as the increase in green 
fluorescence due to oxidation of DHR to rhodamine. The experiment was repeated twice 
with similar results by the Aase group as indicated in the materials and methods section. 
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4.3.2 1B7 and 11E6 bind non-overlapping epitopes on the A and B subunits of PTx 
with a 2:1 stoichiometry  
Using indirect ELISAs to probe antibody binding to the holotoxin, we confirmed 
1B7 and 11E6 binding to the PTx holotoxin with affinities of 0.27 ± 0.14 and 1.24 ± 0.14 
nM respectively (Table 3.4). 1B7 and 11E6 binding to the PTx A subunit or the B 
oligomer respectively were also similarly confirmed. 1B7 binding was confirmed using a 
truncated recombinant version of the A-subunit, PTx S1-220, or the B-oligomer. 
Humanized 1B7 binds the truncated S1 variant, PTx S1-220 with an affinity of 0.008 ± 
0.002 nM. The murine 11E6 binds the PTx B-oligomer with a lower affinity of 1.18 ± 
0.19 nM respectively (Table 3.4). The high affinity binding of 1B7 and 11E6 to the S1 
subunit and B-oligomer respectively confirms their epitopes primarily lie on these 
subunits. 
The epitope of 1B7 however was recently specified to overlap the S1 and S4 
subunits (Sutherland and Maynard 2009), suggesting a weaker affinity site on the second 
S4 subunit in the B oligomer. The 11E6 epitope has also previously been shown to lie to 
on the S2 and S3 subunits. This suggests both 1B7 and 11E6 bind PTx with a 2:1 
stoichiometry. We attempted to determine the stoichiometry of 1B7 binding to PTx using 
various techniques such as analytical ultracentrifugation and column chromatography. 
However, due to the susceptibility of PTx to aggregation (Tamura, Nogimori et al. 1982), 
and non-specific binding through its lectin like properties to various chromatography 
columns (Fowler, Byron et al. 2003), we were unable to determine the stoichiometry of 
1B7 binding to PTx using biophysical methods such as analytical ultracentrifugation and 
gel filtration. To assess the 2:1 antibody:PTx binding stoichiometry, we used an antibody 
capture ELISA with the humanized version of 1B7 or 11E6 coated, to which serially 
diluted PTx was added. Detection of the parental murine antibodies added to the PTx coat 
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suggested 1B7 and 11E6 do bind two unique epitopes on the PTx holotoxin. The binding 
affinity of 11E6 to PTx already bound to 1B7 was estimated to be 1.11 ± 0.05 nM, 
similar to 11E6 binding to free PTx. The binding affinities of 1B7 and 11E6 binding a 
second epitope were estimated to be 26.75 ± 0.19 and 14.18 ± 0.02 nM respectively 
(Figure 4.4), suggesting a lower affinity binding of 1B7 and 11E6 to their succeeding 
epitopes.  
 
 
Figure 4.4:  Simultaneous binding of 1B7 and 11E6 to PTx.  
Serially diluted PTx was added to the humanized versions of 1B7 or 11E6 coated at 
1µg/ml. A concentration of 1µg/ml of the murine 1B7 or 11E6 was then added to the 
antibody-PTx sandwich. Bound murine antibodies were detected using secondary goat-
anti-mouse HRP antibody. The absorbances at 450nm were normalized for each data set 
using GraphPad prism 5 by setting the highest absorbance to 1. Estimates of the affinity 
(EC50) of the murine antibody binding to PTx were determined from the fit of the binding 
curves to the 4PL non-linear equation using GraphPad prism 5. SE - standard error of the 
mean.
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4.3.3 PTx bound to a model receptor can simultaneously bind 1B7 or 11E6 
PTx binds to receptors on host lung resident cells, is internalized and transported 
to the cytosol to exert its toxic effects. While the receptors for PTx are still unknown, 
transferrin and haptoglobin (Heerze and Armstrong 1990, Heerze, Chong et al. 1992) and 
has been co-crystallized with a soluble oligosaccharide from transferrin (Stein, Boodhoo 
et al. 1994).  The receptor-binding sites have also been localized to subunits S2 and S3 
(Schmidt and Schmidt 1989, Schmidt, Raupach et al. 1991, Schmidt, Seitz et al. 1991, 
Heerze, Chong et al. 1992, Stein, Boodhoo et al. 1994). The 1B7 epitope, located 
primarily on the S1 subunit (Bartoloni, Pizza et al. 1988, Cieplak, Burnette et al. 1988) 
and possibly overlapping the S4 subunit (Sutherland and Maynard 2009) is distal to the 
characterized receptor-binding sites. The 11E6 epitope on the other hand is found on 
subunits S2 and S3 (Sato, Sato et al. 1987, Sato, Sato et al. 1990, Rambow-Larsen and 
Weiss 2004).  Consequently, it would be expected that 1B7 would be able to bind PTx 
when already bound to a receptor, while 11E6 would be unable to bind.  
To test the ability of 1B7 and 11E6 to bind PTx and a model receptor, an indirect 
ELISA was used to assess simultaneous binding of the PTx-antibody complex to fetuin. 
Fetuin was immobilized on the plate, incubated with PTx, followed by addition of 
antibody to the PTx bound to fetuin and detection of bound antibody. The PTx-1B7 
complex was able to bind fetuin in a dose-response manner, similarly, the PTx-11E6 
complex also showed specific, but slightly weaker, dose-response binding, while none 
was detected for an irrelevant isotype control antibody (Figure 4.5). 1B7 is expected to 
bind PTx already bound to fetuin is as expected, since its primary epitope is located on 
the S1 subunit, distal from the receptor binding sites in S2 and S3. However, the results 
indicate that while the 11E6 has been hypothesized to directly inhibit PTx receptor 
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interactions, it may only partially block the PTx-receptor interaction, since there are two 
receptor sites are present on each PTx molecule. With one site binding immobilized 
fetuin, the other site is available for 11E6 binding. Two additional PTx-specific, non-
neutralizing antibodies, 3F10 and G9A (Sato, Sato et al. 1987), also exhibited specific 
binding to PTx bound to another model receptor, transferrin (not shown). This data shows 
that an antibody-PTx complex is able to bind a model receptor and may be likely to bind 
a cellular receptor. Similar results have been previously observed for anti-Shiga toxin 
antibodies using flow cytometry analysis (Krautz-Peterson, Chapman-Bonofiglio et al. 
2008). Krautz-Peterson group observed their anti-A chain antibody was competent to 
bind Shiga toxin already bound to receptors on cells. In their studies however, their anti-
B oligomer antibody was not able to bind to Shiga toxin already bound to cells. 
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Figure 4.5: Simultaneous binding of antibodies to PTx bound to fetuin.  
Serially diluted antibodies were added to PTx previously incubated with a coat of fetuin 
at 10 µg/ml. Bound antibodies were detected using secondary goat-anti-mouse HRP 
antibody. Error bars indicated are the standard error of the mean.  
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4.3.4 The PTx-1B7 or PTx-11E6 complex inhibits binding to fetuin 
Many anti toxin antibodies neutralize toxic activity extracellularly by directly 
binding the toxin and sterically blocking key interactions, in particular, initial toxin-
receptor interactions or toxin oligomerization steps occurring prior to receptor mediated 
endocytosis (Pai, Sutherland et al. 2009). For instance, the 14B7 antibody binds an 
epitope on anthrax toxin that overlaps with that of the cellular receptor to block the toxin-
receptor interactions (Leysath, Monzingo et al. 2009).  The 11E6 epitope found on the 
receptor-binding subunits on S2 and S3 (Sato, Sato et al. 1987, Sato, Sato et al. 1990, 
Rambow-Larsen and Weiss 2004), was expected to efficiently inhibit PTx binding to 
fetuin. The 1B7 epitope on the hand, found primarily on the S1 subunit and possibly 
overlapping the S4 subunit (Sutherland and Maynard 2009), was not expected to inhibit 
PTx binding to fetuin. 
 To our surprise, we found both 1B7 and 11E6 were able to block PTx binding to 
fetuin with IC50’s of 0.26 ± 0.05 and 0.11 ± 0.07 nM respectively (Figure 4.6). The 
surprising ability of an anti-PTx S1 subunit antibody blocking PTx binding to fetuin 
although it also readily binds PTx already bound to fetuin has been reported previously 
(Kenimer, Kim et al. 1989). It has been suggested that the orientation of PTx after 
binding a cellular receptor may not completely obscure the S1 epitope (Kaslow and 
Burns 1992), however such anti-S1 antibodies which inhibit PTx binding to receptors 
may interfere with conformational changes induced when PTx binds to a receptor 
(Kenimer, Kim et al. 1989). Further studies would need to be done to elucidate the nature 
of any conformational changes induced in PTx after receptor binding, and how 1B7 may 
interfere with such conformational changes. 
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Figure 4.6: Competition ELISA for 1B7 and 11E6 inhibition of PTx binding to fetuin.  
Serially diluted antibodies with a constant concentration of PTx were added to ELISA 
wells coated with 10 µg/ml fetuin. Bound PTx was detected with a mixture of murine 
anti-PTx antibodies. The IC50 were determined from fitting the inhibition curves to the 
four parameter logistic (4PL) curve using GraphPad Prism 5. The IC50 data represent the 
average of two independent experiments. SE - standard error of the mean. 
 
 
4.3.5 1B7 hinders PTx internalization in CHO cells 
CHO-K1 cells are usually utilized for studies of pertussis toxin toxicity and 
neutralization due to easily observed morphological changes induced in the cells upon 
exposure to the toxin (Hewlett, Sauer et al. 1983). The concentration of 1B7 and 11E6 
able to fully neutralize PTx induced CHO clustering, determined from the change in the 
score from 1 to 0 was approximately 3750 ± 1250 and 1875 ± 625 molar excess of the 
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PTx test dose respectively (Figure 4.7). The higher molar neutralization ratio of 1B7 
compared to 11E6 for the complete neutralization of PTx induced clustering in CHO cells 
is consistent with previous results (Sato, Sato et al. 1987). It is important to note however 
that in in-vivo mice studies, 1B7 was as potent as 11E6 at neutralizing PTx toxicity (Sato, 
Sato et al. 1987, Sato and Sato 1990). In the aerosol challenge 1B7 protected 100% of the 
mice, while 11E6 protected 85%. In the intracerebral challenge, 1B7 protected 83% of 
the mice, while 11E6 protected only 7%. These results may suggest that 1B7 and 11E6 
neutralize PTx differently depending on the cell type. PTx binds to oligosaccharide 
receptors on a variety of mammalian cells, and there are at least two glycoprotein binding 
sites on PTx with variable affinities, one on the S2 subunit (Francotte, Locht et al. 1989, 
Heerze, Chong et al. 1992), and another on the S3 subunit (Schmidt, Raupach et al. 
1991). In spite of the greater than 80% sequence homology between the S2 and S3 
subunits, they each appear to be carbohydrate and cell type specific (Saukkonen, Burnette 
et al. 1992). For instance, residues within the S2 subunit have been shown to have a 
higher affinity for sialic acid containing glycoconjugates such as fetuin (Heerze, Chong et 
al. 1992).  
We observed no neutralization of CHO cell clustering when PTx was first added 
to CHO cells on ice, prior to the addition of 1B7 or 11E6 (not shown), further suggesting 
both 1B7 inhibit PTx toxicity in CHO cells by inhibiting the interaction of PTx 
interaction receptors as the fetuin inhibition assay suggested. The lower neutralization 
capacity of 1B7 compared to 11E6 in the CHO assay may be due to the differences in the 
antibody binding sites and which receptor subunits on PTx interact with receptors on 
CHO cells.   
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Figure 4.7: Antibody neutralization of PTx mediated CHO cell clustering.  
A) A constant concentration of PTx was pre-incubated with serial dilutions of the indicated antibodies and added to a constant 
concentration of CHO cells. The cells were scored 24 hours later. B) Molar neutralization of PTx mediated CHO cell 
clustering by 1B7 11E6 and P-IVIG. The minimum molar concentration of antibody:PTx needed to change the CHO clustering 
score from 1 to 0.
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Retrograde transport of PTx has previously been demonstrated in CHO-K1 
epithelial cells and subsequently in AMJ2-C8 and A549 (alveolar macrophages and lung 
epithelial cell lines respectively) (Plaut and Carbonetti 2008). After binding to a cellular 
receptor, PTx undergoes receptor-mediated endocytosis and follows a path of retrograde 
transport, traveling from the early/recycling endosomes to the Golgi and then to the ER 
(Xu and Barbieri 1996, el Baya, Linnermann et al. 1997, Plaut and Carbonetti 2008). In-
vitro ADPR activity of PTx has been shown to occur by 1 hour suggesting PTx is 
internalized and retrograde transport occurs within this time (Xu and Barbieri 1995). 
Previous co-localization experiments with the Golgi have indicated that PTx begins 
accumulating in this organelle after ~20 minutes (Kugler, Bocker et al. 2007). In other 
studies, tagged PTx-S1 was found to be modified by tyrosine sulfation which occurs in 
the Golgi network within 2 hours suggesting Golgi transport is the slow step in the 
retrograde trafficking (Plaut and Carbonetti 2008). Tagged PTx-S1 has also been found to 
be N-glycosylated, a modification which occurs in the ER, within 3 hours (Plaut and 
Carbonetti 2008).  
We first visualized normal PTx transport in cells via immunofluorescence 
microscopy using CHO-K1 cells as model epithelial cells. Monoclonal antibodies A8 and 
D8, recognizing epitopes on the S1 and B subunits of PTx respectively, were used to 
detect PTx at various times after incubation. Simultaneously, individual organelles were 
visualized with endosome GFP constructs, CellLight® Golgi reagents or anti PDI 
antibodies to the endoplasmic reticulum. Similar PTx localization was observed when 
either the A or B subunit of PTx was used as a detection handle. In the absence of 
antibodies, PTx was observed to co-localize with the early endosomes within 15 to 60 
minutes, started accumulating in the Golgi by 1 hour and started dispersing from the 
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Golgi to co-localize with the ER by ~3 hours (Figure 4.8). Our results are therefore 
consistent with the kinetics of PTx retrograde trafficking (Plaut and Carbonetti 2008).  
 
 
Figure 4.8: Retrograde trafficking of PTx in CHO cells.  
PTx was incubated with CHO cells at 37
o
C for the indicated time points. Intracellular 
PTx was detected by microscopy after fixing and permeabilization with the monoclonal 
antibody, D8, to the B-oligomer. D8 bound to PTx was labeled with a fluorescent anti-
human-IgG-AlexaFluor 594 secondary antibody before imaging. The early endosomes 
and golgi were detected by transfecting the CHO cells a day prior to the trafficking 
experiments with a Rab5-GFP plasmid or CellLight
TM
 Golgi-GFP baculovirus 
respectively. The endoplasmic reticulum was detected after PTx intoxication and fixing 
by primary antibody labeling to the ER-resident protein PDI and detected anti-rabbit-
IgG-Alexa488. The experiments were repeated at least twice with similar results.  
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We note that the early endosomes and Golgi are not completely labeled possibly due to 
fixation with the paraformaldehyde. Further studies are ongoing to test fixation methods 
to improve the visualization of the early endosomes and Golgi. 
In order to directly visualize how 1B7 affects PTx intracellular trafficking, the 
CHO cells were incubated with PTx and 10 000 molar excess 1B7, a concentration 
determined to be approximately 3-fold higher than the neutralizing concentration 
determined from the CHO assay. At this concentration of 1B7, receptor mediated 
endocytosis of the 1B7-PTx complex appeared to be hindered, as PTx remained 
associated with the cell surface/plasma membrane of most cells for the time period tested 
(Figure 4.9). Cells incubated with up to a 10,000 molar excess mIgG2a isotype control 
mouse antibody showed full internalization of PTx with trafficking similar that of toxin 
in the absence of antibodies (not shown). A previous study in our lab has also shown that 
neutralizing concentrations of 1B7 incubated with PTx are also detected at the plasma 
membrane in the presence of PTx, and does not co-localize with any of the retrograde 
organelles (Jamie Sutherland dissertation, 2010). The presence of PTx at the plasma 
membrane suggests two models of 1B7 neutralization of PTx toxicity. In the first model, 
1B7 inhibit PTx internalization by sterically hindering the interaction of PTx with the 
receptors on the surface of the cell. 1B7 primarily binds the S1 subunit, and has been 
hypothesized to bind the S4 subunit as well. We also show in this study that 1B7 does 
have a second lower affinity binding site on PTx. Although the S1 and S4 subunits do not 
have the glycan receptor binding sites (Millen, Schneider et al. 2010), the S4 subunit has 
been implicated in interacting with the cell membrane during the penetration step of PTx 
(Montecucco, Tomasi et al. 1986). The S4 subunit has also been implicated in stabilizing 
the S2 subunit upon formation of the S2S4 dimer (Francotte, Locht et al. 1989).  
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Figure 4.9: 1B7 inhibition of PTx retrograde trafficking in CHO cells.  
PTx incubated with 1B7 was added to CHO cells at 37
o
C for the indicated time points. 
PTx was detected with the monoclonal antibodies, A8, to the A-subunit, and D8, to the B 
subunit after fixing and permeabilization. The antibodies bound to PTx were detected 
with a fluorescent anti-human-IgG-AlexaFluor 594 secondary antibody before imaging. 
The early endosomes and golgi were detected by transfecting the CHO cells with a Rab5-
GFP construct or CellLight
TM
 Golgi-GFP respectively, a day before the trafficking 
experiments. The endoplasmic reticulum was detected after PTx intoxication and fixing 
by primary antibody labeling to the ER-resident protein PDI and detected anti-rabbit-
IgG-Alexa488. The experiments were repeated at least twice with similar results.  
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1B7 binding the high affinity S1-S4 epitope and possibly the second lower affinity S4 site 
could therefore sterically affect toxin-receptor interactions to hinder receptor mediated 
endocytosis. In the second model of 1B7 neutralization, PTx bound to 1B7 may co-
internalize, but be inhibited from the normal retrograde trafficking pathway. Recycling of 
the PTx-1B7 complex back to the cell surface would then lead to accumulation of PTx at 
the surface. Neutralizing antibodies to the Shiga toxin and other small molecules to ricin 
have been shown to neutralize toxicity by inhibiting retrograde trafficking after co-
internalization. Previous studies in our lab suggest the PTx-1B7 complex can remain 
bound in conditions mimicking the retrograde organelles. However, the ability of 1B7 to 
inhibit PTx binding to fetuin also suggests 1B7 may sterically hinder PTx binding to 
receptors. Further studies using methods such as sub-cellular fractionation may therefore 
be needed to fully elucidate the mechanism of 1B7 neutralization in CHO cells. 
  
 
4.4 DISCUSSION 
Recent studies clarifying the potently neutralizing 1B7 epitope in our laboratory 
show the anti S1 antibody overlaps the S4 subunit (Sutherland and Maynard 2009), thus 
possibly “stapling” the A and B subunits. In-vivo, 1B7 neutralizes most of the toxic 
activities attributed to the catalytic activity of the PTx S1-subunit such as leukocytosis-
promoting and islet-activating (Burns et al., 1987). Additionally, 1B7 neutralizes the 
ADP ribosyltransferase (ADPR) activity of S1 in-vitro, suggesting that in-vivo; 1B7 
could competitively inhibit substrate access at the S1 catalytic site. High in-vitro anti 
ADPR activity of S1 antibodies however does not correlate with in vivo neutralizing 
activity (Sato, Sato et al. 1991). Also, it appears unlikely for antibodies to directly 
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interfere with the ADPR activity in the cytosol in living cells, as this would require 
escape from the ER of the antibody toxin complex and re-formation of an antibody-S1 
complex in the cytoplasm. In light of the additional information regarding the interfacial 
epitope of 1B7 spanning the S1 and S4 subunits, we sought to further characterize the 
mechanism of 1B7 neutralization of PTx.  We also further characterized the mechanism 
of neutralization of 11E6 whose epitope is found on the S2 and S3 subunits (Sato, Sato et 
al. 1987, Sato, Sato et al. 1990, Rambow-Larsen and Weiss 2004) and is thought to 
directly inhibit PTx binding to receptors (Sato, Sato et al. 1987). Better understanding of 
the mechanisms of 1B7 and 11E6 neutralization of PTx may aid in antigen engineering of 
the epitope to develop PTx variants inducing stronger protective responses. 
We determined that both the 1B7 and 11E6 epitopes were weakly expressed on 
the surface of live bacteria, but did not observe significant opsonophagocytic activity due 
to the antibodies. Consequently, the potent prophylactic/therapeutic properties of 1B7 
must rely on recognition of secreted PTx. Although 1B7 and 11E6 do not appear to 
induce bactericidal activity, the neutralization of either secreted or cell surface bound 
PTx toxicity, may have implications for PTx mediated adherence. PTx and FHA are 
important for bacterial adherence to eukaryotic macrophages or cilia (Tuomanen and 
Weiss 1985, van't Wout, Burnette et al. 1992). In the absence of either PTx or FHA, no 
adherence to the eukaryotic cells was observed (Tuomanen and Weiss 1985). PTx is a 
however a secreted toxin, and the apparent redundancy of PTx and FHA in bacterial 
adherence has been shown to be due to the PTx mediated release of TNF-α, which may 
damage the pulmonary epithelium to allow more efficient colonization (Alonso, Pethe et 
al. 2001). Through neutralization of PTx toxicity, 1B7 and 11E6 may therefore be able to 
block relevant TNF-α release needed for bacterial adherence. Interestingly, it has been 
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observed that treatment with 1B7 and 11E6 reduces bacterial load in infected mice (Sato, 
Sato et al. 1990) or baboons (Nguyen, et al. 2014, in review).  
To inhibit PTx function, a block in any of the retrograde transport steps can lead 
to toxin neutralization. The first step of the retrograde transport is the interaction of PTx 
with the host cell receptors. Antibodies that block this interaction would most likely 
interact with PTx at its receptor binding sites. We determined that PTx can be 
simultaneously bound to a model receptor, transferrin, and 1B7 or 11E6. This result was 
as expected for 1B7, since its primary epitope is located on the S1 subunit, and not on the 
receptor binding subunits in S2 and S3. This therefore suggested 1B7 may neutralize PTx 
activity after it interacts with a receptor. The weaker but specific simultaneous binding of 
11E6 with the model receptor also indicated 11E6 can bind its second site while bound to 
a receptor. We subsequently confirmed that 11E6 was able to inhibit PTx binding to the 
model receptor, fetuin. Surprisingly we also found that 1B7 was also competent to inhibit 
PTx binding to fetuin, although its binding sites are not on the receptor binding subunits. 
Upon directly visualizing 1B7 effects on PTx trafficking in CHO cells, we 
observed that 1B7 appeared to hinder endocytosis of PTx. Over the time period of 4 
hours of PTx trafficking in the presence of neutralizing 1B7 concentrations, PTx was 
observed be associated with the plasma membrane in the cells imaged. Cells incubated 
with up to a 10,000 molar excess mIgG2a isotype control mouse antibody however 
showed full internalization of PTx with trafficking similar that of toxin in the absence of 
antibodies, further suggesting accumulation of PTx at the plasma membrane to be due to 
1B7-mediated inhibition/hindrance of receptor mediated endocytosis. This result was 
therefore complementary to our observation that 1B7 could inhibit PTx binding to the 
model receptor, fetuin. 1B7 is thought to have a second low affinity site the S4 subunit  
(Sutherland and Maynard 2009). Although the characterized receptor-binding sites of 
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PTx are contained in subunits S2 and S3, possibly interact the S4 subunit is thought to 
interact with the cell membrane during the penetration step (Montecucco, Tomasi et al. 
1986). At least two anti PTx antibodies (1B7 and 7F2) recognizing epitopes spanning the 
A/B interface are highly neutralizing in vivo and in vitro (Sato, Sato et al. 1991). While 
the 1B7 and 7F2 antibodies both bridge the S1/S4 interface, 1B7 predominantly 
recognizes S1 and 7F2 predominantly recognizes S4 (Sato, Sato et al. 1991, Sutherland 
and Maynard 2009). With two copies of S4 on PTx, 1B7 may bind the high affinity S1-
S4 epitope as well as the second low affinity S4 site to possibly affect PTx interactions 
with receptor molecules to hinder endocytosis of PTx. Further studies are needed to 
assess the nature of any conformational changes induced in PTx after receptor binding, 
and how 1B7 may interfere with such conformational changes. 
PTx has a relatively fast internalization time, entering cells within 30 minutes (Xu 
and Barbieri 1995), thus escaping into the cell before uptake by phagocytes. Inhibition of 
endocytosis of PTx by 1B7 could therefore allow cells with PTx trapped on the surface to 
be more easily captured by other professional antigen presenting cells (including 
dendritic cells, B lymphocytes and macrophages), for presentation to conventional CD4
+
 
and CD8
+
  T cells (Cohen et al., 1973; Bilsborough and Viney 2004). Also, PTx 
induces receptor cross linking to initiate signal transduction in cells (Schneider, Weiss et 
al. 2007, Schneider, Millen et al. 2012) which contributes to its toxicity. Antibodies 
spanning the A/B interface may therefore additionally/alternatively inhibit PTx toxicity 
by preventing such receptor cross linking. 
The primary epitope of 1B7 being on the S1 subunit, and its ability to inhibit the 
ADP-ribosyl transferase activity of PTx in-vitro, suggests 1B7 directly blocks S1 subunit-
mediated catalytic activity in the cytosol (Sato, Ito et al. 1984, Kaslow, Schlotterbeck et 
al. 1990, Kaslow, Schlotterbeck et al. 1991). For 1B7 to neutralize PTx intracellularly, it 
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would need to undergo receptor-mediated endocytosis with PTx and retain high affinity 
binding in the unique biochemical conditions corresponding to each sub-cellular 
compartment. Rare, yet protective antibodies, and even novel small molecules have been 
identified which intracellularly protect against Shiga toxins (Krautz-Peterson, Chapman-
Bonofiglio et al. 2008), ricin toxin (Song, Mize et al. 2013), and anthrax toxin (Gillespie, 
Ho et al. 2013). These molecules block toxin retrograde transport, although at the early 
endosome-Golgi step, resulting in toxin transfer to the plasma membrane possibly 
through the recycling endosomes. In the study by Krautz-Peterson et al. (Krautz-Peterson, 
Chapman-Bonofiglio et al. 2008), the neutralizing A-subunit specific antibody, 5C12, 
bound and co-internalized with cell bound Shiga toxin 2 (Stx2).  5C12 also did not 
prevent Stx2 binding to the Gb3 receptor, and protected Stx2 bound HeLa cells. In 
contrast to 5C12, 1B7 inhibits PTx binding to a model receptor, fetuin, and is also unable 
to protect CHO cells pre-incubated with PTx, further suggesting 1B7 protects prior to 
internalization of PTx. 
For 1B7 to directly neutralize PTx activity in the cytosol, it would require 
translocation of the PTx-1B7 complex through the retrograde organelles to reach the 
cytosol. Previous studies in our lab evaluating the affinity of the 1B7-toxin complex 
under varying conditions mimicking the retrograde organelles indicated there was no 
significant change in PTx-1B7 binding. These data suggested that the PTx1B7 complex 
could remain bound as the complex co-traffics through the acidic endosomes. The 
analysis also indicated the EC50 of the complex was unaffected by incubation at 37˚C 
with 8µM PDI and up to 0.5 mM ATP suggesting that 1B7 would be able to remain in 
complex with PTx upon binding of PDI and ATP in the ER. (Jamie Sutherland thesis, 
2010). Stability of the PTx1B7 complex in a reducing environment with ATP is in 
agreement with previous in-vitro studies which showed that 1B7 was able to neutralize 
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the toxin’s ADP-ribosylase activity in the presence of ATP and DTT (Sato, Sato et al. 
1987). 1B7 also recognizes reduced PTx on a Western blot. In addition, 1B7 recognizes 
truncated PTx S1 variants with deletions of the C terminus containing the second cysteine 
needed for forming the disulfide bond holding the S1 subunit together (Bartoloni, Pizza et 
al. 1988, Sutherland and Maynard 2009). These results support some linearity to the 1B7 
epitope or suggest folding due to the disulfide bond does not appear to be important in 
forming the 1B7 epitope. It has also been suggested that Western blot and ELISA 
analyses may represent a heterogeneous mixture of undefined forms of PTx (Kaslow, 
Schlotterbeck et al. 1990). As such, the indication of linearity to the 1B7 epitope may 
therefore not be a clear indication that 1B7 neutralizes PTx toxicity intracellularly. 
Furthermore, for 1B7 to directly neutralize PTx activity in the cytosol, it would 
require translocation of both PTx and 1B7 through the ER to reach the cytosol. The 
molecular details of the membrane translocation step for subsequent transport of the S1 
subunit out of the ER into the cytosol remains unclear, however, it is thought 
retrotranslocation across the ER lipid bilayer may involve the Sec61 channel (Hazes and 
Read 1997). It appears improbable for the immune complex of the large IgG molecule, 
consisting of four polypeptides and 17 di-sulfide bonds, and the S1 subunit to dissociate 
and unfold for transport out of the ER, then refold and re-bind S1 in the cytoplasm. If any 
PTx1B7 complex reaches the ER, it is more likely the complex would be trapped in the 
ER. Antibody-toxin immune complexes however have been shown to be able to be 
delivered to the cytosol (Calafat, Molthoff et al. 1988, Raso, Brown et al. 1997), and such 
antibody-toxin conjugates are being explored for use as therapeutics (Teicher and Chari 
2011). It is therefore possible that sec independent pathways may be utilized for transport 
of a PTx1B7 complex to the cytosol. It has also been suggested that PTx can cross the 
plasma membrane directly without the need for endocytosis, since it does not require an 
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acidic environment for entry into eukaryotic cells (Kaslow and Burns 1992), unlike the 
cholera toxin (Janicot, Fouque et al. 1991). The S1 subunit has also been suggested to 
become more structured following binding to NAD in the cytosol (Pande et al, 2006). As 
such, if 1B7 is able to reach the cytosol in complex with PTx, the presence of NAD may 
further facilitate stability of any PTx1B7 complex that reaches the cytosol to enhance 
1B7 neutralization. Further studies using sub-cellular fractionation are therefore needed 
to assess 1B7 co-trafficking with PTx into the cytosol for intracellular neutralization. 
Live cell imaging with fluorescent PTx may also reveal differences in PTx trafficking in 
the presence or absence of 1B7. 
Intracellular antibody mediated neutralization mechanism could also utilize 
lysosomes for degradation (Mellman and Plutner 1984, Joller, Weber et al. 2010) or 
degradation of the immune complex through other Fc receptor mediated mechanisms 
such as TRIM21 (McEwan, Mallery et al. 2011, McEwan, Tam et al. 2013). Various 
constructs of 1B7, including Fabs, scFvs, and scAbs which all lack Fc regions are 
however able to protect in in vitro and in vivo assays, (Sato, Sato et al. 1987, Sato, Sato et 
al. 1990, Sato, Sato et al. 1991, Sutherland and Maynard 2009) suggesting that any Fc 
receptor functions of 1B7 mediated neutralization may be involved secondarily in other 
target cells such as macrophages, APCs, or neutrophils which do contain Fc receptors. 
1B7 also neutralizes PTx activity in CHO cells, which do not have Fc receptors, further 
consistent with a lack of a role for Fc receptor mediated neutralization. 
In other infectious diseases, notably HIV, potently neutralizing epitopes have 
been identified for which corresponding antibodies protect even at modest serum 
concentrations (Walker, Phogat et al. 2009). Currently licensed acellular vaccines for 
pertussis include chemically detoxified PTx, a process which damages the protective 
epitope recognized by 1B7 (Nencioni, Volpini et al. 1991) resulting in lower protective 
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antibody titers upon vaccination than upon actual infection (Sutherland, Chang et al. 
2011).  Antibodies recognizing the potently neutralizing 1B7  11E6 epitope are more 
common in naturally infected than vaccinated individuals (Sutherland, Chang et al. 
2011), suggesting that this epitope may important for protection. New directions in 
pertussis vaccine design which include S1 subunit DNA and other protein vaccines, also 
have lower protective activity most likely because they too lack this protective epitope 
(Kamachi, Konda et al. 2003, Kamachi and Arakawa 2004, Kamachi and Arakawa 2007). 
Improvements in vaccine design can be made to elicit 1B7-like antibodies for this unique 
epitope similar to current HIV research (Walker, Phogat et al. 2009).  One possibility 
would be to use catalytically inactive genetically detoxified PTx (9K/129G) (Burnette, 
Cieplak et al. 1988, Pizza, Covacci et al. 1989) with some additional genetic 
modifications to the B-subunit in order to block cellular binding and other side-effects 
such as T cell proliferation and cell agglutination (Nencioni, Pizza et al. 1991, Millen, 
Schneider et al. 2013) while retaining protective epitopes. Further research either into 
engineering or isolating unique mAbs which span A/B subunit interfaces may be the 
future in developing passive immunization strategies for pertussis.  
 
4.5 CONCLUSIONS 
The antibodies 1B7 and 11E6 recognize unique and potently neutralizing epitopes 
on PTx. Although their epitopes are exposed on whole bacteria, they appear to lack 
opsonophagocytic activity, indicating their potency lies in neutralizing secreted toxin. 
While PTx is competent to simultaneously bind a model receptor and the 1B7 or 11E6 
antibodies, both the PTx1B7 and PTx11E6 antibody complexes are able to inhibit PTx 
binding to a receptor. This conundrum is likely because both antibodies have multiple 
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binding sites which allow the antibody to be simultaneously bound to PTx and a receptor. 
The observation that 11E6 inhibits PTx binding to a model receptor, is in agreement with 
its epitopes being on the receptor binding subunits, S2 and S3. 1B7 on the other hand, 
which binds on the S1 and possibly S4 subunits, also inhibits PTx binding to a model 
receptor, and hinders typical toxin receptor-mediated endocytosis, trapping the immune 
complex at the plasma membrane. We hypothesize 1B7 inhibits PTx internalization by 
altering the conformation of PTx required to bind the receptors, thus hindering the 
internalization of PTx and subsequent toxicity. The unique non-overlapping epitopes of 
1B7 and 11E6 are useful as serological correlates of protection during development of 
next-generation vaccines, and are candidates for passive immunization strategies. 
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APPENDIX  
A.1: LABORATORY PROTOCOLS 
 
A.1.1 Eukaryotic cell growth and maintenance 
A.1.1.1 Starting up a culture from frozen cells 
 
Reagents needed 
Complete growth media - DMEM + 10% FBS + 1X P/S 
T-25 flask 
 
- Equilibrate the media to 37oC 
- Remove the frozen cells from the liquid nitrogen storage wearing the appropriate 
protective equipment 
- Place the frozen cells in a 37oC water bath to thaw 
- Aseptically transfer the thawed cells into the cell culture hood by spraying down 
with 70% ethanol 
- Transfer the thawed cells to a 15 mL conical tube and dilute the cells stored in 
DMSO 10-fold with complete media.  
- Spin down gently at 300g for 5 minutes and aspirate all media from the culture 
- Resuspend the cells with 5 mL of pre-warmed complete media and  seed into the 
T-25 flask 
- Incubator at 37oC, 5% CO2 and change the media after overnight incubation 
- Passage the cells when they reach 80-90% confluence  
 
A.1.1.2 CHO-K1 adherent cells passaging protocol 
 
Cells need to be passaged every 2-4 days or when they reach up to 90% confluence. This 
protocol is for expanding cells from a T-25 into a T-75 flask. The reagent volumes can be 
scaled up for larger flasks. 
 
Reagents needed 
Complete growth media - DMEM + 10% FBS + 1X P/S 
PBS 
Trypsin-EDTA 
 
- Equilibrate all media to 37oC 
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- Aspirate all media from the culture 
- Wash cells 2X with pre-warmed PBS 
- Add 1 mL of pre-warmed Trypsin-EDTA into the T-25 flask 
- Return cells to incubator for 2-10 minutes to allow the adherent cells to detach 
- Tap the bottom of the flask to allow cells to completely detach 
- Add 4mls of pre-warmed complete media to the cells. The FBS in the complete 
media quenches the trypsin 
- Re-seed the cells using the desired dilution into a T-75 flask (~12mL per T-75 
flask). 
o Eg: To re-seed at a 1:12 dilution, add 1mL of the cells into 12 mL of 
media in the T-75 flask 
o To re-seed at a desired cell concentration, count the cells using the 
hemacytometer and dilute to the desired concentration 
 
A.1.1.3 Hemacytometer cell counting and determination of cell viability 
 
Reagents needed 
0.2% trypan blue 
Hemacytometer and cover slip 
Microscope 
Hand counter 
 
- Add 10µl of 0.2% trypan blue to 10µl of the cell suspension. 
- Load one side of the hemacytometer with 10µl of the 2X diluted cell suspension 
and place on the microscope. 
- Count the number of viable cells in 5 out of 9 squares of the hemacytometer. 
Viable cells are impermeable to the trypan blue dye and remain bright, while non-
viable cells take up the dye and are blue.   
- Divide the total number of cells counted by 5 to get the average number of cells 
per square. 
- Multiply the average count per square by 104 to get the number of cells per ml of 
the diluted cell suspension. 
- Determine the concentration of cells before dilution by multiplying by 2 since the 
cells were diluted into trypan blue. 
o To determine cell viability Eg for suspension cells, count the total number 
of cells, and total number of viable cells.  
 
% viable cells = number of viable cells (unstained cells) x 100% 
                           Total number of cells 
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- Clean the cover slip and hemacytometer with 70% ethanol 
 
 
A.1.1.4 Preparation of 0.2% trypan blue for determining cell viability 
Reagents needed 
Trypan blue powder 
Distilled water 
 
- Dissolve 0.1 g of trypan blue in 50 mL of distilled water  
- Spin down at 3000g for 5 minutes to remove large precipitates. 
- Clarify by filtering with a 0.45 µm or 0.22 µm  filter to remove particulates 
 
A.1.1.5 Cryopreservation of CHO-K1 cells 
Reagents needed 
Complete growth media - DMEM + 10% FBS + 1X P/S 
Freezing media - DMEM + 10% FBS + 1X P/S + 10% DMSO 
PBS 
Trypsin-EDTA 
0.2% trypan blue 
Hemacytometer and cover slip 
Microscope 
Hand counter 
Cryovials 
Ethanol freezing container  
 
- Equilibrate all media to 37oC 
-  Aspirate all media from the culture and trypsinize as for passaging 
- After cells are detached, dilute 10-fold with complete media 
- Count the cells using trypan blue staining. Cell viability to be greater than 90% 
- Spin the cells down at 300g for 5 minutes and aspirate off the growth medium 
- Resuspend the cells in freezing medium to a concentration of 2 x 106 cells/mL 
- Aliquot the cells into cryovials and transfer the cells immediately into the -80oC 
freezer in an ethanol slow freezing container 
- Freeze the cells overnight at -80oC and then transfer to the liquid nitrogen storage 
 
Adapted from  
- Abcam cell culture protocols online. 
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A.1.1.6 Transfection of CHO-K1 cells for transient antibody expression 
Materials needed 
Low passage umber (<10 passages) CHO-K1 Cells 
150 µg Midi-prepped single vector plasmid DNA containing the heavy and light chains 
or 
75 µg midi-prepped light chain plasmid DNA and 75 µg midi-prepped heavy chain 
plasmid DNA 
Opti-MEM (Life Technologies) 
Lipofectamine 2000 (Life Technologies) 
Complete growth media: DMEM + 10% FBS + 1X Penicillin/Streptomyin  
Antibody growth media: DMEM  + 10% Low IgG FBS  + 1X Penicillin/Streptomyin 
1 M Tris pH 8.0, sterile 
 
Day 1 - Cell preparation: 
- Trypsinize CHO-K1 cells 
- Count using the hemocytometer 
- Plate 5 x 106 cells per T-150 flask (3 flasks total) in 24 mL of complete growth 
media  
- Grow overnight in jacketed incubator at 37C and 5% CO2 
- Transfect when the cells reach ~95% confluency 
 
Day 2 - Transfection: 
- Mix 12 mL Opti-MEM with 75 µg of the heavy chain and 75 µg of the light chain 
plasmid 
o For single plasmid vectors, dilute 150 µg of the vector in 12.5 mL of Opti-
MEM 
- Mix 12 mL Opti-MEM with 375 µL Lipofectamine 2000 
- Allow reagents to sit at RT 5 min 
- Mix the diluted DNA and Lipofectamine (24 mL total) 
- Allow to sit at RT for 20 minutes 
- While reagents are sitting, remove media from each flask of cells and replace with 
16 mL antibody growth media 
- Add 8 mL of the transfection mix (DNA + Lipofectamine) to each flask 
- Mix gently and incubate overnight at 37oC, 5% CO2 
 
Day 3 - Media change: 
- Remove the old media from the cells 
- Spin down the old media at 5000g  for 5 minutes to pellet the cells 
- Save the clarified culture supernatant for further antibody purification 
- Add fresh antibody growth media to the cells and return to the incubator 
- To increase yields, the cells from the old flasks can be reseeded into two new 
flasks with fresh antibody growth media. 
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- Replace the media on the cells with fresh antibody growth media every other day 
for a total of three media changes. Saved the media for further purification. 
 
 
 
 
 
A.1.1.7 Guidelines for scaling up or down transfection of DNA into different tissue 
culture vessels  
Table A.1: Required volumes for transfection reagents 
Scale up/down the concentration of cells plated depending on the culture vessel so that 
the cells will be approximately 95% confluent at the time of transfection. 
 
Culture 
vessel 
Low IgG  
media 
Opti-
MEM  
(2 tubes) 
DNA in µg, 
(L+H), Dilution 
volume (µL)  
Lipofectamine-
2000, dilution 
volume (µL) 
Complex 
added 
24-Well 0.4 mL 50 µL 0.6 µg in 50 µL 1.5 µL in 50 µL 100 µL 
12-Well 0.8 mL 100 µL 1.2 µg in 100 µL 3 µL in 100 µL 200 µL 
6-Well 1.5 mL 250 µL 3 µg in 250 µL 7.5 µL in 250 µL 500 µL 
T-150 16 mL 4 mL 50 µg in 4 mL 125 in 4 mL 8 mL 
 
 
Adapted from  
- Lipofectamine® reagent protocols. 
- Optimized transfection protocols from Ellen Wagner 
 
 
A.1.2 Bacteria growth and maintenance 
A.1.2.1 Bordetella growth conditions 
Reagents needed 
Bordet Gengou blood agar plates 
Compplete Stainer Scholte modified medium 
 
- Streak bacteria from frozen stock onto Bordet Gengou blood agar plates and 
incubate at 37˚C. Plates show good hemolysis after 2-3 days of growth. 
- To grow a liquid culture, inoculate a 2 mL starter culture in complete Stainer 
Scholte media.  
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- Incubate shaking at 100 rpm at 37˚C for 2-5 days. 
- Inoculate larger cultures >100 mL of SSM with added supplements and incubate 
at 37˚C for an additional 2-5 days. 
 
 
A.1.2.2 Stainer-Sholte Modified growth medium (SSM) 
 
Complete Stainer Scholte media (SSM) contain the following supplements with basal 
medium (BM) 
 20 µL 100x supplements / 2 mL BM 
 20 µL 100x proline / 2 mL BM 
 30 µL casamino acids / 2 mL BM 
 8 µL heptakis* / 2 mL BM 
* Heptakis is added for production of FHA and PTx (Imaizumi, Suzuki et al. 1983) 
 
 
Basal Medium (BM) 
 Glutamic acid, monosodium salt 5.35 g 
 Tris base - 0.76 g 
 NaCl - 1.25 g 
 KH2PO4 - 0.25 g 
 KCl - 0.1 g 
 MgCl2.6H2O - 0.05 g 
 CaCl2–0 H2O - 0.01 g 
 dH2O to 500 mL 
Adjust with HCl to pH 7.6 (0.25-0.35 mL). 
Autoclave and store at 4°C 
 
 
Supplements (filter sterilize, aliquot <15 mL, and store at -20°C) 
100x SSM Supplement 
 HCl - 2 mL 
 dH2O - 6 mL 
 L-cysteine - 0.8 g 
 ddH2O to 200 mL 
 Add more HCl if cysteine precipitates. 
 FeSO4-7H2O 0.2 g 
 Ascorbic acid - 0.4 g 
 Nicotinic Acid (niacin) - 0.08 g 
 Glutathione (reduced) 2 g 
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100x proline supplement - 4.8 g L-proline / 200 mL dH2O 
Casamino acids supplement - 20 g casamino acids / 200 mL dH2O 
Heptakis supplement *- 5 g heptakis / 20 mL ddH2O 
 
 
 
Blood agar plates* 
SSM basal media with 100 mL less ddH2O/L. 
- Add 15 g/L bacto agar. 
- Autoclave and cool to 50˚C. 
- Add 10 mL of 100x SSM supplement and proline supplement. 
- Heat sheep blood to 37˚C. 
- Pour blood down side of flask, swirl gently and pour plates (~20mL/plate). 
*Bordet Gengou blood agar plates can also be ordered from BD Biosciences (Fisher 
Catalog No.: B97876X)  
 
Adapted from 
- Sutherland J. S. 2010. The Potently Neutralizing Monoclonal Antibody 1B7: its 
Unique Epitope, Effects on Intracellular Trafficking, and Elicitation upon 
Infection with Pertussis. PhD Dissertation to UT, Austin. 
- Menozzi, F. D., R. Mutombo, G. Renauld, C. Gantiez, J. H. Hannah, E. Leininger, 
M. J. Brennan and C. Locht (1994). "Heparin-inhibitable lectin activity of the 
filamentous hemagglutinin adhesin of Bordetella pertussis." Infect Immun 62(3): 
769-778. 
- Imaizumi, A., Y. Suzuki, S. Ono, H. Sato and Y. Sato (1983). "Heptakis(2,6-O-
dimethyl)beta-cyclodextrin: a novel growth stimulant for Bordetella pertussis 
phase I." J Clin Microbiol 17(5): 781-786. 
 
 
A.1.2.3 Bordetella glycerol stocks 
Reagents needed 
50% sterile glycerol 
Cryovials 
 
- Add 500 µL of the bacterial culture to 500 µL of the sterile 50% glycerol 
- Freeze the glycerol stock tubes at -80oC 
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A.1.3 Protein purification 
A.1.3.1 Antibody purification 
Antibodies purified from the cell culture supernatant or ascitic fluid are described.  
 
Materials needed 
Ammonium sulfate 
1 M Tris pH 8.0, sterile 
Binding buffer: 100 mM sodium phosphate buffer, 150 mM NaCl, pH 7 
Elution buffer: 0.1 M Glycine, pH 2.7 
Neutralization buffer: 1M Tris, pH 8 
 
Cell culture supernatant 
Culture supernatant volumes less than 200 mL can be directly applied to the column after 
centrifugation and filtration through a 0.22 µm filter. For culture supernatant volumes 
greater than 200 mL, initially concentrate using ammonium sulfate precipitation or 
tangential flow filtration. 
- Clarify supernatant by centrifuging at 10 000 rpm for 30 minutes. 
- Add 25 mLs of Tris–HCl, pH 8 per 500 mLs of culture supernatant. 
- Precipitate antibody using 50% (w/v) ammonium sulfate (313 g/L of culture), 
gradually, in four parts (1 part per hour) while the supernatant is being slowly 
stirred at 4˚C. 
- Mix the supernatant slowly overnight. 
- After overnight concentration with the 50% ammonium sulfate, spin down the 
supernatant at 10 000 rpm for 30 min.  
- Pour off the supernatant and resuspend the pellet in binding buffer (0.1*volume of 
starting culture volume). 
- Transfer into dialysis membrane and dialyze against 2 L of binding buffer 
overnight at 4
o
C. 
- Spin down the resuspended pellet at 18 000 rpm for 30 min to remove all 
particles. 
- Filter sterilize using a 0.22 µm filter and load onto a protein A/G column (See 
Column purification procedure). 
- Estimate protein concentrations of of mAb containing fractions 
- Determine purity of mAb fractions by SDS-PAGE 
- Pool desired fractions 
- Determine activity using an ELISA 
- Filter sterilize pooled fractions under sterile conditions.  
- Store aliquots at -20oC 
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Ascites fluid 
- Dilute the ascites fluid with the binding buffer. Purify antibodies from 2-3mL of 
the ascitic fluid. 
- Clarify ascites fluid by centrifuging at 12 000 rpm for 15 minutes. 
o Filter through glass wool to remove lipids. 
- Filter using a 0.22 µm filter before loading onto the protein A/G column (See 
Column purification procedure) 
- Estimate protein concentrations of mAb containing fractions 
- Determine purity of mAb fractions by SDS-PAGE 
- Pool desired fractions 
- Determine activity using an ELISA 
- Filter sterilize pooled fractions under sterile conditions 
- Store aliquots at -20oC 
         
Adapted from 
- Harlow E., and Lane D. 1988. Antibodies: A laboratory manual. Cold spring 
harbor laboratory press. Cold spring harbor, New York. 
- Sutherland J. S. 2010. The Potently Neutralizing Monoclonal Antibody 1B7: its 
Unique Epitope, Effects on Intracellular Trafficking, and Elicitation upon 
Infection with Pertussis. PhD Dissertation to UT, Austin. 
- Antibody purification handbook. Amersham Biosciences. 
 
A.1.3.2 Full length FHA purification 
FHA is purified from the culture supernatant of B. pertussis and B. bronchiseptica using 
heparin affinity chromatography as described. FHA from B. parapertussis however does 
not bind heparin. For FHA production, the Bordetella is grown in Stainer Sholte media 
containing 1g/L heptakis. Culture supernatant volumes less than 200 mL can be directly 
applied to the column after centrifugation and filtration through a 0.22 µm filter. For 
culture supernatant volumes greater than 200 mL, initially concentrate using tangential 
flow filtration. 
 
Materials needed 
Binding buffer: 50 mM Tris, pH 8, 50mM NaCl  
Elution buffer: 50 mM Tris, pH 8, 500mM NaCl  
 
- Clarify supernatant by centrifuging at 10 000 rpm for 30 minutes. 
- Filter sterilize using a 0.22 µm filter and  
- Load supernatant onto the heparin column and elute purified FHA (See Column 
purification procedure) 
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Adapted from 
- Menozzi, F. D., R. Mutombo, G. Renauld, C. Gantiez, J. H. Hannah, E. Leininger, 
M. J. Brennan and C. Locht (1994). "Heparin-inhibitable lectin activity of the 
filamentous hemagglutinin adhesin of Bordetella pertussis." Infect Immun 62(3): 
769-778. 
- Stainer, D. W. and M. J. Scholte (1970). "A simple chemically defined medium 
for the production of phase I Bordetella pertussis." J Gen Microbiol 63(2): 211-
220. 
- Imaizumi, A., Y. Suzuki, S. Ono, H. Sato and Y. Sato (1983). "Heptakis(2,6-O-
dimethyl)beta-cyclodextrin: a novel growth stimulant for Bordetella pertussis 
phase I." J Clin Microbiol 17(5): 781-786. 
 
A.1.3.3 Purification of recombinant FHA fragments 
(Using the pMAL c5X vector from BL21 cells) 
 
Materials needed 
TB media (500ml) per prep, autoclaved; adjust with appropriate antibiotic in 2L Flask 
1M IPTG, filter sterile (stored at -20C) 
Binding buffer: 50mM Hepes, 250mM NaCl, 2mM CaCl2, 40mM imidazole, pH 8 (filter 
sterilize) 
Elution buffer: 50mM Hepes, 250mM NaCl, 2mM CaCl2, 40mM imidazole, pH 8, 10mM 
maltose (filter sterilize) 
 
Day 1: Growth 
- Start a 2mL starter culture with antibiotic from a single colony from an agar plate 
at the end of the day at 37
o
C shaking at 225RPM 
 
 
Day 2: Expression 
- Use 500 µL of the starter culture to inoculate 500 mL of TB with antibiotic 
- Grow the cells to an OD600 of approximately 0.5 
- Induce by adding IPTG to a concentration of 1 mM and grow for an additional 2 
hours at 37
o
C 
- Harvest the cells by centrifuging for 30 minutes at 10K rpm 
- Resuspend the cell pellet in 25 mL binding buffer per L of culture 
- Lyse the cells using the French Press 
- Clarify the lysed cells by centrifugation at 18K rpm for 30 minutes 
- Filter using a 0.22 µm filter before loading onto the MBP column (See Column 
purification procedure) 
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- Determine purity by SDS-PAGE 
Adapted from 
- NEB pMAL Protein Fusion & Purification System  
 
A.1.3.4 HiTrap affinity column purification 
- Wash the column with 5-10 column volumes (CVs) of water (max back pressure 
0.3 MPa). 
- Pre-equilibrate the column with 5-10 column volumes (CVs) of binding buffer 
until A280 returns to baseline. 
- Apply sample. 
- Wash the column with binding buffer until A280 returns to baseline (~5-10 CVs). 
- Elute the protein with elution buffer until A280 returns to baseline. 
- After the purification, wash the column with water and then 20% ethanol until 
baseline (~ 5 CV).  
- Store the column at 4˚C.   
 
Adapted from 
- HiTrap column manual  
A.1.4 Protein characterization assays 
A.1.4.1 ELISA 
A.1.4.1.1 Indirect ELISA for estimation of binding affinity  
 
Coating antigen to microplate 
- Dilute the antigen (PTx) to 1 μg/ml in PBS 
- Coat the wells of an ELISA high binding microtiter plate with the antigen by 
pipeting 50 μl of the antigen dilution into all the wells of the plate. 
- Cover the plate with an adhesive plastic and incubate overnight at 4oC.  
- Wash the plate 3X with PBST. 
 
Blocking 
- Block the remaining protein-binding sites in the coated wells by adding 50 μl 
blocking buffer (5% non-fat dry milk in PBST), per well.  
- Cover the plate with an adhesive plastic and incubate for at least 1h at room 
temperature. 
- Wash the plate 3X with PBST.  
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Incubation with the primary antibody 
- Add 50 μl of the primary antibody (Eg. m1B7), diluted to 10 µg/ml in blocking 
buffer. Dilute down the plate as required (Eg. 1:5). 
- Cover the plate with an adhesive plastic and incubate for 1 h at room temperature.   
- Wash the plate 3X with PBST. 
 
 
 
Incubation with the secondary antibody 
- Add 50 μl per well of the secondary antibody (G α M IgG - HRP), diluted 
to1:1000 in blocking buffer. 
- Cover the plate with an adhesive plastic and incubate for 1 h at room temperature.  
- Wash the plate 3X with PBST.  
 
Detection 
- Dispense 50 μl of the substrate solution (TMB:Peroxide 1:1)  per well. 
- After sufficient color development (~1-10mins), add 50 μl of stop solution (1N 
HCl) to the wells. 
- Read the absorbance (optical density) of each well with a plate reader. Softmax 
software. 
 
 
Analysis of data 
- Prepare a curve from the data produced from the serial dilutions with 
concentration on the x axis (log scale) vs absorbance on the Y axis (linear). 
- Estimate the binding affinity fitting the curve to a non-linear equation (Eg 4 
parameter logistic equation).  
 
A.1.4.1.2 Competition ELISA  
 
Eg 1: Antibodies competing for binding to epitopes on PTx 
 
Coating antigen to microplate 
- Dilute the antigen (PTx) to a final concentration of 1 μg/ml in PBS. 
- Coat the wells of an ELISA high binding microtiter plate with the antigen and 
wash as described above for an indirect ELISA. 
 
Blocking 
- Block and wash the plates as described above for an indirect ELISA above. 
o When using biotinylated antibodies, use 5% BSA in PBST to block since 
milk contains free biotin. 
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Incubation with the primary antibody 
- Add the competing antibody (Eg. hu1B7), diluted to the optimal starting 
concentration (Eg 50 µg/ml) in blocking buffer. Dilute down the plate. 
- Add 25 µl of the primary antibody (Eg. biotinylated D8) to a final concentration 
of 0.6 µg/ml to all the wells,  
o Adjust molar ratio of the competing and primary antibodies as desired. 
- Cover the plate with an adhesive plastic and incubate for 1 h at room temperature.  
- Wash the plate 3X with PBST. 
 
Incubation with the secondary antibody 
- Add 50 μl per well of the secondary antibody (Streptavidin-HRP), diluted to 
1:1000 in blocking buffer. 
- Cover the plate with an adhesive plastic and incubate for 1 h at room temperature.  
- Wash the plate 3X with PBST.  
 
Detection and data analysis 
- Dispense 50 μl of the substrate solution (TMB:Peroxide 1:1)  per well. 
- After sufficient color development (~1-10mins), add 50 μl of stop solution (1N 
HCl) to the wells. 
- Read the absorbance (optical density) of each well with a plate reader. Softmax 
software. 
- Prepare a curve from the data produced from the serial dilutions with 
concentration on the x axis (log scale) vs absorbance on the Y axis (linear). 
- If desired, estimate the IC50 by fitting the curve to a non-linear equation (Eg. 4 
parameter logistic equation).  
 
 
Eg 2: Inhibition of PTx binding to fetuin model receptor 
 
Coating receptor to microplate 
- Dilute the fetuin receptor to a final concentration of 10 μg/ml in PBS. 
- Coat the wells of an ELISA high binding microtiter plate with the receptor by 
pipeting 50 μl into all the wells of the plate. 
- Cover the plate with an adhesive plastic and incubate at 4oC overnight.  
- Wash the plate 3X with PBST. 
 
Blocking 
- Block the remaining protein-binding sites in the coated wells by adding 50 μl 
blocking buffer (5% BSA in PBST), per well.  
- Cover the plate with an adhesive plastic and incubate for at least 1h at room 
temperature 
- Wash the plate 3X with PBST.  
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Incubation of PTx and competing antibodies 
- Add the competing antibody (Eg. hu1B7), diluted to 100 µg/ml) in blocking 
buffer to the first well only. Dilute down the plate 1:5 leaving (This leaves 40 µl 
solution per well). 
- Add 10 µl of 0.5 µg/mPTx to all the wells (PTx final concentration - 0.1 µg/ml. 
o Adjust molar ratio of competing antibody: PTx as desired. 
- Cover the plate with an adhesive plastic and incubate overnight at 4oC.  
- After overnight incubation, wash the plate 3X with PBST. 
Incubation with the primary antibody 
- Add 50 μl of primary antibody to detect residual PTx,  (m1B7 + m11E6 + m7F2 
each at a concentration of 0.1 μg/ml). 
- Cover the plate with an adhesive plastic and incubate for 1 h at room temperature.   
- Wash the plate 3X with PBST. 
 
Incubation with the secondary antibody 
- Add 50 μl of the secondary antibody (G α M IgG - HRP), diluted to 1:1000 in 
blocking buffer. 
- Cover the plate with an adhesive plastic and incubate for 1 hour at room 
temperature. 
- Wash the plate 3X with PBST. 
 
Detection and data analysis 
- Dispense 50 μl of the substrate solution (TMB:Peroxide 1:1)  per well. 
- After sufficient color development (~1-10mins), add 50 μl of stop solution (1N 
HCl) to the wells. 
- Read the absorbance (optical density) of each well with a plate reader. Softmax 
software. 
- Prepare a curve from the data produced from the serial dilutions with 
concentration on the x axis (log scale) vs absorbance on the Y axis (linear). 
- Estimate the IC50 by fitting the curve to a non-linear equation (Eg. 4 parameter 
logistic equation). 
 
A.1.4.2.3 ELISA to detect simultaneous binding of antibody to PTx bound to receptor  
 
Coating receptor to microplate 
- Dilute the fetuin receptor to a final concentration of 10 μg/ml in PBS. 
- Coat the wells of an ELISA high binding microtiter plate with the receptor by 
pipeting 50 μl into all the wells of the plate. 
- Cover the plate with an adhesive plastic and incubate at  4oC overnight.  
- After overnight incubation, wash the plate 3X with PBST. 
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Blocking 
- Block the pates with 5% BSA, and wash 3X with PBST. 
 
Incubation with the antigen 
- Add the PTx diluted to 21 µg/ml (200 nM) in blocking buffer to the first well. 
Dilute down the plate as required (Eg. 1:5). 
- Cover the plate with an adhesive plastic and incubate for 1 h at room temperature.  
- Wash the plate 3X with PBST. 
  
Incubation with the primary antibody 
- Add 50 μl of the primary antibody (Eg. hu1B7), diluted to 1 μg/ml in blocking 
buffer (5% BSA in PBS) to all the wells. 
- Cover the plate with an adhesive plastic and incubate for 1 h at 37oC.   
- Wash the plate 3X with PBST. 
 
Incubation with the secondary antibody 
- Add 50 μl of the secondary antibody (Eg. G α Hu Fc - HRP), diluted to the 
optimal concentration (1:1000) in blocking buffer. 
- Cover the plate with an adhesive plastic and incubate for 1 h at 37oC. 
- Wash the plate 3X with PBST. 
 
Detection and data analysis 
- Dispense 50 μl of the substrate solution (TMB:Peroxide 1:1)  per well. 
- After sufficient color development (~1-10mins), add 50 μl of stop solution (1N 
HCl) to the wells. 
- Read the absorbance (optical density) of each well with a plate reader. Softmax 
software. 
- Prepare a curve from the data produced from the serial dilutions with 
concentration on the x axis (log scale) vs absorbance on the Y axis (linear). 
- Estimate the EC50 by fitting the curve to a non-linear equation (Eg. 4 parameter 
logistic equation).  
 
 
Adapted from 
- Schmidt, M. A. and W. Schmidt (1989). "Inhibition of pertussis toxin binding to 
model receptors by antipeptide antibodies directed at an antigenic domain of the 
S2 subunit." Infect Immun 57(12): 3828-3833. 
- Sutherland J. S. 2010. The Potently Neutralizing Monoclonal Antibody 1B7: its 
Unique Epitope, Effects on Intracellular Trafficking, and Elicitation upon 
Infection with Pertussis. PhD Dissertation to UT, Austin. 
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A.1.4.2 CHO cell neutralization assay 
This assay is used to determine the in vitro neutralization ability of anti-PTx antibodies. 
CHO cells normally grow in an elongated morphology. When exposed to PTx, the CHO 
cell morphology changes and the cells grow in clusters. The CHO neutralization assay is 
used to determine the concentration of antibodies which rescues CHO cells from PTx 
induced clustering. 
 
 
 
Morphology is rated on a scale of 0 to 3:  
0 – no clustering                         1 – few clusters/equivocal  
2 – Positive clustering                3 – complete/maximal clustering 
 
 
 
 
 
 
 
Materials needed 
PTx 
Sterile 96 well tissue culture plate 
37
o
C incubator with 5% CO2 
Complete growth medium (DMEM + 10% FBS + 1X P/S) 
PBS 
Antibody 
Trypsin-EDTA 
Microscope 
 
- Add 50 µl of antibody in duplicate starting at 60 000 molar excess of PTx into the 
top row of the plate. Dilute down serially, 1:2 into 25 µl of complete growth 
media (DMEM with 10% FBS and 1X P/S. This leaves 25 µl in each well. 
- Prepare a stock of 10 µg/ml dilute PTx in complete growth media. 
o Prepare a working dilution of 60 pM PTx from the 10 µg/ml stock, add 
25µl/well to the 96 well plate containing the antibody dilutions. 
- Incubate the plate for ½ hr at 37˚C with 5% CO2. 
- While the PTx-antibody complexes are incubating, wash confluent CHO cells 
twice with PBS. 
- Detach cells with Trypsin-EDTA at 37˚C for 1-10 min.  
o Resuspend and dilute the cells to a concentration of 1.5 x 105 cells/ml. 
- Seed 100 µl/well of the diluted CHO cells into the plates containing the incubated 
PTx and antibodies.  
o This results in  
0 1 2 3 
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 a final PTx concentration of 10 pM PTx/well,  
 concentration of antibodies starting at 10 000 molar excess, and 
 a final cell concentration of 1.5 x 104 cells/well. 
- Incubate at 37˚C, 5% CO2 overnight (~17 hours). 
- Score the wells with a microscope based on clustering morphology (Sample 
pictures above). 
 
 
 
Notes: 
 The working concentration of PTx was determined from a preliminary toxin 
concentration series over the range of 12 - 0.094 ng/mL PTx which resulted in 
scoring of 3 to 0. A test dose of 10 pM PTx in the 150µl culture volume 
(approximately four times higher than the minimum PTx dose showing a score of 
3) was used to reduce lot- to - lot variability.  
 A lower concentration of PTx can be used to conserve PTx and antibodies. 
 A lower cell concentration (Eg: 5 x 103 cells/well) is more stringent for assessing 
neutralization. At lower cell concentrations, score cells after 24-48 hours. 
 Neutralization to PTx toxicity is recorded as the lowest molar concentration of 
antibody to PTx that completely inhibits clustering (concentration at which the 
score changes from a 0 to a 1). 
 If no neutralization is observed at 10 000M excess, test higher concentrations of 
antibodies if possible. 
 To score at a later time, cells can be fixed with 4% paraformaldehyde (PFA) at 
RT for 20mins, washed with PBS, and stored at 4
o
C in 1% (PFA). 
 For imaging, cells can be stained with a giemsa stain if using a brightfield 
microscope. The cells however don't need to be stained when using a phase 
contrast or DIC microscope as the contrast allows them to be more visible. 
o The assay can also be performed on coverslips in 6 well plates, placed 
unto glass-slides with mounting media and imaged. DAPI Fluoromount G 
(Southern biotech) can be used to mount the slides to stain the nucleus and 
makes it easy to locate the cells if using a fluorescent microscope. 
 
 
Adapted from 
- Sutherland J. S. 2010. The Potently Neutralizing Monoclonal Antibody 1B7: its 
Unique Epitope, Effects on Intracellular Trafficking, and Elicitation upon 
Infection with Pertussis. PhD Dissertation to UT, Austin. 
- Sato, H., Sato, Y., Ito, A., Ohishi, I. Infect Immun. 1987. 55(4): 909-15. 
- Hewlett, E. L.,Sauer, K. T., Myers, G. A., Cowell, J. L., Guerrant, R. L. Induction 
of a Novel Morphological Response in Chinese Hamster Ovary Cells by Pertussis 
Toxin. Infect Immun. 1983 40 (3): 1198-203. 
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A.1.4.3 Hemagglutination Assay and Inhibition of Hemagglutination 
The lowest amount of FHA that caused hemagglutination was qualitatively determined 
from hemagglutination of 0.5% sheep red blood cells in a round bottom 96 well micro-
titer plate.  Hemagglutination of the RBCs prevent them from settling out of suspension 
while in control wells, the RBCs settle in a pellet at the bottom of the round bottom well. 
 
 
Materials needed 
Round bottom 96 well micro-titer plate 
PBS 
 
FHA hemagglutination assay 
The least amount of FHA that caused complete hemagglutination of 0.5% sheep red 
blood cells was first determined by  
- Serially diluting FHA 1:2 in the 96 well round bottom plate.  
- Add sheep red blood cells (RBC) to 0.5%, and top the volume up to 100 μl per 
well. 
- Incubate the mixture kept at room temperature for approximately 3 hours.  
- The last well showing complete hemagglutination by visual inspection is 
determined to be the limit of detection. 
 
Inhibition of FHA mediated hemagglutination 
- Serially dilute the antibodies first in the micro-titre plate.  
- Add FHA to the antibodies and incubate the mixture at 25°C for 30 minutes. 
- Add sheep RBC to a final concentration of 0.5% and top up the volume to 100 µl. 
- Incubate the mixture at 25°C for approximately 3 hours.  
- The lowest amount of antibody that inhibits hemagglutination is taken as the 
neutralizing dose. 
 
Adapted from 
- Colombi, D., D. S. Horton, M. L. Oliveira, M. A. Sakauchi and P. L. Ho (2004). 
"Antibodies produced against a fragment of filamentous haemagglutinin (FHA) of 
Bordetella pertussis are able to inhibit hemagglutination induced by the whole 
adhesin." FEMS Microbiol Lett 240(1): 41-47. 
 
 
A.1.4.4 PTx trafficking using immunofluorescence microscopy 
 
Day 1 
- Seed CHO cells on autoclaved cover slips in a 6 well tissue culture plate. 
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- Incubate at 37˚C with 5% CO2 until cells are ~70% confluents (1-2 days). 
 
Day 2 
- Wash 2X with HBSS. 
- Aspirate and block irrelevant antigens with blocking buffer for 30mins at 37˚C, 
5% CO2. 
 
Blocking buffer 
DMEM base (-FBS, -antibiotic) 
2mg/ml BSA 
1-5µg/ml irrelevant antibody (Eg. mIgG1) 
 
- Incubate 10 nM PTx with 10,000 nM 1B7 or other co-trafficking antibody in 
50µL 37˚C with 5% CO2 for ½ hour. 
- Place cover slip cell side down on the 50µL drop on parafilm and incubate at 
37˚C for desired trafficking time. 
- Rinse with PBS for 5 min in the 6 well plate. Remove slide 5 min before the end 
of the desired time point to rinse. 
- Fix for 20 min at room temperature.  
 
Fixing buffer 
4% Paraformaldehyde in PBS 
 
- Wash 3X with PBS for 10 min each. 
- Permeate cells with permeabilization buffer for 20 mins at room temperature. 
 
Permeabilization buffer 
1X PBS 
0.1% Triton X-100 
 
- Block intracellular irrelevant antigens with blocking buffer for 1 hr at 37˚. 
- Label by placing the cover slip cell side down on a 50µL drop of primary 
antibody in blocking buffer on parafilm. 
- Incubate in a humid container at 4˚C overnight. 
 
Day 3 
- Wash 3X with PBS for 10 min each. 
- Label by placing the cover slip cell side down on a 50µL drop of secondary 
antibody (fluorescent label) in blocking buffer on parafilm.  
- Incubate in the dark at 37˚C for 1 hr. 
- Wash 3X with PBS for 15 min each. 
- Mount on slides with 1 drop of fluoromount-G or DAPI fluoromount-G 
(SouthernBiotech). 
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- Press gently with Kimwipe to remove excess and to seal the cover slip. 
- Allow the preps to air dry for 5 minutes before examination or storage at 4˚C. 
 
 
Widefield fluorescence microscope (UT Core facilities) 
 
Startup 
- Turn on the arc lamp followed by the microscope. 
o Wait 2 min. 
- Boot up the Zeiss software. 
-  
- Add a small drop of oil onto your slide and focus manually on the microscope. 
- Enter the Zeiss software, and change the light path from the eye to the camera. 
- Set gain to minimize background fluorescence.  
o Do not change this setting once it is set for the experiment. 
- Set up multi-dimensional analysis for different fluorophores to be detected. Set 
exposure time to minimize oversaturation and show maximum pixels.  
- Save files as .tif. Export file to save in color as a .jpeg. 
Shutdown 
- Close the Zeiss software. 
- Wait 1 min. 
- Turn off the microscope followed by the arc lamp. 
- Clean the oil objective with optical tissue and MeOH only wiping once 
 
Confocal scanning fluorescence microscope (UT Core facilities) 
 
Startup 
- Turn on confocal microscope using instructions posted. 
- Login into computer. 
- Startup Zen software 
- Choose objective. If using an oil objective, add a drop of oil to the top of the 
objective. 
- Place sample on the stage, cover slip down. 
- Focus on sample using locate tab. 
- Switch to acquisition for imaging. 
- For multiple dyes, use smart set up to configure acquisition settings depending on 
dyes used. 
o For a brightfield/DIC image, click T-PMT. 
- Proceed to acquiring images 
- Save image at 16 bit .tif for high resolution 
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Shutdown 
- Close the Zeiss software. 
- See instructions posted. 
- Clean the oil objective with optical tissue if used. 
Adapted from 
- Sutherland J. S. 2010. The Potently Neutralizing Monoclonal Antibody 1B7: its 
Unique Epitope, Effects on Intracellular Trafficking, and Elicitation upon 
Infection with Pertussis. PhD Dissertation to UT, Austin. 
- Zeiss 710 user guide. 
 
 
A.1.4.5 Cell adhesion assay  
*FACS method 
 
 
Materials needed 
FITC 
Bacteria 
12-well tissue culture plate 
Cell scrapers 
PBS 
DMEM + 10% FBS 
CHO cells 
 
FITC labeling of B. pertussis  
- Dissolve FITC (Thermoscientific) in DMSO to a concentration of 10 mg/mL. 
- Label 1 x 108 cfu/mL B. pertussis with a concentration of 1 mg/ml FITC in 100 
µL of 100 mM carbonate buffer, pH 9.2.  
- Incubate the bacteria with the FITC at room temperature for 30 minutes 
- Wash the cells three times with PBS to remove excess FITC.  
 
Adherence of Bp-FITC to CHO-K1 cells  
- Add 1 x 106 CHO-K1 cells per well to 12-well plates and allow to adhere for 1 
hour at 37
o
C, 5% CO2.  
- Maintain in media without antibiotics (DMEM buffer with 10% FBS).  
- Pre-incubate the Bp-FITC in the presence of 25 µg/ml antibodies to assess 
antibody inhibition of cell adhesion.  
o Adjust concentrations of antibodies as needed to assess effects of 
concentration on adhesion. 
- Add the Bp-FITC + antibody to the CHO-K1 cells and spin down gently at 300g 
for 2 minutes to promote contact between the bacteria and CHO cells. 
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- Incubate the plates for 1 hour at 37oC.   
- Wash the wells with PBS to remove unbound bacteria. 
- Scrape off adherent cells and resuspend into FACS buffer (PBS + 2% FBS). 
- Analyze bacteria bound to the CHO cells by flow cytometry.  
o The analysis does not differentiate between bound and internalized B. 
pertussis. 
* To analyze visually by light microscopy, cells are seeded on coverslips in 12-well 
tissue culture plates. After the assay, the cells on the coverslips are fixed, stained and 
visualized without scraping the cells off. 
 
Adapted from 
- Hazenbos, W. L., B. M. van den Berg, J. W. van't Wout, F. R. Mooi and R. van 
Furth (1994). "Virulence factors determine attachment and ingestion of 
nonopsonized and opsonized Bordetella pertussis by human monocytes." Infect 
Immun 62(11): 4818-4824. 
- Cotter, P. A., M. H. Yuk, S. Mattoo, B. J. Akerley, J. Boschwitz, D. A. Relman 
and J. F. Miller (1998). "Filamentous hemagglutinin of Bordetella bronchiseptica 
is required for efficient establishment of tracheal colonization." Infect Immun 
66(12): 5921-5929. 
 
 
A.1.4.6 Bactericidal assay  
 
Materials needed 
Bordet Gengou blood agar plates 
Inoculation loop 
96-well round bottom plate 
Stainer Scholte media 
Bacterial plating beads 
 
- Streak out B. pertussis unto fresh Bordet Gengou plates. Grow for 2-3 days at 
37
o
C. 
- Scrape off B. pertussis showing good hemolysis using inoculation loop into 
Stainer Scholte media. 
- Strain to remove cell clumps. 
- Determine the OD600 of the resuspended bacteria. 
- Convert the OD600 of the resuspended bacteria to cfu/ml. 
o OD600 of 0.9 ≡ 5 x 10
9
 cfu/ml (Warfel, Zimmerman et al. 2013) 
- Dilute the B. pertussis to 3 x 105 cfu in 20 µl. 
- Add the antibodies to be assayed to a concentration of 25 µg/m in 20 µl to the 
bacteria in the round bottom 96 well plate. 
- Incubate the bacteria + antibody mixture for 30 minutes at 37oC. 
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- Add IgG depleted complement to a concentration of 10%, and top off the total 
volume to 20 µl. 
- Incubate the bacteria + antibody + complement for 1 hour at 37oC. 
- Add 80 µl of 10% EDTA in PBS to stop the complement reaction. 
- Dilute down the bacteria mixture 1:2 in the 96 well plate. 
- Plate selected dilutions on fresh Bordet Gengou blood agar plates. 
o Eg: 1:16, 1:256, 1:1024 
- Incubate the plates at 37oC and check for growth after 2-5 days. 
- Use the dilution that shows countable the colonies to estimate the bactericidal 
activity. 1:1024 dilution usually has countable colonies. 
- Control plates 
o Bacteria only, without complement 
o Bacteria + complement, no antibody  
o Bacteria + complement + isotype control/irrelevant antibody 
 
Adapted from  
- Barnes, M. G. and A. A. Weiss (2003). "Activation of the complement cascade by 
Bordetella pertussis." FEMS Microbiol Lett 220(2): 271-275.  
 
 
 
A.2 DNA protocols 
A.2.1 Colony pcr for amplification of DNA sequences from Bordetella pertussis 
The pcr reaction mixture includes 5% DMSO for amplification from the GC rich 
genomic DNA of the Bordetella strains. 
PCR reaction mix (50 µl total reaction): 
 2.5 µl 5’ Primer (10 µM)  
 2.5 µl 3’ Primer (10 µM)  
 5 µl Thermopol Buffer  
 1 µl dNTPs (10 µM)  
 5% DMSO 
 0.25 µl Vent DNA Polymerase  
 dH2O to 50 µl 
PCR cycling conditions 
Use the NEB Tm calculator to estimate the annealing temperature for the reaction. 
 94
o
C for 2 minutes (disrupt cells, separate DNA)  
 Cycle 35 times:  
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o 95
o
C for 30 s (melting)  
o 55
o
C for 45 s (annealing)  
o 72
o
C 1 minute per kb (elongation)  
 72 C for 10 minutes (final elongation)  
 15 C forever  
Vary the time for elongation depending on the size of the DNA fragment. Generally 1 
minute per kb of DNA. Check product by running 5 µl PCR sample + 2 µl 6x DNA dye 
on 1% agarose gel  
Adapted from  
NEB online protocols  
 
 
A.2.2 Restriction enzyme cloning  
- Digest the insert DNA and vector DNA separately using the appropriate enzymes 
and reaction buffers.  
 
Restriction enzyme digest mix 
DNA (Insert or vector) 
1 µL of each Restriction Enzyme 
5 µL 10x Buffer 
0.5 µL 100x BSA (if recommended) 
dH2O to 50 µL 
- Incubate tubes at the recommended temperature for the enzymes used. Typically 
37
o
C for 1 hour. 
- Isolate the bands of interest from a 0.8% agarose gel.  
- Ligate the purified insert and vector. Adjust vector to insert ratios to optimize 
ligation. 
- Transform the ligated DNA into competent cells. 
Ligation reaction 
1 µL Vector DNA 
3 µL Insert DNA 
1 µL 10x Ligase Buffer 
1 µL T4 DNA Ligase 
dH2O to 10 µL 
 
Adapted from  
NEB online protocols  
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A.2 SEQUENCES 
A.2.1 Bordetella FHA sequences 
 
Sequence information for B. pertussis TahomaI FHA  
http://www.uniprot.org/uniprot/Q8VV99 
 
 
Sequence information for B. bronchiseptica FHA 
http://www.uniprot.org/uniparc/UPI00001B8D7C 
 
Sequence information for B. parapertussis strain Bpp5  
http://www.genome.jp/dbget-bin/www_bget?tr:K0MH93_BORPB 
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ABBREVIATIONS 
4PL: 4 parameter logistic 
ACT: Adenylate cyclase toxin 
ADPR: Adenosine diphosphate ribosyl transferase 
aP: acellular pertussis 
BrkA: Bordetella resistance to killing protein 
BSA: Bovine serum albumin 
CBD: Carbohydrate binding domain 
CDC: Centers for disease control and prevention 
CDR: Complementarity determining region 
CHO: Chinese hamster ovary 
CM: Carboxymethylated 
CMV: Cytomegalovirus 
CO2: Carbon dioxide 
ColE1: Escherichia coli colicin E1 gene 
CR3: Complement receptor 3 
DMEM: Dulbeco’s Modified Eagle Medium 
DNA: Deoxyribonucleic acid 
DNT: Dermonecrotic toxin 
EC50: Half maximal Effective Concentration 
ELISA: Enzyme linked immunosorbent assay 
ER: Endoplasmic reticulum 
FACS: Fluorescence activated cell sorting 
FHA: Filamentous hemagglutinin 
FIM: Fimbrae 
FITC: Fluorescein isothiocyanate 
HBD: Heparin binding domain 
HCl: Hydrogen chloride 
HEK: Human embryonic kidney 
HIV: Human immunodeficiency virus 
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HRP: Horse radish peroxidase 
IAP: Integrin associated protein 
IC50: Half maximal Inhibitory Concentration 
IMGT: International ImMunoGeneTics information system 
LOS: Lipooligosaccharide 
LRI: Leukocyte response integrin 
Mac1: Macrophage receptor 1 
MCD: Mature C-terminal domain 
Mw: Molecular weight 
NCBI: National Center for Biotechnology Information 
NIAID: National Institute of Allergy and Infectious diseases 
NIBSC: National Institute for Biological Standards and Control 
NIH: National Institute of Health 
OPA: Opsonophagocytic activity 
PBS: Phosphate buffered saline 
pcr: Polymerase chain reaction 
P-IVIG: Pertussis intravenous immunoglobulin 
PTg: Genetically modified Pertussis toxin (9K/129G) in the S1 subunit 
PTx: Pertussis toxin 
PVDF: Polyvinylidene fluoride 
RAD: Arginine-Alanine-Aspartate tripeptide 
RBC: Red blood cells 
RGD: Arginine-Glycine-Aspartate tripeptide 
SPR: Surface plasmon resonance 
TCT: tracheal cytotoxin 
Th cell: T helper cell 
Tm: Melting temperature 
TMB: Tetramethylbenzidine 
wP: Whole cell pertussis 
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